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IN THE UTAH COURT OF APPEALS 
HEIDI PETERSON on behalf 
of MARKELLE FREI-PETERSON, 
Petitioner and Appellant, 
vs. 
UTAH DEPARTMENT OF HEALTH, 
DIVISION OF HEALTH CARE 
FINANCING, 
) 
Respondent and Appellee. i 
BRIEF OF APPELLEE 
JURISDICTION 
In accordance with Rule 410-14-2, Utah Administrative Code, 
a hearing requested by Petitioner Peterson was conducted as a 
formal hearing before the Division of Health Care Financing. The 
provisions of Chapter 4 6b of Title 63, Utah Administrative 
Procedures Act, are applicable ana pursuant to § 63-46b-16(l) 
"all final agency action[s] resulting from formal adjudicative 
proceedings" fall under the jurisdiction of either the Supreme 
Court or the Court of Appeals. In this instance, under § 78-2a-
3(2) (a), Utah Code Ann. (1997), the Court of Appeals has 
appellate jurisdiction over this matter. 
STATEMENT OF NATURE OF PROCEEDINGS BELOW 
This appeal is taken from the Final Agency Order of the 
Division of Health Care Financing (Division/DHCF) adopting the 
Case No. 98-0078-CA 
Category No. 14 
Recommended Decision issued by the Administrative Law Judge 
denying Medicaid funds for growth hormone to treat Markelle Frei-
Peterson for short bowel syndrome. In the time leading up to the 
administrative hearing, Markelle had received growth hormone for 
a few months, paid for by Primary Children's Medical Center 
charitable funds. Her treating physician wanted to treat 
Markelle for a period of time with the growth hormone, prompting 
the request for Medicaid coverage. The Division issued its 
denial dated July 16, 1997, from which the petitioner sought a 
hearing. The hearing was conducted December 8, 1997, resulting 
in the Recommended Agency Decision dated January 7, 1998. The 
Final Agency Order, adopting the Recommended Decision, was dated 
January 15, 1998. Petitionei timely filed her notice of appeal 
with this court February 11, 1998. 
STATEMENT OF THE ISSUE PRESENTED FOR REVIEW 
Whether the use of growth normone to treat short-bowel 
syndrome is properly categorj zed as experimental and therefore 
properly denied coverage under the Medicaid program. 
STANDARD OF REVIEW 
In an instance requiring the reviewing court to consider a 
mixed question of law and fact, the court will review the 
question of law for correctness but apply some degree of 
deference to the agency's determination in its application of the 
law to the facts. Drake v. Industrial Commission, 939 P.2d 177, 
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181 (Utah 199*7) . The degree of discretion granted to the agency 
must be evaluated in light of the particular circumstances. Some 
reasons which support a broader grant of discretion are when (1) 
the facts to which the rule are to be applied are "complex and 
varying [and] no rule [would] adequately address the relevance of 
all . . . [the] facts . . . ; (2) the matter to be decided is 
sufficiently new that a reviewing court would not be able to 
"anticipate and articulate definitively what factors should be 
outcome determinative;" and (3) the witnesses' demeanor is 
relevant and the record cannot adequately reflect those factors. 
State v. Pena, 869 P.2d 932, 939 (Utah 1994). The listing in 
Pena is not exhaustive and additional factors would also be 
considered under the particular situation of a specific case. 
Given the nature of the legal rule and the grant of discretion 
accorded the Division by statute to administer the Medicaid 
program to meet the objectives, see § 26-18-3, Utah Code Ann. 
(1995), this court should grant a degree of discretion to the 
Division m its application of the rule to the set of facts. 
Drake, 939 P.2d at 182, citing Pena, 869 P.2d at 939. Whether 
the decision to deny Medicaid coverage for the Petitioner was 
proper "is a mixed question of law and fact. [A] . . . 
determination of the law is reviewed for correctness, while . . . 
findings of fact are reviewed for clear error. [The agency's] 
application of the law to the facts is reviewed for abuse of any 
3 
discretion granted the [agency] in applying the stated rule . . . 
to the facts of the case." Woodhaven Apartments v. Washington, 
942 P.2d 918, 924, citing Pena, 869 P.2d at 937. 
DETERMINATIVE STATUTES AND RULES 
1. 42 U.S.C. § 1396a(a)(5) 
2. 42 U.S.C. § 1396(a) (10) (A) 
3. 42 U.S.C. § 1396d(a)(4)(B) 
4 . 42 U.S.C. § 1396d(r) 
5. Utah Code Ann. §§ 26-18-3; 26-18-4 
6. Utah Administrative Code R414-1A-200 
7. Utah Administrative Code R414-1A-300 
8. Utah Administrative Code R414-10-6 
9. Utah Administrative Code R414-13x-l.(5)(a) 
STATEMENT OF THE CASE 
Appellant, Markelle Frei-Peterson, diagnosed with short 
bowel syndrome, receives parenteral nutrition. Her treating 
physician wanted to try a regimen of growth hormone, hoping it 
would induce increased function of the intestines thereby 
reducing or eliminating parenteral nutrition. The associated 
problems of short bowel syndrome include the risk of central line 
catheter infections, the loss of intravenous access sites, and, 
potentially, liver dysfunction. The Medicaid program requires 
prior authorization for certain treatments, including the 
treatment proposed for Markelle. The application for Medicaid 
coverage for the growth hormone was submitted to DHCF. Upon the 
initial review, the factors of the case did not meet the 
applicable criteria. Because the proposed use for the drug did 
not meet: the usual criteria, additional documentation supporting 
the use was requested from the physician. The documentation 
received was reviewed and submitted to the Check Utilization 
Review Committee. The Committee determined the proposed use was 
experimental. Accordingly, the Health Program Manager of the 
Utilization Management staff in DHCF notified the parents of 
Markelle that the request for growth hormone therapy was denied 
on the basis the procedure was experimental. The Notice of 
Denial, dated July 16, 1997, included information of the right to 
a hearing if the applicant for Medicaid disagreed with the 
decision. Thereafter, Appellant filed a request for hearing on 
July 28, 1997. During the time from the request for hearing to 
the date the hearing was conducted on December 8, 1997, Markelle 
received growth hormone therapy paid by charitable funds of the 
Primary Children's Medical Center. At the hearing, testimony was 
presented by witnesses for Markelle and on behalf of DHCF as well 
as documentation and exhibits in support of the parties' 
positions. Thereafter, the Administrative Law Judge made the 
Recommended Decision to uphold DHCF's denial of Medicaid coverage 
on the basis it was experimental. This Decision dated January 7, 
1998, was adopted as the Final Agency Order on January 15, 1998. 
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STATEMENT OF FACTS 
Markelle Frei-Peterson, at the time of the Formal Hearing in 
December 1997, was described as a 24-month old child with short 
bowel syndrome. To briefly acquaint this court with the nature 
of the condition, as described more fully in the articles 
submitted by Markelle's physician and made a part of the formal 
hearing record, it is a disorder characterized by "diarrhea, 
dehydration, electrolyte disturbances, malabsorption, and 
progressive malnutrition" resulting from "extensive loss or 
dysfunction of the intestinal absorptive surface area." The 
severity "depends upon the length, location, and absorptive 
function of the remaining bowel and its ability to accommodate 
the reduced absorptive surface area." Compensatory function can 
occur; meanwhile, parenteral nutrition is often necessary. 
Parenteral nutrition may be total (TPN) or partial and may be 
temporary or permanent.- Also at the time of the hearing, 
Markelle received parenteral nutrition for approximately 90 
percent of her needs (T-126-10):. For perhaps the three- to 
*This short definition is taken from Theresa A. Byrne, et 
al., Growth Hormone, Glutamine, and a Modified Diet Enhance 
Nutrient Absorption in Patients With Severe Short Bowel Syndrome, 
Journal of Parenteral and Enteral Nutrition (1995) (R-41-47). 
For additional description of the syndrome, articles submitted by 
Petitioner's physician to DHCF and included in the record are 
found at R-21 to 66. 
References to the transcript of the formal hearing before 
the Utah Department of Health, Division of Health Care Financing, 
shall be designated by the initial "T"; references ro other 
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four-month period prior to the hearing, Markelle's enteral 
feedings had been increasing but she remained dependent upon 
parenteral nutrition. (T-126-10, 11). One of the concerns 
expressed by Markelle's physician, Dr. William D. Jackson, was 
the condition of her liver because the syndrome is characterized 
by progressive liver disease (T-126-31). Liver tests in 
approximately June 1997 showed some marked abnormalities which 
subsequently normalized (T-126-19) independent of the growth 
hormone therapy which had been initiated late in 1997 (T-126-29, 
30). The impetus to the growth hormone therapy was concern for 
the potential of liver disease (T-126-31); however, the basic 
objective of any treatment was to stimulate the ability of the 
intestinal tract to tolerate increasing enteral nutrition, this 
in turn providing the natural protection for the liver function. 
(T-126-31). At the time the growth hormone therapy was 
considered, Markelle was having health problems necessitating 
hospitalization and the liver tests with marked abnormalities 
concerned Dr. Jackson. A few things in her treatment were 
changed in addition to adding growth hormone. (T-126-19). The 
factors changed were not specified and were not definitively 
related to any improvement in enteral feedings; the maturation 
process may have played a role in adapting to increased enteral 
portions of the record before the Division shall be designated by 
the letter "R." 
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feeding or the growth hormone may have provoked a change. (T-
126-19). Markelle had begun to tolerate increasing enteral 
feedings. (T-126-19, 21). The progress in Markelle's condition 
admittedly did not prove the efficacy of the therapy. (T-126-
38) . 
In addition to describing Markelle's condition, Dr. Jackson, 
board certified in pediatrics and pediatric gastroenterology and 
nutrition, made reference to recent articles on the topics of 
short bowel syndrome and growth hormone studies published in 
professional journals. The studies reported were small and short 
term, consisting of eight to 47 study patients in three- to four-
week trials. (R-41; R-28; R-25). Dr. Jackson referred to the 
study results demonstrating some increased measures for 
absorption and function, but over very short terms, with small 
groups of adults. (T-126-28). This is an area of new therapy 
generating active work and controversy. (T-126-15, 16, 28). 
Asked to comment on the therapy as experimental, Dr. Jackson 
elaborated as follows: 
I think there's a lot of therapies that we use that are 
rightfully considered experimental which in terms of --
if you think of it in terms of data being accumulated 
and evaluating the efficacy, the appropriate dosage, 
the appropriate indications, things like that. And 
this one particularly as early a therapy as this is, as 
young a therapy I guess as this is would definitely I 
think have to be considered that. 
(T-126-35). Dr. Jackson's continuing testimony on this point 
addressed his interpretation of his use of the growth hormone fcr 
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Markelle as not being an experiment in the strict sense inasmuch 
as no protocol were being followed and a study of one patient 
wouldn't constitute an experiment in his mind. (T-126-35). Dr. 
Jackson likened his decision to the "art of medicine" wherein 
available data is applied to a "desperate clinical situation" and 
in "adding up pluses and minuses" a judgment is made which "could 
be deemed erroneous by peers or other people," but on the other 
hand other peers agree with trying this as a therapy. He stated 
that as Markelle's physician it was his "judgment . . . that [he] 
would like to try this." Further, he stated he had a certain 
idea about its use but certainly did not have all the information 
. . . and "we often don't in making practice decisions and making 
clinical decisions. . . . We don't know that this indeed is what 
cured the patient or this indeed is what did anything." (T-126-
36). Further questioning elicited testimony that Markelle did 
not have growth hormone deficiency. (T-126-41). The theory 
presented was that growth hormone would be given to "stimulate 
growth factor production in the body, including epidermal growth 
factors, things like that work on the lining of the intestine to 
stimulate growth." Experimental animal studies in which 
excessive amounts of growth hormone are given have produced 
animals expressing hyperplasia (tumors) in the small bowel. (T-
126-42). The theory is to use the growth hormone as a 
pharmacological agent to "actually stimulate the kind of growth 
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factors that would be required to try to make the small bowel 
develop and grow more." (T-126-43). No known level of dosage is 
recognized. (T-126-43) . 
Upon receipt of the request for Medicaid coverage for the 
growth hormone, DHCF reviewed the information presented and 
applied the applicable criteria; at this point Markelle did not 
meet the criteria. (T-126-47, 48). Specifically, Markelle did 
not have documented failure of growth nor of insufficiency caused 
by kidney failure. (T-126-49). The proposed use was not a 
common use for the drug, therefore, DHCF requested additional 
documentation, including any supporting literature, as well as 
liver function tests, clinical records, parenteral and enteral 
nutrition information. (T-126-48). This information was 
reviewed and submitted to the Check Utilization Review Committee. 
The Committee, composed of physicians, nurses, consultants, 
social workers, reviewed the documentation and found the use 
proposed was not typical but was experimental. (T-126-48, 49). 
The Notice of Decision denying Medicaid coverage stated it was 
based on Utah Administrative Code R414-10-5, Physician's Covered 
Services, wherein it provides that "[e]xperimental or medically 
unproven physician services or procedures are excluded from 
coverage." (T-126-51). Duane Park, a registered pharmacist with 
a master's degree in health administration, testified on behalf 
of DHCF concerning effective drug utilization as required by the 
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Medicaid law. Mr. Park develops and coordinates the drug 
utilization review process for the State as mandated by federal 
law. (T-126-52). 
Dr. John Hylen testified on behalf of DHCF. He stated he 
had a doctorate in medicine, a master's degree in public health, 
and was board certified in internal, cardiovascular, and 
geriatric medicine. Dr. Hylen's statements reiterated issues 
raised previously and particularly indicated his concerns that 
growth hormone used as proposed had not yet been proven effective 
in preventing liver disease nor were data available concerning 
toxicities for children. Dr. Hylen's testimony centered on 
concerns that since side effects were unknown, its efficacy in 
preventing progressive liver disease or the need for a liver 
transplantation remained undocumented, and it is an expensive 
medication and alternative cost-effective means exist to address 
the nutritional concerns, that he found many unanswered questions 
weighed against the therapy. (T-126-60, 61). 
SUMMARY OP THE ARGUMENT 
At issue is the proposed use of a drug, humatrope, a 
recombinant human growth hormone, to stimulate gastrointestinal 
function for a child suffering from short bowel syndrome. Under 
applicable Medicaid rules, the drug is approved for use under 
circumstances where a person is deficient in the growth hormone. 
The Appellant Markelle has no growth hormone deficiency. Rather, 
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her treating physician proposes to use growth hormone in the hope 
it will stimulate gastrointestinal function. However, the use 
proposed in the instant case is considered experimental. Under 
Medicaid law, coverage is not permitted for experimental 
procedures. This approach is justifiable because the Medicaid 
program's objectives are not directed toward research. In 
compliance with federal law, Utah, by its designated agency 
charged with the efficient and effective administration of the 
Medicaid program, has established rules addressing Medicaid 
payment policy for experimental or unproven medical practices and 
treatments. 
The agency has defined an "experimental or unproven medical 
practice" as one not proven medically efficacious. Medically 
efficacious practices have been determined effective and widely 
utilized as a standard practice. These practices are approved as 
a covered Medicaid service on the basis of medical necessity. 
Proven effective treatments widely utilized are covered services 
when medically necessary. The determination of medically 
necessary is a proper exercise of agency discretion. A medically 
necessary service must be reasonably calculated to effectively 
address the patient's situation. This entails a consideration of 
the treatment for its preventive, diagnostic or curative use for 
the patient's condition as well as for its effectiveness and 
suitability. 
12 
The Division has essentially defined "necessary treatment" 
as used in the Medicaid Act to exclude experimental treatments. 
This is a valid interpretation by the Division fulfilling its 
role in meeting the objectives of the Act. Absent proven 
effectiveness for a treatment necessary for the patient's medical 
condition, the Division reasonably may deny funds. 
ARGUMENT 
POINT I: 
THE MEDICAID PROGRAM, A COOPERATIVE FEDERAL-STATE 
ENDEAVOR, CREATED TO ASSIST PARTICIPATING STATES BY 
PROVIDING FEDERAL FINANCIAL ASSISTANCE, PROVIDES 
MEDICAL ASSISTANCE TO NEEDY INDIVIDUALS WHO ARE 
ELIGIBLE UNDER THE STATE'S APPROVED PLAN. 
In 1965 Congress established the Medicaid program by 
enacting Title XIX of the Social Security Act. The program is a 
cooperative federal-state endeavor by which federal grants are 
paid to states enabling them to provide medical assistance to 
persons otherwise unable to pay for necessary medical care. 
Although Medicaid is entirely optional, once a state elects to 
participate, the state must comply with all the federal statutory 
and regulatory requirements. Harris v. McRae, 448 U.S. 297, 301, 
100 S.Ct. 2671, 2680 (1980). Participating states must have a 
State plan approved by the Secretary. See 42 U.S.C. § 1396. A 
single agency must be selected to administer the plan. See 42 
U.S.C. § 1396a(a)(5). Although states must comply with the 
federal requirements, they retain broad discretion in determining 
13 
which medical services will be covered under their plans. 
However, to qualify for federal funds the state plan must include 
the seven mandatory medical services referenced at 42 U.S.C. § 
1396a (a) (10) (A), which include inpatient hospital services, 
various outpatient hospital services, laboratory and X-ray 
services, specified nursing facility services, early and periodic 
screening, diagnostic, and treatment services for eligible 
individuals under 21, (42 U.S.C. § 1396d(r)) various physician 
services, nurse-midwife services, and services of certified 
pediatric or family nurse practitioners. 42 U.S.C. § 
1396d(a)(4)(B). 
Utah is a participating Medicaid state having opted to 
participate by adopting the Medical Assistance Act in 1981. See 
Utah Code Ann. §§ 26-18-1 to -11 (1995 and Supp. 1997). Having 
opted into the federally created medical assistance program, Utah 
assumes complete administration of its program. Utah designated 
the Division of Health Care Financing as the single 
administrative agency for the state. As the designated agency, 
the Division is responsible for administering the Medicaid 
program m accordance with federal and state law. The Utah 
legislature granted the Division broad authority to develop 
standards and to develop and administer policies in implementing 
the state's plan. Utah Code Ann. §§ 26-18-3(2), -4(1) (1995). 
Utah has complied with federal requirements by creating a state 
14 
Medicaid plan which has received approval by the Secretary of 
Health and Human Services. Utah Admin. Code R414-1-4. 
A. A state's medical assistance plan must be 
consistent with the objectives of Title XIX; the plan 
must employ reasonable standards for determining 
eligibility for and extent of medical assistance. 
Title XIX's overarching objective is to enable participating 
states, "as far as practicable, to furnish medical assistance to 
individuals whose income and resources are insufficient to meet 
the costs of necessary medical services." Beal v. Doe, 97 S.Ct. 
2366, 2371, 432 U.S. 438 (1977^. Title XIX does not specify 
particular medical procedures to be provided; although 
participating states must provide financial assistance for five 
(the Medicaid statute now mandates seven categories) broad 
categories of medical treatment, states are not required to fund 
every medical procedure falling within the general categories. 
Indeed, the statute expressly provides: "A State plan 
for medical assistance must . . . include reasonable 
standards . . . for determining eligibility for and the 
extent of medical assistance under the plan which . . . 
are consistent with the objectives of this [Title]. . . 
." 42 U.S.C. § 1396a(a)(17) (1970 ed., Supp. V). 
Beal v. Doe, 97 S.Ct. at 2370-71; A.M.L. v. Department of Health, 
863 P.2d 44, 47 (Utah App. 1993). 
To retain the integrity of the program, each participating 
state must submit and receive approval for its state plan. 
However, receiving approval does not mean the state plan is 
minutely managed by federal oversight. In fact, the Beal Court 
15 
goes on to state, "[t]his language confers broad discretion on 
the States to adopt standards for determining the extent of 
medical assistance, requiring only that such standards be 
^reasonable' and ^consistent with the objectives' of the Act." 
Bealr 97 S.Ct. at 2371. 
B. Utah's standards of eligibility and coverage are 
reasonable and in conformance with the objectives of 
the Act. 
In conformance with Title XIX and by the authority granted 
under § 26-18-3(2), Utah Code Ann. (1995), Utah's designated 
Medicaid office has established standards enabling the Division 
to administer its Medicaid program. The specific standards 
applicable to this case provide in pertinent part: 
R414-1A-300. Policy. 
(1) Experimental or unproven medical practices are not 
covered Medicaid services. 
(2) Division staff and physician consultants shall 
establish criteria to determine whether a service or 
procedure is a covered Medicaid service. 
(3) Procedures or services proven to be medically 
efficacious for specific medical conditions may be provided 
as covered Medicaid services only for the conditions 
specified. Such procedures or services are not covered for 
any other conditions or for experimental trials 
The issue before this court concerns DHCF's denial of Medicaid 
coverage for an experimental use of a drug. The policy excludes 
experimental or unproven medical practices; it does not exclude 
procedures or services proven to be medically efficacious. 
Furthermore, the criteria applied to a given situation is the 
result of the combined efforts of Division staff and physician 
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consultants. This is an important issue on which the agency 
should be permitted broad discretion to fashion rules which 
promote the objectives of the Medicaid program. Medicaid was not 
created to promote research for new treatments. In fact, using 
the population of Medicaid-covered individuals as a potential 
pool of research subjects would raise public policy and ethics 
concerns. This population of persons is already vulnerable 
because of lack of sufficient personal funds to obtain needed 
medical services. While the concept of public funding of medical 
research is not a foreign or repugnant one, it would be 
unacceptable to combine the dual purpose of needed medical 
treatment and experimental medical treatment within the single 
program of Medicaid. The Medicaid program is not a research 
program. 
In addition to the rule establishing the Medicaid payment 
policy for experimental or unproven medical practices, the agency 
has by rule defined certain terms which govern the agency in its 
assessment of the set of facts applicable to the particular 
individual. The definitions established by rule provide in 
pertinent part: 
R414-1A-2 00. Definitions. 
(1) Terms used in this rule [R414-1A. Medicaid Policy 
for Experimental or Unproven Medical Practices.] are defined 
in R414-1-1. 
(2) In addition: 
(a) "experimental or unproven medical practice" 
means any procedure, medication product, or service 
that is: 
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(i) not proven to be medically efficacious 
for a given procedure; or 
(ii) performed for or in support of purposes 
of research, experimentation, or testing of new 
processes or products; or 
(iii) both; 
(b) "medically efficacious" means a medical 
practice that: 
(i) has been determined effective and is 
widely utilized as a standard medical practice for 
specific conditions; and 
(ii) has been approved as a covered Medicaid 
service by division staff and physician 
consultants on the basis of medical necessity, as 
defined in R414-13x-l.(5)(a),. . . . 
When determining the application of "experimental medical 
practice" to the facts of the case, the question of "medical 
necessity" may arise because of the specific circumstances. A 
service is "medically necessary" if it is: 
(1) reasonably calculated to prevent, diagnose, or cure 
conditions in the recipient that endanger life, cause 
suffering or pain, cause physical deformity or 
malfunction or threaten to cause a handicap; and 
(2) there is no other equally effective course of 
treatment available or suitable for the recipient . . . 
which is more conservative or substantially less 
costly. 
Utah Admin. Code R414-13x-l.(5)(a). 
Under both the Medicaid Act and Utah law, the Division has 
been granted discretion to establish and implement a program 
designed to furnish medical assistance within the scope and 
intent of the law. The Division has designed a program to meet 
those objectives. Nothing in federal or state law prevents the 
state from denying coverage for medical practices or services 
which do not satisfy reasonable criteria designed to achieve the 
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program's objectives. As the Beal Court noted, u[a]lthough 
serious statutory questions might be presented if a state 
Medicaid plan excluded necessary medical treatment from its 
coverage, it is hardly inconsistent with the objectives of the 
Act for a State to refuse to fund unnecessary though perhaps 
desirable medical services." Beal, 97 S.Ct. at 2371. The 
terminology of "unnecessary" is not precisely the correct 
question in the instant case. Rather, the reference to the quote 
in Beal helps clarify the determination in this case. The 
agency's decision denied the request because the proposed use was 
experimental. The medical procedure is unproven; and without a 
certain quantum of reliable authority establishing a procedure's 
safety and effectiveness, the agency is justified in exercising 
its discretion not to fund a questionable medical service. 
POINT II: 
UTAH'S STANDARD GOVERNING EXPERIMENTAL 
MEDICAL PRACTICES IS REASONABLE AND AS 
APPLIED TO THE FACTS OF THE CASE WAS A 
REASONABLE EXERCISE OF AGENCY DISCRETION. 
The rule applied in this case denied Medicaid coverage for 
an experimental use of growth hormone to treat short bowel 
syndrome. In essence, if the practice or service is determined 
experimental, then it has not been proven medically efficacious 
for that purpose. In Rush v. Parham, 625 F.2d 1150, 1156 (5th 
Cir. 1980), that court had occasion to consider the question 
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presented when applying the standard of experimental within the 
definition of medically necessary services. The case concerned a 
request for transsexual surgery and presented that court with the 
problem of whether the Georgia Medicaid program's definition of 
medically necessary services could exclude experimental 
treatments. The court concluded that it was a valid exercise of 
the agency's discretion to exclude experimental treatments. Its 
support was found in a letter Medicare3 uses to explain why 
certain services are ineligible for reimbursement. The 
supportive information contained in the opinion at footnote 11 
states: 
The clearest articulation of the considerations 
that go into determining whether a particular service 
is experimental is found in a letter Medicare uses to 
explain to its clients and providers why a service is 
ineligible for reimbursement: 
In making such a decision [whether to provide 
payment for a particular service], a basic 
consideration is whether the service has come to be 
generally accepted by the professional medical 
community as an effective and proven treatment for the 
condition for which it is being used. If it is, 
Medicare may make payment. On the other hand, if the 
service or treatment is not yet generally accepted, is 
rarely used, novel or relatively unknown, then 
authoritative evidence must be obtained that it is safe 
and effective before Medicaid may make payment. 
Enclosure # 2 to Intermediary Letters Nos. 77-4 & 77-5, 
3The Medicare program, which is administered directly by the 
federal government on a nationwide basis, shares similarities 
with the Medicaid program, including the relationship between the 
private physician and the federal government wherein the 
physician's judgment plays a central role yet the physician must 
operate within the reasonable limits established by the state. 
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[1976 Transfer Binder] Medicare & Medicaid Guide (CCH) 
1 28,152 (1976). 
Rush v. Parnam, 625 F.2d at 1156 n. 11. 
Following Rush, the question of experimental treatment has 
been considered in a variety of settings, not all of which 
actually turn on the application of that standard to the facts of 
the case. A number of cases cited by Appellant as having 
followed -Rush's lead on this point are, in fact, distinguishable. 
In Weaver v. Reagan, 886 F.2d 194 (8th Cir. 1989), a class 
of Medicaid-eligible individuals were denied coverage for AZT to 
treat their AIDS. The Missouri Department of Social Services 
defended their action claiming the coverage was limited to only 
those patients whose condition met the FDA labeling statement 
and, secondarily, any use outside the labeling statement was per 
se experimental. Not only did an FDA bulletin refute the 
Department's position with respect to the controlling nature of 
the labeling statement, out the Weaver court applying the Rusn 
definition found the use of AZT beyona the labeled uses was not 
experimental masmucn as it was commonly prescribed for the use 
requested by plaintiffs and was generally accepted in the medical 
community as an effective treatment. In sum, Missouri's action 
was arbitrary since the rule created an irrebuttable presumption. 
Such is not the case with Utah's standard which takes into 
consideration factors such as acceptance in the medical community 
as an efficacious treatment. 
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In Montoya v. Johnston, 654 F.Supp. 511 (W.D.Tex. 1987), the 
Texas Department of Human Services placed a cap of $50,000 on the 
amount Medicaid would pay for inpatient hospital services during 
any 12-month period. This effectively precluded the liver 
transplants, costing approximately $200,000, sought by two young 
children otherwise eligible for Medicaid. In support of the 
request, the children's physicians submitted affidavits stating 
that liver transplants were not considered experimental. 
Additionally, the court found the Texas Medicaid cap was 
arbitrary and unreasonable. The cap was contrary to Medicaid 
regulations which prohibit restrictions which "arbitrarily deny 
or reduce the amount, duration or scope of a required service . . 
. to an otherwise eligible recipient solely because of the 
diagnosis, type of illness or condition." Montoya v. Johnston, 
654 F.Supp. at 513. While the Montoya court cited to Rush and 
the definition of experimental treatment, the facts of Montoya 
distinguish it from the instant case. Appellant Markelle did nor 
come up against an arbitrary cap or restriction nor did the 
evidence submitted state unequivocally the procedure was not 
experimental. Rather, the contrary situation exists in that 
there is no unequivocal statement that the use of growth hormone 
for the use requested is not experimental. 
In Miller by Miller v. Whitburn, 10 F.3d 1315 (7th Cir. 
1993), the issue of experimental is framed in a somewhat 
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different manner. The question decided was that the district 
court could review Wisconsin's Department of Health and Social 
Services' definition of experimental to ensure it complied with 
federal mandates that standards applied by states be reasonable. 
The court took care to reiterate that states retained significant 
discretion in deciding which treatments to cover. The actual 
determination of whether the liver-bowel transplantation at issue 
was covered by Medicaid remained to be considered. The court 
noted the record did not contain facts addressing matters such as 
efficacy or the opinion of the medical community. In citing to 
Rush, the Miller court cited the definition of experimental in 
its entirety; it then made further comments on the term. It 
stated x>[c]learly, the best indicator that a procedure is 
experimental is its rejection by the professional medical 
community as an unproven treatment." Miller by Miller v. 
Whitburn, 10 F.3d at 1320. This would be correct if the 
scientific studies had been properly conducted and confirmed the 
conclusion the treatment was worthless. As it stands, it perhaps 
states too much until the confirming results; therefore, it is of 
dubious use in analyzing the instant matter. However, further on 
the Miller court states that "certain procedures may be so new 
and . . . relatively unknown, that the medical community may not 
yet have formed an opinion as to their efficacy." Miller by 
Miller v. Whitburn, Id. The court then stated "[i]f 
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'authoritative evidence' exists that attests to a procedure's 
safety and effectiveness, it is not ^experimental.'" Miller by 
Miller v. Whitburn, Id. Taken together these statements indicate 
that experimental determinations require authoritative evidence 
establishing safety and effectiveness. Therefore, DHCF's 
determination in the present case is reasonable if the same 
factors are applied. 
And, finally, in McLaughlin v. Will ia.iu.Sf 801 F.Supp. 633 
(S.D. Fla. 1992), the court considered Florida's denial of 
Medicaid for a liver-small bowel transplantation because it was 
deemed experimental. The definition of experimental found in 
Rush was applied as binding precedent as the McLaughlin court 
considered a possibly fatal situation and so the court found 
useful the determination that a relatively new procedure can be 
found medically necessary if "authoritative evidence" established 
it was "safe and effective." McLaughlin v. Williams, 801 F.Supp. 
at 639, citing from Rush. Of concern to the court were factors 
of safety and effectiveness where new procedures are considered. 
Risks and benefits must be balanced. Rapid medical advances made 
determinations difficult and rigid standards applied by the state 
compounded the problem. The court identified in some detail that 
"simple demarcation" was not a workable means of defining 
experimental. McLaughlin v. Williams, 801 F.Supp. at 638-40. 
Such is not the case in the instant matter. The standard applied 
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by DHCF permits evaluation of the effectiveness of the procedure 
and its utilization in the medical community along with the 
physician's determination of medical necessity. Appellant argues 
that DHCF's definition of experimental should include specific 
demarcation to define "how widely used" a practice should be to 
avoid the same fate as the court identified in McLaughlin. In 
point of fact, this would not benefit the decision making 
process. In these cases the Division needs to be able to 
exercise its discretion so that a reasoned and reasonable 
decision is made. 
The Recommended Decision, adopted as the Final Agency Order, 
(R-109-114), sets forth the decision to deny on the basis of 
experimental treatments not being covered by Medicaid. In her 
findings, the administrative law judge (ALJ) identified 
Markelle's diagnosis and prior and current condition. She also 
identified the proposed treatment as still controversial 
notwithstanding a number of reputable physicians were motivated 
to prescribe the treatment. She also alluded to the fact growth 
hormone was not included in the package labeling statement. The 
record transcript and exhibits and submitted articles when taken 
as a whole justify the ALJ's conclusion even though the findings 
are somewhat cursory. Further, the reasoning given by the ALJ 
identifies those additional factors necessary to support the 
conclusion. Of importance is the recognition that the testimony 
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does not refute the experimental nature of the treatment and that 
it remains controversial. (R-113). Also, while the ALJ writes 
"Dr. Jackson made compelling arguments for the medical necessity 
of using growth hormone" (R-113), that is not the same as stating 
he established the medical necessity. A careful reading of the 
transcript and the recommended decision shows the ALJ did not 
reject the treating physician's testimony. Her decision weighed 
all the evidence and finding the treatment remained controversial 
even by Dr. Jackson's own testimony gave reason and credibility 
to the decision. Frey v. Bowen, 816 F.2d 508 (10th Cir. 1987). 
In fact, nowhere in the record does Dr. Jackson unequivocally 
state the treatment is medically necessary. 
Even assuming the Division has applied the wrong standard to 
the facts of this matter, Appellant's position is not supported 
upon a review of the entire record. Assuming the review standard 
applied by Appellant is to succeed in claiming that the ALJ's 
decision should fail for lack of sufficient evidence, Appellant 
must marshall all the evidence presented and show that 
notwithstanding the evidence contrary to the decision there is 
insufficient evidence to adequately support the conclusion. 
A.M.L. v. Department of Health, 863 P.2d at 46-47; Zissi v. State 
Tax Comm'n of Utah, 842 P.2d 848, 852-53 (Utah 1992). The record 
as a whole provides sufficient evidence which a reasonable person 
could accept as adequate to support the conclusion reached by the 
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administrative law Judge. Appellant's position is that even if 
the procedure is not widely utilized as a standard medical 
practice, novel or relatively unknown procedures can be found 
medically necessary if authoritative evidence shows the treatment 
is safe and effective. Appellant claims the authoritative 
evidence to be relied upon in this case is the "testimony of Dr. 
Jackson, together with extensive medical literature" (Appellant's 
Br. at 20). Appellant's summary of Dr. Jackson's testimony 
identifies eight points as determinative. Point 1: ["higher 
indicated" use of the drug] While using a drug to possibly save 
a life could reasonably be classified as a "higher indication" 
for the drug than its approved use for short statured persons, 
this does not equate with effectiveness. Point 2: [cost 
effective alternative] While the limited data suggests growth 
hormone treatment costs less than either TPN or a liver 
transplant, the critical factor is whether the drug effectively 
eliminates or prevents either of the alternative treatments and 
the attendant costs; and, the evidence does not establish that 
fact. (T-126-26, 27, 29-31). Point 3: [studies by "mainstream" 
professionals supporting use] While Dr. Jackson testified the 
proposed use found support among "mainstream" professionals, the 
fact remains that these studies describe limited trials which 
remain in the investigational stage and are still controversial. 
(T-126-27-28) . Point 4: [short-term studies show some increase 
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in absorption and amino acid uptake] While study trial results 
may show some of the hoped-for benefits, the results obtained 
suggested to those conducting the trials that additional trials 
should be undertaken to determine effectiveness. (R-25, 28-29, 
37-38). Point 5: [apparent improvement in Markelle's enteral 
nutrition while taking growth hormone] While testimony indicated 
some increased ability to tolerate oral feedings, Dr. Jackson 
testified he could not tie that change to any treatment and it 
could be the result of the maturation process. (T-126-18, 19). 
Point 6: [use of growth hormone reasonably calculated to prevent 
death, improve quality of life] While Dr. Jackson did testify 
that his goals with respect to the use of growth hormone would be 
to achieve the definitional elements contained in the "medically 
necessary" rule read at the hearing, he further testified that it 
was a new therapy, still controversial and it may not turn out to 
be effective. (T-126-26). Point 7: [growth hormone would lessen 
suffering] While eliminating the need for TPN would also 
eliminate suffering caused by infections, and so forth, this 
would only occur if the treatment proved safe and effective and 
in fact eliminated the parenteral nutrition; that was one of Dr. 
Jackson's goals but that is different than stating the proposed 
experimental use will achieve that goal. Point 8: [no 
alternative treatment for less cost] Assuming the proposed growth 
hormone treatment worked as hoped and was of limited duration, 
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the testimony supports this conclusion. As further testimony 
indicates, Markelle receives TPN which is expensive; however, her 
oral feedings have increased. (T-126-18). 
Four published studies, previously referred to generally, 
were submitted at the time of the administrative hearing; and, 
unfortunately and inexplicably, the literature had not been 
received for the Division's medical expert to review and comment 
upon during testimony. Whether this legitimately constitutes 
extensive, authoritative evidence which proves safety and 
effectiveness is questionable. If Appellant's standard should 
apply, one question to be addressed is what constitutes 
authoritative evidence. It is not unreasonable to require a 
certain quantum of such evidence such that a person would 
reasonably believe it established the safety and effectiveness of 
the experimental procedure. Are these studies sufficient to meet 
the proposed standard. The studies submitted for support contain 
statements of reservation and these reservations are acknowledged 
by Dr. Jackson in his testimony. The studies state their initial 
results suggest a potential alternative treatment and therefore 
further trials are required to determine matters such as timing, 
dosage, combinations for optimal effect, and safety and 
effectiveness. The studies were very small and conducted over 
very short periods of time using adult subjects. One reference 
is made to a group of 12 children having received treatment (R-
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17); however, the details of treatment and results are limited 
and cannot reasonably justify finding the treatment proposed for 
Markelle is not experimental. The study size and duration, 
participant composition, and multiple factors (growth hormone, 
glutamine and specialized diet) administered to the participants 
in the clinical trials combine to raise significant concerns 
justifying the Division's decision. Since the elements of the 
proposed standard of "safe and effective" require a factual 
analysis, this should be left to the agency's discretion and the 
reviewing court should grant deference to the agency's expertise. 
CONCLUSION 
The Medicaid program is a publicly funded program designed 
to assist individuals who lack sufficient funds to obtain needed 
medical services. Since it is a public program, it must function 
according to rules and regulations to ensure efficient and 
effective use of limited resources. Medicaid never has been 
considered a research program. While new, evolving treatments in 
medical research are anticipated, it is unacceptable to 
contemplate using a vulnerable population as potential research 
subjects. To protect both the individuals needing the Medicaid 
services necessary and appropriate to the specific condition and 
the integrity of the Medicaid program, the Division should have 
policies in place to prevent unintended as well as intended 
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abuses. It is entirely appropriate for the Division to exclude 
experimental medical services. 
The agency's application of the rule to the facts of the 
case resulted in a final agency order denying Medicaid coverage 
for an experimental treatment. In reviewing the record as a 
whole, and in the absence of an abuse of the discretion granted 
the agency to establish and administer the State's Medicaid 
program, the agency's decision is reasonable and should be 
affirmed. 
Respectfully submitted this day of June, 1998. 
JAN GRAHAM 
Attorney General/ 
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MARKELLE FREI-PETERSON 
Petitioner 
vs. 
UTAH DEPARTMENT OF HEALTH 
DIVISION OF HEALTH CARE FINANCING, 
Respondent. 
FINAL AGENCY ORDER 
Case No. 97-209-11 
IF YOU ARE NOT SATISFIED WITH THIS DECISION, YOU MAY REQUEST A 
RECONSIDERATION FROM THE DIRECTOR OF HEALTH CARE FINANCING 
WITHIN TWENTY (20) DAYS AFTER THIS DECISION IS SIGNED. IF YOU WOULD 
LIKE TO APPEAL THIS DECISION, YOU MAY FILE A PETITION IN THE UTAH 
COURT OF APPEALS WITHIN THIRTY (30) DAYS AFTER THIS DECISION IS 
SIGNED. IF YOU DECIDE TO APPEAL, YOU ARE NOT REQUIRED TO ASK FOR A 
RECONSIDERATION FIRST, BUT YOU MAY DO SO IF YOU WISH. IF YOU HAVE 
QUESTIONS, CALL (801) 538-6576. 
The enclosed Recommended Decision has been reviewed pursuant to Section 63-46b-12 
Utah Code Ann. 1953, as amended, entitled "Agency Review - Procedure," and Department 
of Health Administrative Rule R410-14, entitled "Division of Health Care Financing 
Administrative Hearing Procedures for Medicaid/UMAP Applicants, Recipients, and 
Providers." 
I hereby adopt Recommended Decision No. 97-209-11 in its entirety. 
RIGHT TO JUDICIAL REVIEW 
Within twenty (20) days after the date that this Final Agency Order is issued, you may file a 
written request for reconsideration with the Director of the Division of Health Care Financing. 
Any request for reconsideration must state the specific grounds upon which relief is requested. 
The filing of such a request is not a prerequisite for seeking judicial review. 
Judicial review may be secured by filing a petition in the Utah Court of Appeals within thirty 
(30) days of the issuance of this Final Agency Action or, if a request for reconsideration is 
ihC\ 
filed and denied, within thirty (30) days of the denial for reconsideration. The petition shall 
be served upon the Director of Health Care Financing and shall state the specific grounds upon 
which review is sought. Failure to file such a petition within the 30-day time limit may 
constitute a waiver of any right to appeal the Final Agency Order. 
A copy of this Final Agency Order shall be sent to Petitioner or representative at the last 
known address by certified mail, return receipt requested. 
DATED this /r day of January 1998 
BY: 
Michael Deily, D 
Division of Heal 
UTAH DEPAR' 
lare Financing 
1ENT OF HEALTH 
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BEFORE THE UTAH DEPARTMENT OF HEALTH 
DIVISION OF HEALTH CARE FINANCING 
STATE OF UTAH 
MARKELLE FREI-PETERSON 
Petitioner, 
RECOMMENDED DECISION 
vs. 
UTAH DEPARTMENT OF HEALTH Case No. 97-209-11 
DIVISION OF HEALTH CARE Margaret J. Clark 
FINANCING, Administrative Law Judge 
Respondent. 
Pursuant to Rule R410-14 of the Utah Department of Health and the Utah Administrative 
Hearing Procedures Act, Title 63, Chapter 46b, Utah Code Annotated, 1953, as amended, a 
formal administrative hearing for the above captioned case was held on December 8, 1997, at 
8:00 a.m., in Room 344, Cannon Health Building, 288 North 1460 West, Salt Lake City, 
Utah 84116, Margaret J. Clark, Administrative Law Judge, presiding. Daniel Jackson, M.D., 
testified on behalf of the petitioner. The petitioner's mother was present at the hearing. Steven 
Gatzemeier represented the Division of Health Care Financing ("DHCF"). John C. Hylen, 
M.D., and Duane Parke testified on behalf of DHCF. 
ISSUE 
SHOULD UTAH MEDICAID COVER GROWTH HORMONE TO TREAT SHORT 
BOWEL SYNDROME FOR MARKELLE FREI-PETERSON? 
FINDINGS OF FACT 
1. Markelle Frei-Peterson is approximately twenty four months old, suffers from short bowel 
syndrome, and is dependent on parenteral nutrition for approximately 90% of her nutritional 
needs. 
2. In the past three or four months she has begun to tolerate some oral feedings, but remains 
dependent on parenteral nutrition. 
3. Short bowel syndrome requires expensive technology and possibly a lifetime of parenteral 
nutrition. 
4. The goal of Markelle's treating physician is to accelerate her gastrointestinal adaptation 
by administering the growth hormone for about one year. 
5. Because she has short bowel syndrome, Markelle is at risk of central line catheter 
infections, eventual loss of intravenous access sites, and progressive liver dysfunction. 
6. Markelle has been receiving growth hormone for approximately three months. The 
hormone has been supplied by a Primary Children's Hospital charity. 
7. Usage of growth hormone for short bowel syndrome is considered an "off-label" use by the 
Federal Food and Drug Administration. 
8. The data is sufficient to motivate a number of reputable physicians to prescribe growth 
hormone for short bowel syndrome, but it is still considered to be controversial. 
RECOMMENDED CONCLUSIONS OF LAW 
The use of growth hormone to treat small bowel syndrome is "experimental" as defined in: 
Utah Administrative Code R414-1A-200, and is therefore not covered by Utah Medicaid [see 
R414-1A-300(1)]. 
REASONS FOR PRESIDING OFFICER'S DECISION 
DHCF denied reimbursement for growth hormone for Markelle because it contended that the 
drug is experimental for usage in treating short bowel syndrome, and it has not been approved 
by the Federal Drug Administration for that purpose. 
DHCF's policy regarding experimental or unproven medical practices is contained in Utah 
Administrative Code R410A. R410A-300 states in relevant part: 
(1) Experimental or unproven medical practices are not covered Medicaid 
services. 
R410A-200 defines "experimental or unproven medical practice" as "(2)(i) not proven to be 
medically efficacious for a given procedure." "Medically efficacious" is defined in R410-1A-
200(iii)(b) as "a medical practice that has been determined effective and is widely utilized as a 
standard medical practice for specific conditions." 
W. Daniel Jackson , M.D., Markelle's treating physician testified on her behalf. Dr. 
Jackson is board certified in pediatrics and pediatric gastroenterology and nutrition. He is an 
Assistant Professor of Pediatrics at the University of Utah School of Medicine, and Medical 
Director of Nutrition Support Services at Primary Children's Hospital. 
Dr. Jackson testified that growth hormone for short bowel syndrome is being used by a 
number of reputable physicians in the United States. He testified that it was controversial, but 
it had promise. 
Dr. Jackson testified that growth hormone is commonly used in many children to treat short 
stature, and since Medicaid covers the drug for that use, it should also cover its usage for 
short bowel syndrome, which he believes has a "higher indication." 
Dr. Jackson made compelling arguments for the medical necessity of using growth hormone 
for Markelle. He testified that he thought that use of growth hormone in this case would be a 
cost effective approach when compared to the potential cost of lifetime parental nutrition or 
liver transplantation, both of which could result from small bowel syndrome. He testified 
that more conservative approaches to treat Markelle were not successful, and as her treating 
physician, he had weighted the pluses and minuses of using the growth hormone. 
Dr. Jackson testified that the impetus for trying the growth hormone was the fact that Markelle 
was showing signs of accelerated liver disease. Upon cross examination, John C. Hylen, 
M.D., and Physician Consultant for DHCF asked Dr. Jackson if he could provide 
documentation of whether or not Markelle's liver function had normalized as a result of 
receiving the growth hormone. Dr. Jackson replied that he did not know why her liver 
functions had improved, but he thought that it had normalized "independent of growth 
hormone." He testified that Markelle had improved after receiving growth hormone, but that 
improvement could also have come from the maturation process and the oral feedings Markelle 
has recently begun to tolerate. 
Dr. Jackson conceded that the use of growth hormone for short bowel syndrome is an area 
where there is active work and controversy, and, "The indications are not in your code for 
using it this way." 
As the expert witness for the moving party, the burden of proof was on Dr. Jackson to prove 
by the preponderance of the evidence that the growth hormone should be covered. Despite his 
convincing testimony regarding the medical necessity of using the drug for Markelle, he was 
not able to overcome DHCF's evidence that the use of growth hormone to treat short bowel 
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syndrome is an off-label usage of the drug, and it has not yet been proven to be effective for 
that usage. Although treatment of short bowel syndrome with growth hormone might be more 
highly indicated than its usage for children of short stature, the law prohibits the use of 
experimental treatments, and Dr. Jackson's testimony clearly indicated that the use of growth 
hormone to treat short bowel syndrome was not "widely utilized as a standard medical 
practice," and therefore meets the criteria for an "experimental procedure." 
RECOMMENDED AGENCY ACTION 
I recommend that DHCF's action be UPHELD. 
RIGHT TO REVIEW 
This Recommended Decision will be automatically reviewed by the Department of Health, 
Division of Health Care Financing, prior to its release. Both the Recommended Decision and 
a Final Agency Action, which represent the results of that review, will be released 
simultaneously by the Department of Health, Division of Health Care Financing. 
DATED this 7 day of January 1998 
Ma*g£fct J. Cttrk 
Administrative Law Judge 
The following exhibits were admitted into evidence: 
RESPONDENT'S EXHIBIT 1: Off-Label Drug Policy 
PETITIONER'S EXHIBIT 1: Medical Literature Regarding Short Bowel Syndrome and 
Growth Hormone 
PETITIONER'S EXHIBIT 2: Billing Records for Markelle 
No: 97-209-11 
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the foregoing FINAL AGENCY ORDER AND RECOMMENDED DECISION, to the following parties: 
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SALT LAKE CITY, UTAH 84113-1100 
EVY SMITH, PEDIATRIC CONTINUUM CARE MANAGER 
IHC ACCESS 
MEMORIAL CLINIC 
20TH SOUTH 900 EAST 
SALT LAKE CITY, UTAH 84105 
JULIE RICH 
IHC HOME CARE 
MCKAY-DEE HOSPITAL CENTER 
P. O. BOX 9370 
OGDEN, UTAH 84409-9980 
INTER-DEPARTMENTAL MAIL 
STEVE GATZEMEJER 
HEALTH PROGRAM MANAGER 
COVERAGE & REIMBURSEMENT POLICY 
DIVISION OF HEALTH CARE FINANCING 
UTAH DEPARTMENT OF HEALTH 
DR. JOHN HYLEN 
COVERAGE & REIMBURSEMENT POLICY 
DIVISION OF HEALTH CARE FINANCING 
UTAH DEPARTMENT OF HEALTH 
PENNI NAHLEY 
COVERAGE & REIMBURSEMENT POLICY 
DIVISION OF HEALTH CARE FINANCING 
UTAH DEPARTMENT OF HEALTH 
DUANE PARKE 
COVERAGE & REIMBURSEMENT POLICY 
DIVISION OF HEALTH CARE FINANCING 
UTAH DEPARTMENT OF HEALTH 
MICHAEL DEILY, DIRECTOR 
DIVISION OF HEALTH CARE FINANCING 
UTAH DEPARTMENT OF HEALTH 
CHRIS SMITH 
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Note 2 
When state voluntarily elects to participate m State and federal regulations arbitrarily and1 
Medicaid program, it must comply with require- capriciously limited to $1,500 the automobile ele-
ments of the Act and applicable regulations. elusion m calculating family resources for pur-
& ? J ; ^ £ t l H ^ d W * ^ Poses of eligibility for Aid to Families with Idaho 1991,813 P.2d 345,120 Idaho d. Dependent Children (AFDC) and Medicaid in 
3. Eligibility that reason initially offered for automobile asset 
Omnibus Budget Reconciliation Act does not limitation, in allowing recipients to retain pos* 
prevent otherwise eligible pregnant women who session of a car, could no longer provide rational 
are not permanently residing in this country basis for the regulation in light of inflation, even 
under color of Uw (PRUCOL) from receiving though Congress did not mandate review to 
M^d ^^red j ^ ^ ^ ^ where ^r ^mt for mflation Hazard v g ^ ^ 
^ U ^ ^ c t ^ ^ l i ^ t ' G ^
 S J « « F % U » » - l l : 
CA2 (NT.) 1992.965 F2A1206. F** 899-
§ 1396a. State plans for medical assistance 
(a) Contents 
A State plan for medical assistance must— 
(1) provide that it shall be in effect in all political subdivisions of the State, and, if 
administered by them, be mandatory upon them; 
(2) provide for financial participation by the State equal to not less than 40 per 
centum of the non-Federal share of the expenditures under the plan with respect to 
which payments under section 1396b of this title are authorized by this subchapter; 
and, effective July 1, 1969, provide for financial participation by the State equal to 
all of such non-Federal share or provide for distribution of funds from Federal or 
State sources, for carrying out the State plan, on an equalization or other basis 
which will assure that the lack of adequate funds from local sources will not result 
in lowering the amount, duration, scope, or quality of care and services available 
under the plan; 
(3) provide for granting an opportunity for a fair hearing before the State agency 
to any individual whose claim for medical assistance under the plan is denied or is 
not acted upon with reasonable promptness; 
(4) provide (A) such methods of administration (including methods relating to the 
establishment and maintenance of personnel standards on a merit basis, except that 
the Secretary shall exercise no authority with respect to the selection, tenure of 
office, and compensation of any individual employed in accordance with such 
methods, and including provision for utilization of professional medical personnel in 
the administration and, where administered locally, supervision of administration of 
the plan) as are found by the Secretary to be necessary for the proper and efficient 
operation of the plan, (B) for the training and effective use of paid subprofessionai 
staff, with particular emphasis on the full-time or part-time employment of recipi-
ents and other persons of low income, as community service aides, in the adminis-
tration of the plan and for the use of nonpaid or partially paid volunteers in a social 
service volunteer program in providing services to applicants and recipients and in 
assisting any advisory committees established by the State agency, and (C) that 
each State or local officer or employee who is responsible for the expenditure of 
substantial amounts of funds under the State plan, each individual who formerly 
was such an officer or employee, and each partner of such an officer or employee 
shall be prohibited from committing any act, in relation to any activity under the 
plan, the commission of which, in connection with any activity concerning the United 
States Government, by an officer or employee of the United States Government, an 
individual who was such an officer or employee, or a partner of such an officer or 
employee is prohibited by section 207 or 208 of Title 18; 
(5) either provide for the establishment or designation of a single State agency to 
administer or to supervise the administration of the plan; or provide for the 
establishment or designation of a single State agency to administer or to supervise 
the administration of the plan, except that the determination of eligibility for 
medical assistance under the plan shall be made by the State or local agency 
administering the State plan approved under subchapter I or XVI of this chapter 
(insofar as it relates to the aged) if the State is eligible to participate in the State 
plan program established under subchapter XVI of this chapter, or by the agency 
or agencies ad^ninistering the supplemental security income program established 
under subchapter XVI or the State plan approved under part A of subchapter IV of 
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this chapter if the State is not eligible to participate in the State plan program 
established under subchapter XVI of this chapter; 
(6) provide that the State agency will make such reports, in such form and 
containing such information, as the Secretary may from time to time require, and 
comply with such provisions as the Secretary may from time to time find necessary 
to assure the correctness and verification of such reports; 
(7) provide 3afeguards which restrict the use or disclosure of information con-
cerning applicants and recipients to purposes directly connected with the adminis-
tration of the plan; 
(8) provide that all individuals wishing to make application for medical assistance 
under the plan shall have opportunity to do so, and that such assistance shall be 
furnished with reasonable promptness to all eligible individuals; 
(9) provide— 
(A) that the State health agency, or other appropriate State medical agency 
(whichever is utilized by the Secretary for the purpose specified in the first 
sentence of section 1395aa(a) of this title), shall be responsible for establishing 
and mamtaining health standards for private or public institutions in which 
recipients of medical assistance under the plan may receive care or services, 
(B) for the establishment or designation of a State authority or authorities 
which shall be responsible for establishing and mamtaining standards, other 
than those relating to health, for such institutions, and 
(C) that any laboratory services paid for under such plan must be provided 
by a laboratory which meets the applicable requirements of section 1395x(e)(9) 
of this title or paragraphs (13) and (14)l of section 1395x(s) of this title, or, in 
the case of a laboratory which is in a rural health clinic, of section 
1395x(aaX2)(G) of this title; 
(10) provide— 
(A) for making medical assistance available, including at least the care and 
services listed in paragraphs (1) through (5), (17) and (21) of section 1396d(a) of 
this title, to— 
(i) all individuals— 
(I) who are receiving aid or assistance under any plan of the State 
approved under subchapter I, X, XIV, or XVI of this chapter, or part 
A or part E of subchapter IV of this chapter (including individuals 
eligible under this subchapter by reason of section 602(a)(37), 606(h), 
or 673(b) of this title, or considered by the State to be receiving such 
aid as authorized under section 682(e)(6) of this title), 
(II) with respect to whom supplemental security income benefits 
are being paid under subchapter XVI of this chapter or who are 
qualified severely impaired individuals (as defined in section 1396d(q) 
of this title), 
(HI) who are qualified pregnant women or children as defined in 
section 1396d(n) of this title, 
(IV) who are described in subparagraph (A) or (B) of subsection 
(I )(1) of this section and whose family income does not exceed the 
minimum income level the State is required to establish under subsec-
tion (I )(2)(A) of this section for such a family;1 
(V) who are qualified family members as defined in section 
1396d(m)(l) of this title;1 
(VI) who are described in subparagraph (C) of subsection (I )(1) of 
this section and whose family income does not exceed the income level 
the State is required to establish under subsection (I )(2)(B) of this 
section for such a family, or 
(VII) who are described in subparagraph (D) of subsection (Z )(1) of 
this section and whose family income does not exceed the income level 
the State is required to establish under subsection (I )(2)(C) of this 
section for such a family; 
(ii) at the option of the State, to any group or groups of individuals 
described in section 1396d(a) of this title (or, in the case of individuals 
described in section 1396d(a)(i) of this title, to any reasonable categories of 
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Note 32 
Undocumented alien whose chronic alcoholism 
had so compromised her liver and central ner-
vous system before she appeared at hospital 
that lack of immediate medical attention would 
not have resulted in more serious jeopardy to 
her health did not possess "emergency medical 
condition," such that would be eligible for assis-
tance under Medical Care and Assistance Pro-
gram. Norwood Hosp. v. Commissioner of Pub-
lic Welfare, Mass.1994, 627 N.E.2d 914, 417 
Mass. 64. 
Statute which states that Medicaid payment 
shall be made for care and services to alien 
who is not lawfully admitted for permanent 
residence, only if such care and services are 
necessary for treatment of emergency medical 
condition and alien otherwise meets eligibility 
requirements for medical assistance of a State 
plan, is exception to rule that prohibits Medic-
aid not only to nonresident aliens, but also to 
resident aliens whose residency is unlawful; it 
does not affect status of nonresident aliens. 
Salem Hosp. v. Commiasioner of Public Wel-
fare, Mass. 1991. 574 N.E.2d 385, 410 Mass. 
625. 
33. Relief from judgment or order 
State of New York was entitled to relief from 
consent decree establishing Medicaid pharmacy 
reimbursement methodology, where Secretary 
of Health and Human Services had subsequently 
established reimbursement cap on Medicaid re-
imbursements for certain denned medications, 
creating risk that state would lose federal finan-
cial participation if it did not comply. Pharma-
ceutical Soc of the State of New York, Inc. v. 
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Cuomo, S.D.N.Y.1991, 774 F.Supp. 826, affirmed 
in part, reversed in part 981 F.2d 632. 
34. Similarly situated individuals—General-
ly 
Under federal Medicaid statute pursuant to 
which federal payment for organ transplant will 
not be made unless state plan provides for writ-
ten standards and such standards provide that 
similarly situated individuals are treated alike, 
"similarly situated" means all patients who can 
be treated effectively by same organ transplant 
procedure. Salgado v. Kirschner, Ariz.1994,878 
P.2d 659, 179 Ariz. 301, certiorari denied 115 
a c t 1102,130 L.EcL2d 1069. 
35. Other necessary services 
Provision of state Medicaid plan that allowed 
state to deny life-sustaining over transplant cov-
erage to otherwise eligible Medicaid recipient 
solely because she was over 21 years of age. 
violated requirement of federal Medicaid statute 
that state standards for organ transplants treat 
similarly situated individuals alike; recipient 
was within class of all patients who could be 
treated effectively by liver transplant, and catch-
all provision of Medicaid statute dealing with 
federal early and periodic health screening diag-
nostic and treatment services (EPSDT) did not, 
as state apparently contended, define substan-
tive scope of medically necessary procedures 
and draw distinction for such procedures be-
tween children and adults. Salgado v. Kir-
schner, Ariz.1994, 878 PJ2d 659, 179 Ariz. 301, 
certiorari denied 115 S.Ct 1102, 130 L.EA2d 
1069. 
§ 1396c. Operation of State plans 
NOTES OF DECISIONS 
9. Hearing 
Decision of Secretary of Health and Human 
Services (HHS) as to whether to hold hearing on 
compliance with federal Medicaid requirements 
is discretionary. Phoenix Baptist Hosp. and 
Medical Center, Inc. v. UJS., CA9 (Ariz.) 1991, 
937F.2d452. 
§ 1396d. Definitions 
For purposes of this subchapter— 
(a) Medical assistance 
The term 'inedical assistance" means payment, of part or all of the cost of the 
following care and services (if provided in or after the third month before the month in 
which the recipient makes application for assistance or, in the case of medicare cost-
sharing with respect to a qualified medicare beneficiary described in subsection (p)(l) of 
this section, if provided after the month in which the individual becomes such a 
beneficiary) for individuals, and, with respect to physicians, or dentists' services, at the 
option of the State, to individuals (other than individuals with respect to whom there is 
being paid, or who are eligible, or would be eligible if they were not in a medical 
institution, to have paid with respect to them a State supplementary payment and are 
eligible for medical assistance equal in amount, duration, and scope to the medical 
assistance made available to individuals described in section 1396a(a)(10)(A) of this title) 
not receiving aid or assistance under any plan of tfie State approved under subchapter I, 
X, XIV, or XVI, or part A of subchapter IV, and with respect to whom supplemental 
security income benefits are not being paid under subchapter XVI of this chapter, who 
are— 
(i) under the age of 21, or, at the option of the State, under the age of 20, 19, or 
18 as the State may choose, 
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(ii) relatives specified in section 606(b)(1) of this title with whom a child is living 
if such child is (or would, if needy, be) a dependent child under part A of subchapter 
IV of this chapter, 
(iii) 65 years of age or older, 
(iv) blind, with respect to States eligible to participate in the State plan program 
established under subchapter XVI of this chapter, 
(v) 18 years of age or older and permanently and totally disabled, with respect to 
States eligible to participate in the State plan program established under subchap-
ter XVI of this chapter, 
(vi) persons essential (as described in the second sentence of this subsection) to 
individuals receiving aid or assistance under State plans approved under subchapter 
I, X, XTV, or XVI of this chapter, 
(vii) blind or disabled as defined in section 1382c of this title, with respect to 
States not eligible to participate in the State plan program established under 
subchapter XVI of this chapter, 
(viii) pregnant women, 
(ix) individuals provided extended benefits under section 1396r-6 of this title, 
(x) individuals described in section 1396a(u)(l) of this title, or 
(xi) individuals described in section 1396a(z)(l) of this title, 
but whose income and resources are insufficient to meet all of such cost— 
(1) inpatient hospital services (other than services in an institution for mental 
diseases); 
(2) (A) outpatient hospital services, (B) consistent with State law permitting such 
services, rural health clinic services (as defined in subsection (I )(1) of this section) 
and any other ambulatory services which are offered by a rural health clinic (as 
defined in subsection (I )(1) of this section) and which are otherwise included in the 
plan, and (C) Federally-qualified health center services (as defined in subsection 
(I )(2) of this section) and any other ambulatory services offered by a Federally-
qualified health center and which are otherwise included in the plan; 
(3) other laboratory and X-ray services; 
(4) (A) nursing facility services (other than services in an institution for mental 
diseases) for individuals 21 years of age or older; (B) early and periodic screening, 
diagnostic, and treatment services (as defined in subsection (r) of this section) for 
individuals who are eligible under the plan and are under the age of 21; and (C) 
family planning services and supplies furnished (directly or under arrangements 
with others) to individuals of child-bearing age (including minors who can be 
considered to be sexually active) who are eligible under the State plan and who 
desire such services and supplies; 
(5) (A) physicians' services furnished by a physician (as defined in se<!tion 
1395x(r)(l) of this title), whether furnished in the office, the patient's home, a 
hospital, or a nursing facility, or elsewhere, and (B) medical and surgical services 
furnished by a dentist (described in section 1395x(r)(2) of this title) to the extent 
such services may be performed under State law either by a doctor of medicine or 
by a doctor of dental surgery or dental medicine and would be described in clause 
(A) if furnished by a physician (as defined in section 1395x(r)(l) of this title); 
(6) medical care, or any other type of remedial care recognized under State law, 
furnished by licensed practitioners within the scope of their practice as defined by 
State law; 
(7) home health care services; 
(8) private duty nursing services; 
(9) clinic services furnished by or under the direction of a physician, without 
regard to whether the clinic itself is administered by a physician, including such 
services furnished outside the clinic by clinic personnel to an eligible individual who 
does not reside in a permanent dwelling or does not have a fixed home or mailing 
address; 
(10) dental services; 
(11) physical therapy and related services; 
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(12) prescribed drugs, dentures, and prosthetic devices; and eyeglasses pre-
scribed by a physician skilled in diseases of the eye or by an optometrist, whichever 
the individual may select; 
(13) other diagnostic, screening, preventive, and rehabilitative services, including 
any medical or remedial services (provided in a facility, a home, or other setting) 
recommended by a physician or other licensed practitioner of the healing arts 
within the scope of their practice under State law, for the maximum reduction of 
physical or mental disability and restoration of an individual to the best possible 
functional level; 
(14) inpatient hospital services and nursing facility services for individuals 66 
years of age or o"er in an institution for mental diseases; 
(15) services in an intermediate care facility for the mentally retarded (other 
than in an institution for mental diseases) for individuals who are determined, in 
accordance*with section 1396a(a)(31)(A) of this title, to be in need of such care; 
(16) effective January 1,1973, inpatient psychiatric hospital services for individu-
als under age 21, as defined in subsection (h) of this section; 
(17) services furnished by a nurse-midwife (as defined in section 1395x(gg) of this 
title) which the nurse-midwife is legally authorized to perform under State law (or 
the State regulatory mechanism provided by State law), whether or not the nurse-
midwife is under the supervision of, or associated with, a physician or other health 
care provider, and without regard to whether or not the services are performed in 
the area of management of the care of mothers and babies throughout the 
maternity cycle; 
(18) hospice care (as defined in subsection (o) of this section); 
(19) case-management services (as defined in section 1396n(g)(2) of this title) and 
TB-related services described in section 1396a(z)(2)(F) of this title; 
(20) respiratory care services (as defined in section 1396a(e)(9)(C) of this title); 
(21) services furnished by a certified pediatric nurse practitioner or certified 
family nurse practitioner (as defined by the Secretary) which the certified pediatric 
nurse practitioner or certified family nurse practitioner is legally authorized to 
perform under State law (or the State regulatory mechanism provided by State 
law), whether or not the certified pediatric nurse practitioner or certified family 
nurse practitioner is under the supervision of, or associated with, a physician or 
other health care provider; 
(22) home and community care (to the extent allowed and as defined in section 
1396t of this title) for functionally disabled elderly individuals; and 
(23) community supported living arrangements services (to the extent allowed 
and as defined in section 1396u of this title); 
(24) personal care services furnished to an individual who is not an inpatient or 
resident of a hospital, nursing facility, intermediate care facility for the mentally 
retarded, or institution for mental disease that are (A) authorized for the individual 
by a physician in accordance with a plan of treatment or (at the option of the State) 
otherwise authorized for the individual in accordance with a service plan approved 
by the State, (B) provided by an individual who is qualified to provide such services 
and who is not a member of the individual's family, and (C) furnished in a home or 
other location; and 
(25) any other medical care, and any other type of remedial care recognized 
under State law, specified by the Secretary. 
except as otherwise provided in paragraph (16), such term does not include— 
(A) any such payments with respect to care or services for any individual who is 
an inmate of a public institution (except as a patient in a medical institution); or 
(B) any such payments with respect to care or services for any individual who 
has not attained 65 years of age and who is a patient in an institution for mental 
diseases. 
For purposes of clause (vi) of the preceding sentence, a person shall be considered 
essential to another individual if such person is the spouse of and is living with such 
individual, the needs of such person are taken into account in determining the amount of 
aid or assistance furnished to such individual (under a State plan approved under 
subchapter I, X, XTV, or XVI of this chapter), and such person is determined, under 
such a State plan, to be essential to the well-being of such individual. The payment 
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In the case of any State which is providing medical assistance to its residents under a 
waiver granted under section 1315 of this title, the Secretary shall require the State to 
meet the requirement of section 1396a(a)(10)(E) of this title in the same manner as the 
State would be required to meet such requirement if the State had in effect a plan 
approved under this subchapter. 
(q) Qualified severely impaired individual 
The term "qualified severely impaired individual" means an individual under age 65— 
(1) who for the month preceding the first month to which this subsection applies 
to such individual— 
(A) receded (i) a payment of supplemental security income benefits under 
section 1382(b) of this title on the basis of blindness or disability, (ii) a 
supplementary payment under section 1382e of this title or under section 212 of 
Public Law 93-66 on such basis, (iii) a payment of monthly benefits under 
section 1382h(a) of this title, or (iv) a supplementary payment under section 
1382e(c)(3) of this tide, and 
(B) was eligible for medical assistance under the State plan approved under 
this subchapter; and 
(2) with respect to whom the Commissioner of Social Security determines that— 
(A) the individual continues to be blind or continues to have the disabling 
physical or mental impairment on the basis of which he was found to be under 
a disability and, except for his earnings, continues to meet all non-disability-
related requirements for eligibility for benefits under subchapter XVI of this 
chapter, 
(B) the income of such individual would not, except for his earnings, be 
equal to or in excess of the amount which would cause him to be ineligible for 
payments under section 1382(b) of this title (if he were otherwise eligible for 
such payments), 
(C) the lack of eligibility for benefits under this subchapter would seriously 
inhibit his ability to continue or obtain employment, and 
(D) the individual's earnings are not sufficient to allow him to provide for 
himself a reasonable equivalent of the benefits under subchapter XVI of this 
chapter (including any federally administered State supplementary payments)* 
this subchapter, and publicly funded attendant care services (including personal 
care assistance) that would be available to him in the absence of such earnings. 
In the case of an individual who is eligible for medical assistance pursuant to section 
1382h(b) of this title in June, 1987, the individual shall be a qualified severely impaired 
individual for so long as such individual meets the requirements of paragraph (2).' 
(r) Early and periodic screening, diagnostic, and treatment services 
The term "early and periodic screening, diagnostic, and treatment services" means the 
following items and services: 
(1) Screening services— 
(A) which are provided— 
(i) at intervals which meet reasonable standards of medical and dental 
practice, as determined by the State after consultation with recognized 
medical and dental organizations involved in child health care and, with 
respect to immunizations under subparagraph (B)(iii), in accordance with 
the schedule referred to in section 1396s(c)(2)(B)(i) of this title for pediatric 
vaccines, and 
(ii) at such other intervals, indicated as medically necessary, to deter-
mine the existence of certain physical or mental illnesses or conditions; 
and 
(B) which shall at a niinimum include— 
(i) a comprehensive health and developmental history (including assess-
ment of both physical and mental health development), 
(ii) a comprehensive unclothed physical exam, 
(iii) appropriate immunizations (according to the schedule referred to in 
PUBLIC HEALTH AND WELFARE 42 § 1396d 
(iv) laboratory tests (including lead blood level assessment appropriate 
for age and risk factors), and 
(v) health education (including anticipatory guidance). 
(2) Vision services— 
(A) which are provided— 
(i) at intervals which meet reasonable standards of medical practice, as 
determined by the State after consultation with recognized medical organi-
zations involved in child health care, and 
(ii) at such other intervals, indicated as medically necessary, to deter-
mine th? existence of a suspected illness or condition; and 
(B) which shall at a minimum include diagnosis and treatment for defects in 
vision, including eyeglasses. 
(3) Dental services— 
(A) which are provided— 
(i) at intervals which meet reasonable standards of dental practice, as 
determined by the State after consultation with recognized dental organi-
zations involved in child health care, and 
(ii) at such other intervals, indicated as medically necessary, to deter-
mine the existence of a suspected illness or condition; and 
(B) which shall at a minimum include relief of pain and infections, restora-
tion of teeth, and maintenance of dental health. 
(4) Hearing services— 
(A) which are provided— 
(i) at intervals which meet reasonable standards of medical practice, as 
determined by the State after consultation with recognized medical organi-
zations involved in child health care, and 
(ii) at such other intervals, indicated as medically necessary, to deter-
mine the existence of a suspected illness or condition; and 
(B) which shall at a minimum include diagnosis and treatment for defects in 
hearing, including hearing aids. 
(5) Such other necessary health care, diagnostic services, treatment, and other 
measures described in subsection (a) of this section to correct or ameliorate defects 
and physical and mental illnesses and conditions discovered by the screening 
services, whether or not such services are covered under the State plan. 
Nothing in this subchapter shall be construed as limiting providers of early and periodic 
screening, diagnostic, and treatment services to providers who are qualified to provide 
all of the items and services described in the previous sentence or as preventing a 
provider that is qualified under the plan to furnish one or more (but not all) of such 
items or services from being qualified to provide such items and services as part of early 
and periodic screening, diagnostic, and treatment services. The Secretary shall, not 
later than July 1, 1990, and every 12 months thereafter, develop and set annual 
participation goals for each State for participation of individuals who are covered under 
the State plan under this subchapter in early and periodic screening, diagnostic, and 
treatment services. 
(s) Qualified disabled and working individual 
The term "qualified disabled and working individual" means an individual— 
(1) who is entitled to enroll for hospital insurance benefits under part A of 
subchapter XVIII of this chapter under section 1395i-2a of this title; 
(2) whose income (as determined under section 1382a of this title for purposes of 
the supplemental security income program) does not exceed 200 percent of the 
official poverty line (as defined by the Office of Management and Budget and 
revised annually in accordance with section 9902(2) of this title) applicable to a 
family of the size involved; 
(3) whose resources (as determined under section 1382b of this title for purposes 
of the supplemental security income program) do not exceed twice the maximum 
amount of resources that an individual or a couple (in the case of an individual with 
a spouse) may have and obtain benefits for supplemental security income benefits 
under subchapter XVI of this chapter; and 
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(c) mandatory outpatient, rather than inpatient, surgery in appropriate 
cases; 
(d) second surgical opinions; 
(e) procedures for encouraging the use of outpatient services; 
(f) coordination of benefits; and 
(g) review and exclusion of providers who are not cost effective or who 
have abused the Medicaid program, in accordance with the procedures and 
provisions of federal law and regulation. 
(3) The director of the division shall periodically assess the cost effective-
ness and health impUcations of the existing Medicaid program, and consider 
alternative approaches to the provision of covered health and medical services 
through the Medicaid program, in order to reduce unnecessary or unreason-
able utilization. 
History: C. 1953, 26-18-2.3, enacted by L. Social Security Act, cited in Subsection (1), is 
1988, ch. 21, § 4. compiled as 42 U.S.C. § 1396 et seq. 
Federal Law. — Title XIX of the federal 
NOTES TO DECISIONS 
ANALYSIS 
Discretion of division. 
Resource preservation. 
Discretion of division. 
The legislature has, by virtue of Subsection 
(1), explicitly granted the Division of Health 
Care Financing (DHCF) discretion to establish 
criteria concerning medical reimbursement. 
When a hospital failed to submit a physician 
certification before admission of a Medicaid-
eligible patient and never obtained physician 
recertification at any time during the patient's 
three-month stay in acute care, the DHCF 
reasonably denied reimbursement to the hospi-
tal. South Davis Community Hosp. v. Depart-
ment of Health, 860 R2d 979 (Utah Ct. App. 
1994). 
26-18-3. Administration of Medicaid program by depart-
ment — Disciplinary measures and sanctions — 
Funds collected. 
(1) The department shall be the single state agency responsible for the 
administration of the Medicaid program in connection with the United States 
Department of Health and Human Services pursuant to Title XIX of the Social 
Security Act. 
(2) The department shall develop implementing policy in conformity with 
this chapter, the requirements of Title XIX, and applicable ^ federal regulations. 
(3) The department may, in its discretion, contract with the Department of 
Human Services or other qualified agencies for services in connection with the 
administration of the Medicaid program, including but not limited to the 
determination of the eligibility of individuals for the program, recovery of 
overpayments, and enforcement of fraud and abuse laws to the extent 
permitted by law and quality control services. 
Resource preservation. 
Utah does not have a "resource spend down* 
provision in its Medicaid plan, nor any state-
ment of policy expressing a desire to preserve 
the resources of potential beneficiaries. Utah's 
statutes seem to evince a legislative concern for 
economy and efficiency in the Medicaid pro-
gram, not the preservation of applicants' assets. 
Allen v. Utah Dep't of Health, 829 R2d 122 
(Utah Ct. App. 1992), affd, 850 P.2d 1267 (Utah 
1993). 
It is not unreasonable for the division to 
apply a fixed asset limit forbidding persons to 
adjust their assets to become eligible for Medi-
caid benefits. Allen v. Utah Dep't of Health, 850 
P.2d 1267 (Utah 1993). 
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(4) The department shall provide, by rule, disciplinary measures and 
sanctions for Medicaid providers who fail to comply with the rules and 
procedures of the program, provided that sanctions imposed administratively 
may not extend beyond: 
(a) termination from the program; 
(b) recovery of claim reimbursements incorrectly paid; and 
(c) those specified in Section 1919 of Title XIX of the federal Social 
Security Act. 
(5) Funds collected as a result of a sanction imposed under Section 1919 of 
Title XIX of the federal Social Security Act shall be deposited in the General 
Fund as nonlapsing dedicated credits to be used by the division in accordance 
with the requirements of that section. 
History: C. 1953, 26-18-3, enacted by L. Social Security Act is compiled as 42 U.S.C. 
1981, ch. 126, § 17; 1988, ch. 21, § 5; 1989, § 1396 et seq. Section 1919 of Title XDC is 42 
ch. 165, § 1; 1990, ch. 183, § 9. U.S.C. § 1396r. 
Federal Law. — Title XDC of the federal 
NOTES TO DECISIONS 
ANALYSIS ent. By these standards, a child's temporary 
absence from home will not qualify him or her 
_ ,
 r , for benefits independent of parental resources. 
Temporary absence from home. Bleazard v. Utah Dep't of Health Care Fin., 861 
Children. 
—Tempoi 
Federal law. 
Children 
P.2d 1048 (Utah Ct. App. 1993). 
Federal law. 
—Temporary absence from home. Medicaid is not intended to provide benefits 
Federal law requires that eligibility for "med- to the medically needy in circumstances where 
ically needy" Medicaid benefits be determined financial need is not fully demonstrated and 
consistently with the methods of the Aid to where benefits would be inconsistent with re-
Families with Dependent Children program quirements for the higher priority classification 
and the Supplemental Security Income Pro- of the categorically needy. Bleazard v. Utah 
gram. In the case of an unemancipated child, Dep't of Health Care Fin., 861 P.2d 1048 (Utah 
resources include those available from a par- Ct. App. 1993). 
COLLATERAL REFERENCES 
C.J.S. — 81 C.J.S. Social Security and Public Key Numbers. — Social Security and Public 
Welfare § 126. Welfare «=» 241 et seq. 
26-18-3.1. Medicaid expans ion . 
(1) The purpose of this section is to expand the coverage of the Medicaid 
program to persons who are in categories traditionally not served by that 
program. 
(2) Within appropriations from the Legislature, the department may amend 
the state plan for medical assistance to provide for eligibility for Medicaid: 
(a) on or after July 1, 1994, for children 12 to 17 years old who live in 
households below the federal poverty income guideline; and 
(b) on or after July 1, 1995, for persons who have incomes below the 
federal poverty income guideline and who are aged, blind, or disabled. 
(3) (a) Within appropriations from the Legislature, on or after July 1,1996, 
the Medicaid program may provide for eligibility for persons who have 
incomes below the federal poverty income guideline. 
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26-18-4. Department standards for eligibility under Medi-
caid — Funds for abortions. 
(1) The department may develop standards and administer policies relating 
to eligibility under the Medicaid program. An applicant receiving Medicaid 
assistance may be limited to particular types of care or services or to payment 
of part or all costs of care determined to be medically necessary. 
(2) The department shall not provide any funds for medical, hospital, or 
other medical expenditures or medical services to otherwise eligible persons 
where the purpose of the assistance is to perform an abortion, unless the life 
of the mother would be endangered if an abortion were not performed. 
(3) Any employee of the department who authorizes payment for an abor-
tion contrary to the provisions of this section is guilty of a class B misdemeanor 
and subject to forfeiture of office. 
(4) Any person or organization that, under the guise of other medical 
treatment, provides an abortion under auspices of the Medicaid program is 
guilty of a third degree felony and subject to forfeiture of license to practice 
medicine or authority to provide medical services and treatment. 
History: C. 1953, 26-18-4, enacted by L. nies, §§ 76-3-201, 76-3-203. 76-3-301. 
1981, ch. 126, § 17; 1987, ch. 181, § 2. Sentencing for misdemeanors, §§ 76-3-201, 
Cross-References. — Sentencing for felo- 76-3-204, 76-3-301. 
NOTES TO DECISIONS 
ANALYSIS Standards for eligibility. 
Federal law. —Temporary absence from home. 
Standards for eligibility. Federal law requires that eligibility for "med-
—Temporary absence from home. ically needy" Medicaid benefits be determined 
consistently with the Aid to Families with De-
Federal law. pendent Children program and the Supplemen-
Medicaid is not intended to provide benefits tal Security Income Program. In the case of an 
to the medically needy in circumstances where unemancipated child, resources include those 
financial need is not fully demonstrated and available from a parent. By these standards, a 
where benefits would be inconsistent with re- child's temporary absence from home will not 
quirements for the higher priority classification qualify him or her for benefits independent of 
of the categorically needy. Bleazard v. Utah parental resources. Bleazard v. Utah Dep't of 
Dep't of Health Care Fin., 861 R2d 1048 (Utah Health Care Fin., 861 P.2d 1048 (Utah Ct. App. 
Ct. App. 1993). 1993). 
26-18-5. Contracts for provision of medical services — 
Federal provisions modifying department rules 
— Compliance with Social Security Act. 
(1) The department may contract with other public or private agencies to 
purchase or provide medical services in connection with the programs of the 
division. Where these programs are used by other state agencies, contracts 
shall provide that other state agencies transfer the state matching funds to the 
department in amounts sufficient to satisfy needs of the specified program. 
(2) All contracts for the provision or purchase of medical services shall be 
established on the basis of the state's fiscal year and shall remain uniform 
during the fiscal year insofar as possible. Contract terms shall include 
provisions for maintenance, administration, and service costs. 
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another state, to the same extent that Medicaid is 
furnished to residents in the state. 
R414-1-19. R e t r o a c t i v e Coverage . 
Individuals are entitled to Medicaid services un-
der the plan during the three months preceding the 
month of application, if they were, or would have 
been, eligible at t ha t time. 
R414-1-20. F r e e d o m of Choice of P r o v i d e r . 
Unless an exception under 42 CFR 431.55 applies, 
any individual eligible under the plan may obtain 
Medicaid services from any institution, pharmacy, 
person, or organization that is qualified to perform 
the services and has entered into a Medicaid pro-
vider contract, including an organization tha t pro-
vides these services or arranges for their availability 
on a prepayment basis. 
R414-1-21. Avai lab i l i ty of P r o g r a m M a n u a l s 
a n d Po l i cy I s s u a n c e s . 
Program manuals and other policy issuances tha t 
affect recipients, providers and the public, including 
the Medicaid agency's rules governing eligibility, 
need and amount of assistance, recipient rights and 
responsibilities, and services offered by the agency 
are maintained in the state office and in each local 
and district office for examination and, upon re-
quest, are available to individuals for review, study, 
or reproduction. All requirements of 42 CFR 431.18 
are met. 
R414-1-22. General Rule Format. 
(1) The following format is used generally 
throughout the rules of the Division. Section head-
ings as indicated and the following general defini-
tions thereunder are for guidance only. The section 
headings are not part of the rule content itself. In 
certain instances, such format may not be appropri-
ate and will not be implemented due to the na ture of 
the subject mat ter of a specific rule. 
(a) Policy Statement. A concise statement as to 
what Medicaid service is covered by the rule. 
(b) Authority. A listing of specific federal s tatutes 
and regulations and state statutes that authorize or 
require the rule. 
(c) Definitions. Definitions that have special 
meaning to the particular rule. 
(d) Client Eligibility. Categories of Medicaid cli-
ents eligible for the service covered by the rule: 
Categorically Needy or Medically Needy or both. 
Conditions precedent to the client's obtaining cover-
age such as age limitations or otherwise. 
(e) Program Access Requirements. Conditions pre-
cedent external to the client's obtaining service such 
as type of certification needed from attending phy-
sician, whether available only in an inpatient set-
ting or otherwise. 
(f) Service Coverage. Detail of specific services 
available under the rule, including limitations such 
as number of procedures in a given period of t ime or 
otherwise. 
(g) Prior Authorization. As necessary, a descrip-
tion of the procedures for obtaining prior authoriza-
tion for services available under the particular rule. 
(h) Other Sections. As necessary under the par-
ticular rule, additional sections may be indicated. 
References: 26-1-5, 26-18-1. 
History: 11559, NSC, 02/15/91; 14034, AMD, 02/08/93. 
NOTES TO DECISIONS 
ANALYSIS 
Compliance with federal law. 
Efficiently and economically operated. 
Spend down. 
Compliance with federal law. 
A reasonable basis existed for the Department to find 
that proposed rates were reasonable and adequate to meet 
the costs of an efficiently and economically operated facility 
as required by federal law: Ninety-three percent of all 
long-term health care facilities in Utah were shown to be 
meeting their costs under the modified flat rate plan, with 
a majority showing a profit. Weber Mem. Care Ctr. v. Utah 
Dep't of Health, 751 P.2d 831 (Utah Ct. App.), cert, denied, 
765 P.2d 1278 (Utah 1988). 
Efficiently and economically operated. 
Setting rates for payment for services that the state 
deems reasonable and adequate and maintaining that an 
"efficiently and economically operated facility" is one that 
ia able to operate at or below that standard ia a proper 
alternative to defining "efficiently and economically oper-
ated." Weber Mem. Care Ctr. v. Utah Dep't of Health, 751 
P.2d 831 (Utah Ct. App.), cert, denied, 765 P.2d 1278 (Utah 
1988). 
Since the modified flat rate implicitly defines an effi-
ciently and economically operated facility, evidence of a 
nursing home's costs and operation was irrelevant and, 
therefore, inadmissible in an action challenging the modi-
fied rate plan. Weber Mem. Care Ctr. v. Utah Dep't of 
Health, 751 P.2d 831 (Utah Ct. App.), cert, denied, 765 P.2d 
1278 (Utah 1988). 
Spend down. 
Federal Medicaid regulations did not require states to 
allow an applicant to spend down excess resources by 
applying them to outstanding medical bills, thereby becom-
ing eligible for Medicaid. (Former R810-304-411, R455-1 to 
R455-48.) Allen v. Utah Dep't of Health, 829 P.2d 122 (Utah 
Ct. App. 1992), afTd, 850 P.2d 1267 (Utah 1993). 
R414-1A. Medicaid Pol icy for Experimen-
tal or Unproven Medical Pract ices . 
R414-1A-100. Authority and Purpose. 
R414-1A-200. Definitions. 
R414-1A-300. Policy. 
R414-1A-100. Authority and Purpose . 
(1) This rule establishes Medicaid payment policy 
for experimental or unproven medical practices. 
(2) This rule is authorized by Sections 26-1-5, 
26-1-15, and 26-18-6, and by Subsections 26-18-3(2) 
and 26-18-5(4). 
R414-1A-200. Definitions. 
(1) Terms used in this rule are defined in R414-
1-1. 
(2) In addition: 
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(a) "experimental or unproven medical practice" 
means any procedure, medication product, or service 
tha t is: 
(i) not proven to be medically efficacious for a 
given procedure; or 
(ii) performed for or in support of purposes of 
research, experimentation, or testing of new pro-
cesses or products; or 
(iii) both; 
(b) "medically efficacious" means a, medical prac-
tice that : 
(i) has been determined effective and is widely 
utilized as a standard medical practice for specific 
conditions; and 
(ii) has been approved as a covered Medicaid 
service by division staff and physician consultants 
on the basis of medical necessity, as defined in 
R414-13x-l.(5)(a), and in accordance with R414-26-
l.(2)(f); 
(c) "supporting services" means supplies or labo-
ratory, X-ray, physician, pharmacy, therapy, or 
transportation services. 
R414-1A-300. Policy. 
(1) Experimental or unproven medical practices 
are not covered Medicaid services. 
(2) Division staff and physician consultants shall 
estabHsh criteria to determine whether a service or 
procedure is a covered Medicaid service. 
(3) Procedures or services proven to be medically 
efficacious for specific medical conditions may be 
provided as covered Medicaid services only for the 
conditions specified. Such procedures or services are 
not covered for any other conditions or for experi-
mental trials. 
(4) Inpatient or outpatient hospitalization for the 
purpose of receiving services or procedures tha t are 
experimental or medically unproven, or in support of 
such services or procedures, is not a covered Medic-
aid service. However, when such services or proce-
dures are provided incidentally during a hospitaliza-
tion for an otherwise medically necessary and 
appropriate service, only the experimental or un-
proven medical procedures and any supporting ser-
vices specifically identifiable with such services and 
procedures are excluded from payment. 
References: 26-1-5, 26-18-3(2). 
History: 13288, AMD, 10/08/92. 
R414-2A. Inpatient Hospital Services. 
R414-2A-100. Authority and Purpose. 
R414-2A-300. Program Access Requirements. 
R414-2A-400. Services. 
R414-2A-500. Limitations. 
R414-2A-600. Prior Authorization. 
R414-2A-100. Authority and Purpose . 
(1) This rule defines the scope of inpatient hospital 
benefits available for the care and t rea tment of 
Medicaid clients who meet the level of care criteria 
for admission to an acute-care general hospital for 
t reatment of disorders other than mental disease. 
(2) Inpatient hospital services are required under 
Section 1901 et seq. and Section 1905(a)(1) of the 
Social Security Act, and by 42 CFR 440.10 (October 
1, 1991, edition). 
(3) This rule is authorized by Sections 26-1-5, 
26-1-15, and 26-18-6, and by Subsections 26-18*3(2) 
and 26-18-5(3) and (4). 
R414-2A-300. Program Access Requirements . 
(1) Each hospital providing inpatient services 
must have a utilization review plan, as described in 
42 CFR 482.30 (October 1, 1991, edition), which is 
incorporated by reference. 
(2) The attending physician or other practitioner 
of the healing ar ts must sign a physician attestation 
statement tha t meets the requirements of 42 CFR 
412.46 (October 1, 1991, edition), which is incorpo-
rated by reference. 
(3) The attending physician must certify and re-
certify the need for inpatient care as described in 42 
CFR 441.152 and 456.60 (October 1, 1991, edition), 
which are incorporated by reference. 
(4) All hospital admissions are subject to review by 
the department for appropriateness and medical 
necessity as detailed in R414-2A. 
(5) For purposes of reimbursement, the day of 
admission is counted as a full day; the day of 
discharge is not counted. 
(6) When a patient receives SNF-level, ICF-level, 
or other sub-acute care in an acute-care hospital or 
in a hospital with swing-bed approval, payment 
shall be made at the SNF or ICF rate . 
(7) Inpatient hospital psychiatric services are cov-
ered Medicaid services for clients who live in the 
counties identified in Table 1 only when such ser-
vices are coordinated through the contractor identi-
fied for the specified county: 
TABLE 1 
I. Counties: Salt Lake County 
Summit County 
Contractor: Salt Lake Valley Mental Health, 
Salt Lake City, Utah 
II. Counties: Carbon County 
Emery County 
Grand County 
Contractor: Four Corners Community Mental Health 
Center, 
Price, Utah 
HI. Counties: Beaver County 
Garfield County 
Kane County 
Iron County 
Washington County 
Contractor: Southwest Utah Mental Health Center, 
St. George, Utah 
R414-2A-400. Services . 
(1) Inpatient hospital services encompass all 
medically necessary and therapeutic Medicaid ser-
vices and supplies tha t are ordered by a physician or 
other practitioner of the healing ar ts and are appro-
priate for the adequate diagnosis and t reatment of a 
patient's illness. These services include nursing, 
therapy services, use of hospital facilities, the tech-
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Physician services are available to categorically and medically needy eligible individuals. 
R414-10-4. Program Access Requirements. 
(1) Physician services are available only from a physician who meets all requirements 
necessary to participate in the Utah Medicaid Program and who has signed a provider agreement. 
(2) Physician services are available only from a physician who renders medically necessary 
physician services in accordance with his specific provider agreement and with Department rules. 
(3) An eligible Medicaid client may seek physician services from: 
(a) a physician in private practice who is an enrolled Medicaid provider; 
(b) a Health Maintenance Organization (HMO) that has a contract with the Department; 
(c) a federally qualified community health center; or 
(d) any other organized practice setting recognized by the Department for providing 
physician services. 
R414-10-5. Service Coverage. 
(1) Physician services involve direct patient care and securing and supervising appropriate 
diagnostic ancillary tests or services in order to diagnose the existence, nature, or extent of 
illness, injury, or disability. In addition, physician services involve establishing a course of 
medically necessary treatment designed to prevent or minimize the adverse effects of human 
disease, pain, illness, injury, infirmity, deformity, or other impairments to a client's physical or 
mental health. 
(2) Physician services may be provided only within the parameters of accepted medical 
practice and are subject to limitations and exclusions established by the Department on the basis 
of medical necessity, appropriateness, and utilization control considerations. 
(3) Program limitations and noncovered services are established by specific program policy 
maintained in the Physician Provider Manual and updated by notification through Medicaid 
Provider Bulletins. Following is a general list of medical and health care services excluded from 
coverage: 
(a) Services rendered during a period the recipient was ineligible for Medicaid; 
(b) Services medically unnecessary or unreasonable; 
(c) Services which fail to meet existing standards of professional practice, or which are 
currently professionally unacceptable; 
(d) Services requiring prior authorization, but for which such authorization was not received; 
(e) Services, elective in nature, based on patient request or individual preference rather than 
medical necessity; 
(f) Services fraudulently claimed; 
(g) Services which represent abuse or overuse; 
(h) Services rejected or disallowed by Medicare when the rejection was based upon any of 
the reasons listed above. 
(4) Experimental or medically unproven physician services or procedures are excluded from 
coverage. Criteria established and approved by the Department staff and physician consultants 
are used to identify noncovered services and procedures. Policy statements developed by the 
Department of Health and Human Services, Health Care Financing Administration, Coverage 
Issues Bureau, are also used to determine Department policy for noncovered services. 
(5) Certain services are excluded from coverage because medical necessity, appropriate 
utilization, and cost effectiveness of the services cannot be assured. A variety of lifestyle factors 
contribute to the "syndromes" associated with such services, and there is no specific therapy or 
treatment identified except for those that border on behavior modification, experimental, or 
unproven practices. Services include: 
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(a) Sleep apnea or sleep studies, or both; 
(b) Pain clinics; and 
(c) Eating disorders clinics. 
(6) When a service or procedure does not qualify for coverage under the Medicaid program 
because it is an elective cosmetic, reconstructive, or plastic surgery, all related services, supplies, 
and institutional costs are excluded from coverage. 
(7) Medications for appetite suppression, surgical procedures, unproven or experimental 
treatments, or educational, nutritional support programs for the treatment of obesity or weight 
control, are excluded from coverage. 
(8) Cognitive or Office Services: 
(a) Cognitive services by a provider are limited to one service per client per day. These 
services are defined as office visits, hospital visits except for those following a package surgical 
procedure, therapy visits, and other types of nonsurgical services. When a second office visit for 
the same problem or a hospital admission occurs on the same date as another service, the 
physician shall combine the services as one service and select a procedure code that indicates the 
overall care given. 
(b) Routine physical examinations, not part of an otherwise medically necessary service, are 
excluded from coverage, except in the following circumstances: 
(i) Preschool and school age children, including those who are EPSDT (CHEC) eligible, 
participating in the ongoing CHEC program of scheduled services and follow-up care. 
(ii) New patients seeing a physician for the first time with an initial complaint where a 
comprehensive physical examination, including a medical and social history, is necessary. 
(iii) Medically necessary examinations associated with birth control medication, devices, and 
instructions. 
(c) Family planning services may be provided only by or under the supervision of a 
physician and only to individuals of childbearing age, including sexually active minors. The 
following services are excluded from coverage as family planning services: 
(i) Experimental or unproven medical procedures, practices, or medication. 
(ii) Surgical procedures for the reversal of previous elective sterilization, both male and 
female. 
(iii) Infertility studies. 
(iv) In-vitro fertilization. 
(v) Artificial insemination. 
(vi) Surrogate motherhood, including all services, tests, and related charges. 
(vii) Abortion, except where the life of the mother would be endangered if the fetus were 
carried to term, or where pregnancy is the result of rape or incest. 
(d) After-hours service codes may be used only by a private physician, primary care 
provider, who responds to treat a patient in the physician's private office for a medical 
emergency, accident, or injury after regular office hours. Only one of the after hours CPT codes 
may be used per visit. 
(e) Only the laboratory tests in the following list are covered as part of a physician's office 
service. An independent laboratory shall provide all other laboratory services. The independent 
laboratory completing the service must bill the Department directly to receive payment for the 
service. 
(i) 81000 Urinalysis by reagent strips, any number of components: with microscopy; 
(ii) 81002 Urinalysis without microscopy; 
(iii) 82270 Blood: occult, feces, screening; 
(iv) 82948 Glucose: blood, stick test; 
(v) 84702 Gonadotropin, chorionic: quantitative; 
(vi) 84703 Gonadotropin, chorionic: qualitative; 
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(vii) 85007 Blood count: manual differential WBC (includes RBC morphology and platelet 
estimation); 
(viii) 85014 Blood count: hematocrit; 
(ix) 85021 Blood count: hemogram, automated (RBC, WBC, HgB, Hct and indices only); 
(x) 85022 Blood count: hemogram, automated, and manual differential WBC count (CBC); 
(xi) 85023 Blood count: hemogram and platelet count, automated, and manual differential 
WBC count (CBC); 
(xii) 85024 Blood count: hemogram and platelet count, automated, and automated partial 
differential WBC count (CBC); 
(xiii) 85025 Blood count: hemogram and platelet count, automated, and automated complete 
differential WBC count (CBC); 
(xiv) 85027 Blood count: hemogram and platelet count, automated; 
(xv) 85031 Blood count: hemogram, manual, complete CBC (RBC, WBC, HgB, Hct, 
differential and indices); 
(xvi) 85048 Blood Count: white blood cell (WBC); 
(xvii) 85650 Sedimentation rate (ESR): Wintrobe type; 
(xviii) 85651 Sedimentation rate: Westergren type; 
(xix) 86300 Heterophile antibodies: screening (includes monotype test) slide or tube; 
(xx) 86317 Immunoassay for infectious agent antigen or antibody, each; 
(xxi) 86403 Particle agglutination, rapid test for infectious agent, each antigen; 
(xxii) 86580 Skin test: tuberculosis, intradermal; 
(xxiii) 86585 Skin test: tuberculosis, tine test; 
(xxiv) 87081 Culture, bacterial, screening only, for single organisms; 
(xxv) 87082 Culture, presumptive, pathogenic organisms, screening only, by commercial 
kit; for single organisms; 
(xxvi) 87210 Smear, primary source: wet mount with simple stain, for bacteria, fungi, ova, 
and parasites; 
(xxvii) 87220 Tissue examination for fungi (e.g., KOH slide). 
(f) In addition to the above laboratory services, the following services are covered when a 
private physician personally collects the specimen: 
(i) 85095 Bone marrow smear or cell block or both: aspiration only; 
(ii) 85102 Bone marrow biopsy, needle or trocar. 
(g) A specimen collection fee is covered for service in a physician's office only when a 
specimen is to be sent to an outside laboratory, and the physician or one of his office staff under 
his personal supervision actually extracts the specimen from a patient, and only by one of the 
following procedures: 
(i) Drawing a blood sample through venipuncture, i.e., inserting into a vein a needle with 
syringe or vacutainer to draw the specimen; or 
(ii) Collecting a urine sample by catheterization. 
(h) Eye examinations are covered, but only once each calendar year. 
(i) Contact lenses are covered only for aphakia, nystagmus, keratoconus, severe corneal 
distortion, cataract surgery, and in those cases where visual acuity cannot be corrected to at least 
20/70 in the better eye. 
(9) Psychiatric Services: 
(a) Psychiatric services or psychosocial diagnosis and counseling are specialty medical 
services. Psychiatric services, whether in a private office, a group practice, or private clinic 
setting, may only be provided directly and documented and billed to the Department by the 
private physician. Charting and documentation must clearly reflect the private physician's direct 
provision of care. 
(b) Nonphysician psychosocial counseling services are excluded from coverage as a 
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Medicaid benefit. The personal supervision policy, R414-45-1. may not be applied to psychiatric 
services. 
(c) Admission to a general hospital for psychiatric care by a physician requires prior 
authorization and is limited to those cases determined by established criteria and utilization 
review standards to be of a severity that appropriate intensity of service cannot be provided in 
any alternate setting. 
(10) Laboratory and Radiology Services: 
(a) Laboratory services identified by CPT codes 80000 through 89999, and radiology 
services identified by CPT codes 70000 through 79999 are ancillary medical services with both a 
technical and professional component. The professional component, e.g., analysis, interpretation 
and written report, represented by modifier 26, may be provided only by a pathologist or a 
radiologist practicing in an independent or hospital laboratory or radiology setting. Pri\ate 
physicians who are not pathologists or radiologists may not bill for the service described by 
modifier 26 for telling a patient the results of laboratory or radiology procedures as noted on the 
laboratory or radiology printout or the written report. Providing such information to the patient is 
part of the office call rather than a separate service. 
(b) Physicians prepared in a highly specialized field of practice, e.g., neurology or 
neurosurgery, who provide consultation and diagnostic radiology services in an independent 
setting at the request of a private physician may bill for both the technical and professional 
component of the radiology service. 
(11) Hospital Services: 
(a) A patient hospitalized for nonsurgical services may require more than one visit per day 
because of the patient's condition and treatment needs. Since physician visits are limited to one 
per day, the physician shall select one procedure code to define the overall care given. If 
intensive care services are provided, or critical care service codes are used to define sendee 
provided, the Department requires additional documentation from the physician. The medical 
record must show documentation of medical necessity and result of the additional service. 
(b) If, for the convenience of the physician and not for medical necessity, a patient is 
transferred between physicians within the same hospital or from one hospital to another hospital, 
both physicians may only use subsequent hospital care service codes to define and bill for 
services provided. Under this policy limitation, services associated with the following codes are 
excluded from coverage as a Medicaid benefit: 
(i) Consultation; and 
(ii) Initial hospital care services. 
(c) Treatment of alcoholism or drug dependency in an inpatient setting is limited to acute 
care for detoxification only. 
(12) Abortion, Sterilization and Hysterectomy: 
(a) Abortion procedures are limited only to those with medical certification of necessity as 
described in 42 CFR 441.203, October 1994 edition, which is adopted and incorporated by 
reference. 
(b) Sterilization and hysterectomy procedures are limited to those which meet the 
requirements of 42 CFR 441, Subpart F, October 1994 edition, which is adopted and 
incorporated by reference. 
(13) Cosmetic, Plastic, or Reconstructive Services: 
(a) Cosmetic, plastic, or reconstructive surgery procedures may only be covered when 
medically necessary to: 
(i) correct a congenital anomaly; 
(ii) restore body form or function following an accidental injury; or 
(iii) revise severe disfiguring and extensive scarring resulting from neoplastic surgery. 
(14) Surgical Services: 
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(a) Surgical procedures defined and coded in the CPT Manual are limited by Utah Medicaid 
policy to place of service, to prior authorization, or are excluded from coverage. Limitations are 
documented on the Medical and Surgical Procedures Prior Authorization List, reviewed and 
revised yearly and maintained in the Physician Provider Manual through notification by Provider 
Bulletins. 
(b) Surgical procedures are "package" services. The package service includes: 
(i) the preoperative examination, initiation of the hospital record, and development of a 
treatment program either in the physician's office on the day before admission, or in the hospital 
or the physician's office on the same day as admission to the hospital; 
(ii) the operation; 
(iii) any topical, local, or regional anesthesia; and 
(iv) the normal, uncomplicated follow-up care covering the period of hospitalization and 
office follow-up for progress checks or any service directly related to the surgical procedure for 
up to six weeks post surgery. 
(c) Interpretation of "package" services: 
(i) A physician may not bill for an office visit the day prior to surgery, for preadmission or 
admission workup, or for subsequent hospital care while the patient is being prepared, 
hospitalized, or under care for a "package" surgical service. 
(ii) Consultation services may be billed by the consulting physician only when consultation 
and no other service is provided. When a consulting physician admits and follows a patient, 
independently or concurrently with the primary physician, only admission codes and subsequent 
care codes may be used. 
(iii) Office visits for up to six weeks following the hospitalization which relate to the same 
diagnosis are part of the "package" service. The only exception to either inpatient or office 
service is for service related to complications, exacerbations, or recurrence of other diseases or 
problems requiring additional or separate service. 
(d) Procedures exempt from the "package" definition are identified in the CPT Manual by an 
asterisk. The CPT Manual outlines the surgical guidelines which apply to documentation and 
billing of procedures marked by an asterisk. 
(e) Complications, exacerbations, recurrence, or the presence of other diseases or injuries 
requiring services concurrent with the initial surgical procedure during the listed period of 
normal follow-up care, may warrant additional charges only when the record shows extensive 
documentation and justification of additional services. 
(f) When an additional surgical procedure is carried out within the listed period of follow-up 
care for a previous surgery, the follow-up periods continue concurrently to their normal 
terminations. 
(g) Preoperative examination and planning are covered as separate services only in the 
following circumstances: 
(i) When the preoperative visit is the initial visit for the physician and prolonged detention or 
evaluation is required to establish a diagnosis, determine the need for a specific surgical 
procedure, or prepare the patient; 
(ii) When the preoperative visit is a consultation and the consulting physician does not 
assume care of the patient; or 
(iii) When diagnostic procedures, not part of the basic surgical procedure, e.g., bronchoscopy 
prior to chest surgery, are provided during the immediate preoperative period. 
(h) Exploratory laparotomy procedures confirm a diagnosis and determine the extent of 
necessary treatment. A physician may request payment only if the exploratory procedure is the 
only procedure done during an operative session. Exploratory laparotomy services identified by 
CPT Codes 49000-49060 may not be billed in conjunction with any services identified by the 
following CPT Codes: 43500 - 44346 - 44600 - 45180 - 47400 - 47490 - 47600 - 48999 - 49002 -
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49999 - 58140 - 58285 - 58400 - 58960. 
(i) The services of an assistant surgeon are covered only on very complex surgical 
procedures. Procedures not authorized for assistant surgeon coverage are listed in the Physician 
Provider Manual and updated by Medicaid Provider Bulletins as necessary. Medicare guidelines 
for limitation of assistant surgeon coverage are used, since those decisions are made at the 
national level with physician consultation. 
(15) Diagnostic and Therapeutic Procedures: 
(a) Diagnostic needle procedures; e.g., lumbar puncture, thoracentesis, and jugular, femoral 
vein, or subdural taps, when performed as part of a necessary workup for a serious medical 
illness or injury, are covered in addition to other medical care on the same day. 
(b) Diagnostic "oscopy" procedures, e.g., endoscopy, bronchoscopy, and laparoscopy, are 
covered separately from any major surgical procedure. However, when an "oscopy" procedure is 
done the same day or at the same operative session as another procedure, the "oscopy" procedure 
may only be covered as a multiple procedure. 
(c) Magnetic resonance imaging (MRI) is covered only for service to the brain, spinal cord, 
hip, thigh and abdomen. 
(d) Therapeutic needle procedures, e.g., scalp vein insertion, injections into cavities, nerve 
blocks, are covered in addition to other medical care on the same day. 
(e) Puncture of a cavity or joint for aspiration followed by injection of a medication is 
covered as one procedure and identified by specific CPT code. 
(16) Anesthesia Services: 
Anesthesia services are covered only when administered by a licensed anesthesiologist or 
nurse anesthetist who remains in attendance for the sole purpose of rendering general anesthesia 
services. Standby or monitoring by the anesthesiologist or anesthetist during local anesthesia is 
not a covered Medicaid anesthesia service. 
(17) Transplant Services 
Organ transplant services are limited to those procedures for which selection criteria have 
been approved and documented in R414-10A. 
(18) Modifiers: 
Modifiers may be used only, as defined in the CPT Manual, to show that a service or 
procedure has been altered to some degree but not changed in definition or code. The following 
limitations apply: 
(1) The professional component, modifier 26, may be used only with laboratory and 
radiology service codes by a pathologist or radiologist and only when direct analysis, 
interpretation, and written report of findings are provided on a laboratory or radiology procedure. 
Private physicians may not use this modifier. 
(2) Unusual services are identified by use of modifier 22, along with the appropriate CPT 
code. A prepayment review of unusual services shall be completed by Medicaid professional 
staff or physician consultants. A report of the service and any important supporting 
documentation must be submitted with the claim for review. 
(3) Anesthesia by surgeon is identified by use of modifier 47. The operating surgeon may 
not use modifier 47 in addition to the basic procedure code. Anesthesia provided by the surgeon 
is part of the basic procedure being provided. 
(4) Mandated services as defined by CPT and identified by modifier 32 are noncovered 
services. 
(5) Reference laboratory services identified by modifier 90 are noncovered services. 
(19) Medications: 
(a) Drugs and biologicals are limited to those approved by the Food and Drug 
Administration (FDA). Medicaid coverage of drugs and biologicals is based on individual need 
and orders written by a physician when the drug is given in accordance with accepted standards 
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of medical practice and within the protocol of accepted use for the drug. 
(i) Generic drugs shall be used whenever a generic product approved by the FDA is 
available. If the physician determines that a brand name drug is medically necessary, the 
physician may override the generic requirement by writing on the prescription in his own hand 
writing "name brand medically necessary", Preprinted messages, abbreviations, or notations by a 
second party, do not meet the override requirement. The pharmacist shall fill the prescription 
with the generic equivalent product if the override procedure is not followed. 
(ii) Injectable medications approved in HCPCS are identified in the "J" code list published 
by the Health Care Financing Administration or the Department, or both. The list is reviewed 
and revised yearly and maintained in the Physician Provider Manual by notification and update 
through Medicaid Provider Bulletins. 
(iii) The "J" code covers only the cost of an approved product. 
(iv) Office visits only for administration of medication are excluded from coverage. 
However, an injection code which covers the cost of the syringe, needle and administration of the 
medication may be used with the "J" code when medication administration is the only reason for 
an office call. 
(v) When an office service is provided for other purposes, in addition to medication 
administration, only the office visit and a "J" code may be used to bill for the service provided. 
(vi) The office visit code and injection code may never be used together. Only one of the 
codes may be used to define the service provided. 
(vii) Vitamin B-12 is limited to use only in treating conditions where physiological 
mechanisms produce pernicious anemia. Use of Vitamin B-12 in treating any unrelated 
condition is excluded from coverage. 
(b) Vitamins may be provided only for: 
(i) Pregnant women: Prenatal vitamins with 1 mg folic acid, 
(ii) Children through age five: Children's vitamins with fluoride, 
(iii) Children through age 15: Fluoride supplement. 
(c) Human growth stimulating hormones are not a covered service. 
(d) Methylphenidates, amphetamines, and other central nervous system stimulants require 
prior authorization and may be provided only for treatment of Attention Deficit Disorder (ADD) 
in children between the ages of six and 18 years. 
(e) Medications for appetite suppression are not a covered service. 
(f) Non-prescription, over-the-counter items are limited, and notification of changes 
consistent with this rule is made by Provider Bulletin and Provider Manual updates. 
(g) Nutrients may be provided only as established in R414-24A. 
References: 26-1-5, 26-18-3. 
History: 11442, NEW, see CPR; 11442, CPR, 04/15/91; 17705, AMD, 06/07/96; 18823, 5YR, 
03/18/97. 
NOTES TO DECISIONS 
Breast reduction surgery. 
Breast reduction surgery is authorized in particular cases of "medical necessity." Therefore, 
because the patient's attending physicians testified regarding the medical necessity of the 
procedure and the Department of Health Care Finance failed to give a reasoned basis for 
declining to give deference to the testimony of the treating physician, the agency's finding that 
the breast reduction surgery was not medically necessary was not supported by substantial 
evidence and was reversed. (R414-10-6.) A.M.L. v. Department of Health, Div. of Health Care 
Fin., 863 P.2d 44 (Utah Ct. App. 1993). 
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2) the medical services for which payment is 
claimed were actually furnished to the person iden-
tified as the recipient at the time and in the manner 
stated; 
3) the payment claimed does not exceed the pro-
vider's usual and customary charges (or the maxi-
mum amount negotiated under applicable regula-
tions of the Division of Health Care Financing); and 
4) the information submitted in, with, or in sup-
port of the claim is true, accurate, and complete. The 
Division of Health Care Financing may terminate 
any provider from further participation in the Title 
XEX program if the provider shall fail or cease to 
satisfy all applicable criteria for eligibility as a 
Medicaid Provider as explained in provider manu-
als. 
b. Ineligibility of Provider 
The Department may refuse to grant provider 
privileges to anyone who has been convicted of a 
criminal offense relating to that person's involve-
ment in any program established under Title XVTH, 
XJX, or XX of the Social Security Act, or of a crime of 
such nature that, in the judgment of the Depart-
ment, the participation of such Provider would com-
promise the integrity of the Medical Assistance 
Program. 
4. QUALITY ASSURANCE 
In order for the state to meet Title XIX require-
ments, certain procedures are required. The State is 
responsible to monitor all programs with respect to 
medical need, extent and appropriateness of care, 
and program effectiveness. These procedures in-
clude, but are not limited to: 
(a) Audit Procedures 
(b) On-Site Reviews 
(c) Quality Assurance 
(d) Utilization Review 
5. MEDICAL STANDARDS 
a. A Provider must furnish or prescribe medical 
services to the recipient only when, and to the extent 
that, it is medically necessary. A service is "medi-
cally necessary" if it is (1) reasonably calculated to 
prevent, diagnose, or cure conditions in the recipient 
that endanger life, cause suffering or pain, cause 
physical deformity or malfunction, or threaten to 
cause a handicap; and (2) there is no other equally 
effective course of treatment available or suitable for 
the recipient requesting the service which is more 
conservative or substantially less costly. Medical 
services shall be of a quality that meets profession-
ally recognized standards of health care, and shall 
be substantiated by records including evidence of 
such medical necessity and quality. Those records 
shall be made available to the Department upon 
request. 
b. Determination of Compliance with Medical 
Standards 
A provider's failure to comply with medical stan-
dards may be determined by peer review. Initial 
determinations as to whether or not a provider has 
failed to comply with medical standards, will be 
made by Division of Health Care Financing employ-
ees or consultants. If the determination has been 
made by the Division of Health Care Financing that 
noncompliance exists, the Division of Health Care 
Financing will notify the provider of the failure to 
comply in writing pursuant to the notice provisions 
of the Division of Health Care Financing ADMINIS-
TRATIVE HEARING PROCEDURES Section 2. 
Either the Division of Health Care Financing or 
the provider may request to have formal peer review 
of the Department's detennination. 
A written request by either the Division of Health 
Care Financing or provider for formal review must 
be made within 30 days following the date of the 
original notice to the provider of the Division of 
Health Care Financing determination that noncom-
pliance had occurred. The written request from the 
provider must be submitted by him/her to: 
Division of Health Care Financing 
Bureau of Program Review 
ATTN: PEER REVIEW 
P. O. Box 16580 
Salt Lake City, Utah 84116-0580 
This written request will be submitted to the 
appropriate Professional Society requesting that 
their Peer Review Committee conduct a formal peer 
review of the Division of Health Care Financing 
determination. 
The informal hearing requirements of Section 
26-23-2-d) UCA, (1953) are satisfied by the profes-
sional peer review process. 
If either the Division of Health Care Financing or 
the provider is dissatisfied with the results of the 
formal peer review they may request a formal hear-
ing before the Department of Health pursuant to 
Section 23-32-2, UCA (1953) by complying with the 
formal hearing procedures set forth in the Division 
of Health Care Financing ADMINISTRATIVE 
HEARING PROCEDURES. 
In situations of violations of compliance of profes-
sionally recognized medical standards, identified by 
peer review, the Division of Health Care Financing 
may pursue any legal sanction for recovery of over-
payments. 
Should Federal Financial Participation (the 
amount the federal government contributes to pro-
vider reimbursement) be disallowed on reimburse-
ments made to the provider, the provider will reim-
burse to the State the total amount that the State 
paid for the services disallowed (including Federal 
audit, quality assurance review, or prior authoriza-
tion requirements) only if the provider was at fault. 
References: 26-1-5. 
History: 13550, 5YR, 11/15/92. 
R414-14. Home Health Service. 
R414-14-0. Policy Statement. 
R414-14-1. Authority and Purpose. 
R414-14-2. Definitions. 
R414-14-3. Eligibility Requirements/Coverage. 
R414-14-4. Program Access Requirements. 
R414-14-5. Service Coverage. 
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2 
3 |j * * * * * 
4 
5 
6 II THE COURT: I have Mrs. Peterson here and 
7 Juliana Rich. And then for Health Care Financing, Utah 
8 Medicaid, Dr. John Hylen and Penny Nahley who's an R.N. 
9 And then Steve Gatzemeier will be coming shortly. I 
10 think I'm going to have you testify first, Dr. Jackson, 
11 and I'll get into that a little bit more in a moment. 
12 Basically I need to tell you that the tape 
13 recorder is on now and it's a formal hearing in the 
14 matter of Markelle Frei-Peterson versus Utah Department 
15 of Health, Division of Health Care Financing and the 
16 Case Number is 97-209-11. My name is Margaret Clark. 
17 I'm the administrative law judge assigned to preside 
18 over today's hearing. Today is Monday, December 8th, 
19 and it's approximately 8:30 in the morning. 
20 Procedures for today's hearing are governed 
21 by the Utah Administrative Procedures Act, Title 63, 
22 Chapter 46(b) of the Utah Code and Utah Administrative 
23 Rule R410-14. Mr. Gatzemeier just entered the room and 
24 also Duane Park, who's a pharmacist for Health Care 
25 Financing. 
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1 As I was saying the procedures are governed 
2 by Title 63, Chapter 46(b) and Utah Administrative Rule 
3 R410-14 which contain the Division of Health Care 
4 Financing's hearing policies. After today's hearing I 
5 will prepare what is called a Recommended Decision. 
6 That decision will contain my Findings of Fact and my 
7 Conclusions of Law. The director of the Division of 
8 Health Care Financing will then issue a final decision 
9 called a Final Agency Order and that order may affirm, 
10 reverse, remand or modify my Recommended Decision based 
11 only upon the evidence from the record as a whole, and 
12 that would be the sworn testimony taken today or any 
13 exhibits that are entered into evidence. 
14 Should the outcome be unfavorable my 
15 assistant has provided copies of appeals rights to Mrs. 
16 Peterson. If you have any questions should you need 
17 them feel free to call our office. 
18 First I'm going to have Health Care Financing 
19 enter their appearances. Are you going to be 
20 representing, Mr.Gatzemeier? 
21 MR. GATZEMEIER: Yes. 
22 THE COURT: Would you like to introduce 
23 yourself? 
24 MR. GATZEMEIER: Okay. My name is Steven 
25 Gatzemeier. I'm a Health Program Manager for Coverage 
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1 and Reimbursement Policy, Division of Health Care 
2 Financing. Testifying today will be Penny Nahley, who 
3 is a registered nurse and who is the prior 
4 authorization reviewer and was the evaluator, the 
5 initial evaluator in this case. We also have Dr. John 
6 Hylen who is an M.D. who will be available for 
7 testimony. And we have Duane Park who is a registered 
8 pharmacist. 
9 THE COURT: Okay. Dr. Peterson, are you able 
10 to hear? I'm sorry. Dr. Jackson, are you able to hear 
11 us okay. 
12 DR. JACKSON: Yes. For the state was that 
13 Mr. Gatzemeier? 
14 THE COURT: Yes. Okay. I'm having to move 
15 his speaker a little bit closer. 
16 I'd like to have you testify first, Dr. 
17 Jackson, since you have the burden of proof, or Miss 
18 Peterson has the burden of proof of as the moving 
19 party. And the issues, as I understand it from the 
20 pleadings and the prehearing conference, is whether or 
21 not Utah Medicaid should cover payment for a growth 
22 hormone. And this is not normally covered by Health 
23 Care Financing as I understand it because it's 
24 considered to be experimental and experimental 
25 procedures are excluded from coverage by the 
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1 Administrative Code. 
2 Is that the issue as everyone understands it? 
3 Mr. Gatzemeier? 
4 MR. GATZEMEIER: Yes. Experimental and I 
5 believe it's our understanding that this drug is also 
6 being used for an off-legal use. That may or may not 
7 be but that's the understanding I have. 
8 THE COURT: Okay. And, Dr. Jackson, is that 
9 the issue as you understand it? 
10 DR. JACKSON: Right. It's the use of growth 
11 hormone for an indication other than stimulating 
12 somatic growth. It's for accelerating intestinal 
13 adaptation. 
14 THE COURT: Okay. 
15 DR. JACKSON: Although it's not within the 
16 specific experimental protocol like some other 
17 therapies that we sometimes used it's not exactly... 
18 THE COURT: I'm sorry, doctor, before you go 
19 any further I need to swear you in so everything you 
20 say is accountable. If you'll raise your right hand, 
21 please. 
2 2 DR. JACKSON: Okay. 
23 WILLIAM DANIEL JACKSON, M.D., 
24 appearing as a witness on behalf of the 
25 Petitioner, having been first duly sworn, 
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1 testified as follows: 
2 DIRECT TESTIMONY 
3 THE COURT: State your name for the record 
4 again. 
5 DR. JACKSON: William Daniel Jackson. 
6 THE COURT: Thank you. I'm sorry. Now if 
7 you'd like to start testifying in narrative fashion if 
8 you'd like. I think a couple of things that you'd like 
9 to address being not — not being represented by an 
10 attorney is the medical necessity role which I believe 
11 Health Care Financing was supposed to have sent you a 
12 copy. Did you receive that? 
13 DR. JACKSON: Yes, I did. 
14 THE COURT: Okay. If you could possibly in 
15 your testimony address those two elements of medical 
16 necessity, and then anything else you'd like to tell 
17 us, and also why you think this procedure, this use of 
18 the drug is not experimental in this case, if that's 
19 what you're contending. I'll just leave it up to you, 
20 but I'm just trying to kind of give you some guidance 
21 here. 
22 DR. JACKSON:. Okay. Some of these issues we 
23 went over in the previous hearing. 
24 THE COURT: Right. And that was just a 
25 prehearing and that wasn't on the record, so we need to 
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1 reiterate anything that's important because this is the 
2 official hearing record. 
3 DR. JACKSON: Okay. Markelle Frei-Peterson 
4 is a 24-month-old toddler now with short bowel 
5 syndrome. Is dependent upon parenteral nutrition 
6 support for much of her nutritional needs. 
7 THE COURT: Okay. I need to back up just one 
8 more second. I'm sorry to do this to you again. I 
9 need to get your credentials for the hearing record. 
10 DR. JACKSON: M.D. 
11 THE COURT: Uh-huh. 
12 DR. JACKSON: Do you need to know where I 
13 trained or what do you need to know? 
14 MR. GATZEMEIER: Specialties. 
15 THE COURT: Specialties, board certification, 
16 anything that tells us — 
17 DR. JACKSON: I'm board certified in 
18 pediatrics and board certified in pediatric 
19 gastroenterology and nutrition. Recently recertified. 
20 Have fellowship training in pediatric gastroenterology 
21 and nutrition. Have an M.D. and a bachelor's degree. 
2 2 THE COURT: Okay. And where are you working 
2 3 now? 
24 DR. JACKSON: I'm an assistant professor of 
25 pediatrics at University of Utah School of Medicine and 
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1 I'm based at Primary Children's Medical Center where 
2 I'm the Medical Director of Nutrition Support Services. 
3 THE COURT: Okay, thank you. 
4 DR. JACKSON: And I practice in pediatric 
5 gastroenterology. 
6 THE COURT: Thank you. I hope I won't be 
7 interrupting any more. I'll let you go ahead. You 
8 were starting to tell us that Markelle Frei-Peterson is 
9 a toddler about 2 4 months old? 
10 DR. JACKSON: Yes, she's a two-year-old 
11 little girl with short bowel syndrome dependent upon 
12 parenteral nutrition support which is I.V. nutrition 
13 for I would say 9 0 percent of your nutritional needs. 
14 She is receiving continuous gastrostomy feeds which are 
15 feedings into her gastrointestinal tract. And around --
16 variable amounts but generally around 2 0 cc's per hour. 
17 She has begun to eat and she does consume a certain 
18 amount, it's difficult to quantify, of oral feedings 
19 now. These are ~- some of these are new changes that --
2 0 THE COURT: How recent approximately? 
21 DR. JACKSON: This is over the last two to 
22 three — you know, I'd say last two to three, maybe 
2 3 three to four months that she's having increasing 
24 intake of oral feedings. 
25 THE COURT: Okay. 
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1 DR. JACKSON: And her stool consistency has 
2 changed at times. So there's been a number of changes 
3 that have occurred in the past few months since we 
4 started this appeal process. 
5 THE COURT: Uh-huh. 
6 DR. JACKSON: In any case she still remains 
7 dependent upon parenteral nutrition and our main 
8 project and the number one I guess impetus and concern 
9 in a patient with short bowel syndrome is dependent 
10 upon such an expensive technology and possibly lifetime 
11 technology of parenteral nutrition is to get them off 
12 of that and get there G.I. tract, the gastrointestinal 
13 tract to adapt and to accommodate enteral nutrition and 
14 basically take over all of their needs. 
15 The other I guess omen along the path for her 
16 besides the risk of central line catheter infections 
17 and eventual loss of I.V. access sites is consequences 
18 on the liver. In children that have short bowel 
19 syndrome who can't be fed adequately enterally they 
20 develop liver dysfunction that is progressive. You can 
21 biopsy these patients7 livers and you see fibrosis, 
22 like a scarring process --
2 3 THE COURT: Uh-huh. 
2 4 DR. JACKSON: — that occurs in the liver. 
25 And it goes at various different rates in different 
KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS 
JANE G. SAVILLE, C.S.R. 
Markelle Frei-Peterson Hearing, 12/8/97 
1 patients• So I think that's probably the biggest 
2 concern is that a lot of our patients that have short 
3 bowel syndrome that are parenterally nutrition 
4 dependent who can't adequately adapt their G.I. tract 
5 have a risk of progressing to -- well, have a high risk 
6 of progressing to liver failure and require liver 
7 transplantation. 
8 So not only do they have the cost of chronic 
9 TPN and the cost of maintaining the central line which 
10 requires repeated hospital admissions as well as they 
11 have the risk long term of possibly requiring a liver 
12 transplantation. Which is covered by Medicaid in 
13 certain situations as is the TPN. 
14 So I guess my impetus in this case, the 
15 bottom line in my case is a clinical judgment as to — 
16 I consider it a medical judgment — 
17 THE COURT: Uh-huh. 
18 DR. JACKSON: — rather than a legal 
19 judgment. Although I understand that, you know, her 
20 survival and her situation in this case and the 
21 reimbursement situation is from public funds. 
22 THE COURT: Right. 
23 DR. JACKSON: And there's a responsibility. 
24 I completely understand this. I've been over this with 
25 Dr. Hylen before with some other transplantation 
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1 issues. And those are larger ethical, economic — 
2 THE COURT: Right. 
3 DR. JACKSON: — issues. And I completely 
4 understand all those. In this case on the other hand I 
5 think from both the citizen point of view and the 
6 public trust point of view and a money point of view, 
7 although perhaps it might be premature in terms of the 
8 letter of law and the indications for example, the off 
9 label, et cetera, the evidence that it's experimental, 
10 et cetera like that, even though that may be, from a 
11 medical point of view I — and there are a number of 
12 other physicians around the country, many much smarter 
13 than I am, including Dr. Book who's a division chief, 
14 who feel that in certain situations using growth 
15 hormone which is commonly used in many, many children 
16 for the indications of just somatic growth, it's not 
17 going to threaten their life, it doesn't threaten much 
18 of anything except for their — it threatens self 
19 esteem, et cetera. But growth hormone for 
20 short-stature patients, that is covered by Medicaid as 
21 an on-label use. 
22 In this case we're using it off of that label 
23 but for what I think is a higher indication which is — 
24 and obviously has to do with judgment and making a 
25 guess of probabilities, but for saving someone's life. 
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1 THE COURT: Okay. What — 
2 DR. JACKSON: But also I think from an 
3 economic point of view the way I add up I thought that 
4 a reasonably short-term course of this would be — if 
5 it worked would be a cost effective approach in terms 
6 of the huge magnitude of the cost of lifetime TPN 
7 and/or liver transplantation. 
8 THE COURT: What is the growth hormone called 
9 specifically? 
10 DR. JACKSON: It's called — well, it's 
11 recombinant human growth hormone. 
12 THE COURT: Okay. 
13 DR. JACKSON: And it's called humatropef 
14 h-u-m-a-t-r-o-p-e. 
15 THE COURT: Thank you. Okay. So if I 
16 understand your testimony are you saying that this 
17 growth hormone in this procedure would be reasonably 
18 calculated to prevent liver dysfunction? 
19 DR. JACKSON: Indirectly. 
2 0 THE COURT: Okay. 
21 DR. JACKSON: What it promotes — its direct 
22 role — and there's a lot — in fact there's more 
23 than — I said some to you, but there's been more since 
24 then. There's a lot of data about effects on 
25 adaptation in terms of absorption of electrolytes, 
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1 amino acids. There's also a lot of data on protein, 
2 carbohydrate absorption and changes of stool output. 
3 There's — from animal studies. And there's also some 
4 studies of human studies recently that are just been 
5 published. 
6 The question is are these studies — in my 
7 mind these studies are not large, they're not the kind 
8 of studies in which someone would say on a blanket case 
9 that this would be a — that you will do this for 
10 everybody. But for certain indications there's enough 
11 promise there to motivate a number of different people 
12 to continue to work along these lines. And they're not 
13 fringe people, they're mainstream. In fact one of 
14 biggest protagonists of this is the person that 
15 actually developed total parenteral nutrition, Doug 
16 Wilmore, in 1968. It's been — these are people that 
17 have been with this for a long time. And there's — 
18 there is controversy. 
19 THE COURT: Uh-huh. 
20 DR. JACKSON: It's like any other kind of 
21 burgeoning, you know, new therapy. But there's enough 
22 promise there. I don't think it's cold fusion. So 
23 anyway, there's a lot of data on growth hormone itself 
24 stimulating transcription of certain regulatory genes 
25 that turn on growth of the lining of the intestine. 
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1 And there's lots of demonstrations in certainly animal 
2 models and there's some reports in human studies of 
3 mucosal growth. 
4 There's also some where they looked, for 
5 short term at least, like three-week studies, where 
6 they weren't able to see a change, but they were able 
7 to see some changes in absorption and amino acid 
8 uptake. 
9 So it's — it definitely is an area where 
10 there's active work and controversy. But there is — 
11 the basic science elements of it at least are the 
12 growth factors including those stimulated by growth 
13 hormone stimulating intestinal growth. 
14 The big question is — one of the big 
15 questions is what is the timing for doing this, what is 
16 the outcome? Wilmore's group, the group that's 
17 published some, has shown even in patients who have had 
18 their — lost their intestine years and years ago still 
19 show response. And that doesn't make sense to some 
20 people. But anyway. So there's — I've kind of sent 
21 most of that information over. 
22 THE COURT: Okay. Actually I don't have 
23 copies of that. Will the Respondent's be entering — 
24 DR. JACKSON: I sent some articles over with 
25 my appeal to Ms. Nahley back on June 23rd of '97. And 
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1 then there was — I just did a search and I found some 
2 more things. So there's — 
3 THE COURT: What I'd like to do is keep the 
4 record open so you could submit whatever you found 
5 recently, 
6 DR. JACKSON: One other piece of information 
7 in the letters I read -- I read two letters. One was 
8 June 2 3rdf the other one was — I didn't date it but it 
9 was a little bit later. I guess it was about seven 
10 months ago. Anyway, since then she has been able to 
11 get growth hormone and so she's been on that for a 
12 number of months now. And one of my recommendations 
13 was to do growth hormones for a short period of timef a 
14 limited time such as three months back in June. 
15 THE COURT: Uh-huh. 
16 DR. JACKSON: And the argument then was this 
17 is worth itf try it. If there is no — if there is 
18 signs of some benefit then we would like to pursue this 
19 and keep going. The trial process or the hearing 
20 process has basically dragged on over this six months 
21 so in the meantime we've already used it. So can I 
22 attribute what's happening to her now on that? 
2 3 THE COURT: Yes, I think it's relevant. 
24 DR. JACKSON: It's circumstantial, but 
25 there's been some -- I mean I think Ms. Peterson can 
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1 probably attest to what's happening with respect to 
2 Markelle7s ability to eat, take some solid foods, do 
3 some things that are often great — one of the biggest 
4 challenges you have with some of these patients that 
5 have been chronically fed with TPN and tube feeding is 
6 inability to take things orally. So the fact that 
7 she's been able to get her to eat things is a big step 
8 forward. 
9 THE COURT: Would you like — 
10 DR. JACKSON: Billy Rich perhaps might be 
11 someone else from a medical or nursing background who 
12 could comment on things like that. So, you know, have 
13 there been some changes? Yeah, I think there have been 
14 some changes. Is that something that she would have 
15 done anyway without this? That's why we do randomized 
16 trials. And Dr. Hylen would certainly say, yes, of 
17 course. So this could all just be anecdotal, et 
18 cetera. 
19 THE COURT: Could you — do you know how 
20 long — how long will she be needing this growth 
21 hormone? I mean is it indefinite or do you have any 
22 idea how long she would need it? 
23 DR. JACKSON: I think it's self limited- I 
24 think that my original feeling would be to use it for a 
25 year. But I think that her ability to adapt or start 
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1 being able to accommodate to more enteral feeding, that 
2 by itself is somewhat protective on the liver. The 
3 feedings itself are stimulatory to the G.I. tract. 
4 Though we are really stuck — when we first 
5 proposed this in June the impetus behind this was — 
6 and I was actually slower than some of my colleagues to 
7 want to go for this therapy. But I think that her 
8 liver tests — she had kind of a marked abnormalities 
9 of her liver test at that time. I was basically 
10 worried that she was starting to show signs of 
11 accelerated liver disease. 
12 And her — since then her liver tests have 
13 normalized. And I — but anyway, at that time that was 
14 a concern. We weren't making any progress. She was 
15 stuck in terms of her ability to take in things. And 
16 it was — she was in and out of the hospital. We were 
17 having lots of troubles. 
18 So there are a few things that we changed at 
19 the time. But the biggest one since then has been 
20 basically adding the growth hormone. So I don't 
21 know — I think she's a different baby now, different 
22 child now than she was before, and that could just be a 
23 maturity process, it could just be that she's gradually 
24 been able to, you know, adapt from the feedings or 
25 could be, you know, or it could be due to this. 
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1 That's why we do these kind of trials is to 
2 know for sure what it is. I would say that at the end 
3 of that year period I don't think there is any — in my 
4 mind at that point, particularly given what — the 
5 progress she's made so far, I would think at that point 
6 there would be diminishing returns because we're 
7 getting at the point now where she taking in — it 
8 won't be that much more. But she could take in more 
9 enteral feedings where that whole — that process may 
10 hopefully sustain itself. The feeding itself 
11 stimulates the G.I. tract to adapt. 
12 THE COURT: Okay. 
13 DR. JACKSON: And whoever — the people, you 
14 know — I think that, you know, whoever provided the 
15 growth hormone to date — I think I.H.C. has been doing 
16 that, you know, they've been quite generous. So... 
17 THE COURT: Okay, thank you. I'm going to 
18 swear Mrs. Peterson in and then you will be able to ask 
19 some questions but since this is on the same track I 
20 just want to ask her about the changes. 
21 MR. GATZEMEIER: I have some questions about 
22 his testimony. 
23 THE COURT: Right. 
24 MR. GATZEMEIER: Going to swear both of them 
25 at the same time? 
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1 THE COURT: I'd just like to get comments on 
2 that one area and then you can ask them both questions. 
3 Will you raise your right hand, please? 
4 HEIDI PETERSON, 
5 appearing as a witness on behalf of the 
6 Petitioner, having been first duly sworn, 
7 testified as follows: 
8 DIRECT TESTIMONY 
9 THE COURT: Your name for the record. 
10 MS. PETERSON: My name's Heidi Peterson and 
11 I'm Markelle Frei-Peterson's aunt. 
12 THE COURT: Okay. I was just going to ask 
13 and I'll probably want you to testify later, but just 
14 if you wanted to comment on Dr. Jackson's remarks about 
15 how she had improved since the hormone therapy. 
16 MS. PETERSON: Markelle used to stool up to a 
17 thousand cc's of stool a day and now we're down to 
18 between three and four hundred cc's of stool a day. I 
19 have upped her feedings from — the maximum we used to 
2 0 get three months ago — we're on our third month of 
21 growth hormone this month — the maximum we got to in 
22 her tube feedings was 15 cc's an hour. And that was 
23 with turning her on and off through the night. Now I'm 
24 up to 21 cc's an hour. 
25 We are doing feeding therapy through a speech 
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1 therapist. She eats with her mouth every meal that we 
2 eat. We7re teaching her how to drink juices and that 
3 kind of thing. So I mean it's a lot. 
4 THE COURT: Okay. Do you have any questions 
5 you want to ask Miss Peterson now? Okay. 
6 Then I'll go back to Dr. Jackson. And before 
7 1 finish questioning you then Health Care Financing has 
8 the right to cross-examine so they7re going to ask some 
9 questions. Then I'm going to have them put on their 
10 case. You will be able to cross-examine them, ask any 
11 questions you'd like to ask of them. And then at the 
12 end if you'd like to provide any rebuttal evidence and 
13 both sides can summarize. Okay? 
14 WILLIAM DANIEL JACKSON, M.D.f 
15 appearing as a witness on behalf of the 
16 Petitioner, having been previously duly sworn, 
17 testified further as follows: 
18 DIRECT TESTIMONY (CONTINUING) 
19 THE COURT: Dr. Jacksonf since I need to 
20 consider this in my decision and I'm bound by the Utah 
21 Administrative Code, could you just go over the medical 
22 necessity role and state why or why not, why you think 
23 that Markelle Frei-Peterson needs this? And I'm just 
24 going to read it and let you address it. And then you 
25 can add anything else you want. Then we'll have both 
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1 your findings and questions• 
2 It says a service is medically necessary if 
3 it's reasonably calculated to prevent, diagnose or cure 
4 conditions in the recipient that endanger life, cause 
5 suffering or pain, cause physical deformity or 
6 malfunction, or threaten to cause a handicap. Do you 
7 want to take that one on first? That's the first part. 
8 DR. JACKSON: Well, from my biased 
9 perspective I feel like it's reasonably calculated to 
10 use this agent and the goal would be to basically 
11 prevent premature death, reduce — or improve quality 
12 of life by reducing dependence on total parenteral 
13 nutrition, and increasing her chances of becoming 
14 independent of that by being able to eat and consume 
15 foods normally. 
16 Avoid the future suffering of — well, future 
17 and things that she's already encountered of central 
18 line infections, complications of central venous 
19 catheters to provide the total parenteral nutrition. 
20 Including infection and dislodgement and vascular 
21 thrombosis. And finally to prevent chronic liver 
22 disease that plagues so many patients that are on 
23 chronic TPN, with the possibility of requirement for a 
24 liver transplantation. 
25 THE COURT: Okay. And then the second part: 
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1 There is no other equally effective course of treatment 
2 available or suitable for the recipient requesting this 
3 service which is more conservative or substantially 
4 less costly. Could you address that too? 
5 DR. JACKSON: There's no — the alternative 
6 basically is to do what we've done before which is to 
7 try to encourage feedings and give time. 
8 THE COURT: Has that worked? 
9 DR. JACKSON: To my — in my estimation it 
10 hadn't worked. We were stalemated and it wasn't 
11 working. And my experience has been that patients with 
12 severe short bowel that she hasf that have been on TPN 
13 as long as she had, with the struggles that she had had 
14 did not have a good prognosis. In other words had a — 
15 were destined to be TPN dependent for a long — we see 
16 many babies in situations like this who have progressed 
17 on to get liver disease. 
18 I have one patient who has a similar 
19 situation where she lost — she basically had somewhat 
20 less bowel than Markelle has, but ended up progressing 
21 on and she ended up getting a liver and small bowel 
22 transplant. We have others that have gone on to get 
23 liver transplants. We have others that have basically 
24 because they haven't been able to adapt their G.I. 
25 tracts have not been counted for liver transplants and 
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1 so they just died, 
2 So that's -- I guess in the life of a 
3 pediatric enterologist an infant with short bowel 
4 syndrome that's dependent on total parenteral nutrition 
5 who can't adapt their G.I. tract is — has a very high 
6 likelihood of progressing on to end stage liver 
7 disease, cirrhosis and the complications related to 
8 that. 
9 So in some ways I guess that's probably what 
10 powers our urgency and interest in wanting to do things 
11 like this. And maybe put a product on line before it's 
12 gone through the randomized — called the randomized 
13 controlled type of trials, the large ones. 
14 THE COURT: Okay. 
15 DR. JACKSON: So anyway, I would say that the 
16 customary standard therapy that we've used for this has 
17 not worked. Or at least has a very low probability of 
18 working. And the only alternative that has any 
19 credibility and has quite a few — you know, has an 
20 accumulating number of people working on it and 
21 publishing in it, is this combination of growth hormone 
22 therapy, glutamine, which in this case is provided in 
2 3 the Vivonex, which is the formula which she's getting, 
24 and a relatively high carbohydrate diet. Those are the 
25 things that we have data on. 
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THE COURT: Okay. Is there anything else 
you'd like to add at this time or should I let Health 
Care Financing ask their questions? 
DR. JACKSON: I think that our — I can admit 
up front that the indications are not in your code for 
using it this way. The area is -- does have 
controversy as with any new therapy, and there is a 
possibility that this could be disproved. And there 
have been other times when medicine has gone down the 
wrong path and thought they were — had a therapy that 
was helpful but it turned out not to be true. 
Or there's some other element that they 
weren't quite right on, they didn't know the dose, or 
the timing, or the combinations weren't exactly right. 
So all those kinds of things are things that can be 
granted. However, the relationship between the patient 
and this physician at least in terms of background, 
training, and the colleagues that I've consulted and 
worked with has been — have basically led me to 
advocate the use of this therapy. And at least in my 
judgement and tying together the benefits outweigh the 
risks and the costs. 
THE COURT: Okay. 
DR. JACKSON: The costs if it's successful 
will be much, much less than the alternative. 
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1 THE COURT: Okay, thank you. Dr. Hylen, do 
2 you have questions for Dr. Jackson? 
3 DR. HYLEN: Yeah, I have a question. 
4 Have you given any patient growth hormone 
5 that clearly prevented liver disease or liver 
6 transplant over the long term? 
7 DR. JACKSON: It's a new — no, it's a new — 
8 for us, our particular group here, it's a new approach. 
9 We have probably — Dr. Book has two patients that are 
10 receiving it. I have one other patient that's 
11 receiving it. And they're our most difficult patients. 
12 So they're desperate situations actually for those 
13 patients. And Dr. Book's impression, albeit anecdotal, 
14 is that those patients have shown some improvement 
15 since being started on it. 
16 These are, you know, these are rightfully 
17 labeled and disparaged as anecdotes and that's where we 
18 are. The only stronger data I can have that would 
19 justify doing this are those from the people who have 
20 published in the field from Mayo Clinic and from — 
21 particularly from Brigham and Women's Hospital in 
22 Boston. 
2 3 THE COURT: Okay. Have those articles 
24 already been submitted? 
25 DR. JACKSON: Several of those articles have 
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1 been submitted. There's been some recent ones in 
2 October '97 and there's some others. You know, some of 
3 these come down on the side of — and there's an 
4 editorial in that same article. So I could fax those 
5 over to Dr. Hylen. 
6 They don't — they don't in my mind — they 
7 demonstrate increased — you know, some measures of 
8 increased absorption and function but over the short 
9 term. And this one small human study, eight humans in 
10 a crossover study for 21 days, which is a very short 
11 period of time, and these are adults, those ones don't 
12 show morphologic changes. And there was changes in 
13 what you could see when you looked microscopically at 
14 the bowel. 
15 THE COURT: Well, I'll leave that up to you 
16 if you think that would be helpful then. 
17 DR. JACKSON: It will just be — I don't 
18 think it strengthens the case over what previous things 
19 I've submitted. But — 
2 0 THE COURT: Okay. 
21 DR. JACKSON: It would certainly maybe give 
22 Dr. Hylen more — I mean since it just says it's more — 
23 it's just a controversial area. 
24 THE COURT: Okay. Thank you. I'll give you 
25 10 days if you want to — 
/ « -
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1 DR. JACKSON: Okay. 
2 THE COURT: — submit that or even fax that 
3 over to us. 
4 DR. JACKSON: Okay. 
5 THE COURT: Dr. Hylen? 
6 DR. HYLEN: What's the longest that any of 
7 your patients have been on growth hormone for this sort 
8 of problem? 
9 DR. JACKSON: I think Dr. Book's — I think 
10 we're on about six months on one of my other patients, 
11 five months on my other patient. And Dr. Book's 
12 patient is probably greater than that. Probably six or 
13 seven months. 
14 DR. HYLEN: One comment you made was that 
15 since she's been on growth hormone that her liver 
16 function tests have normalized. Does that mean that 
17 they're totally normalf and what were they before, and 
18 can you give us more documentation of — 
19 DR. JACKSON: Yes, I can. I don't know why 
20 her -- I actually don't know why her liver tests jumped 
21 as they did. But -- and they have — my feeling is 
22 that if I look back I think they jumped up and 
23 normalized independent of growth hormones. In other 
24 words I think by September they had come back down. 
25 And I think — 
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1 DR. HYLEN: What — 
2 DR. JACKSON: Growth hormone was initiated in 
3 December. So I don't know that — I have the data 
4 right here. They weren't completely normal then but 
5 they had come back down some. 
6 THE COURT: Doctor, do you want to come up — 
7 can you hear Dr. Hylen okay? 
8 DR. HYLEN: Yeah, he can hear me. 
9 DR. JACKSON: He's in the distance but I can 
10 hear him. 
11 THE COURT: Okay. All right. 
12 DR. HYLEN: Anyway, we would like 
13 quantification of the date she was started on growth 
14 hormone and what her liver function tests were before 
15 and subsequent to the — through the whole time period 
16 what her liver functions did. 
17 DR. JACKSON: Okay. I think --
18 DR. HYLEN: Because it's hard for us to 
19 comment on some of the things that you're saying growth 
20 hormone's going to do when we don't have — 
21 DR. JACKSON: I don't — I don't really — I 
22 think that growth hormone did not — in my mind I 
23 don't think growth hormone caused the normalization of 
24 these liver tests. 
25 DR. HYLEN: Okay. 
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1 DR. JACKSON: I don't think that it did that. 
2 1 think that was an acute -- I don't know what caused 
3 that exactly. We didn't do a liver biopsy. Her 
4 transaminases went up into the several hundreds without 
5 much cholestasis. And her GGT went up a little bit. 
6 And that's basically what one of our concerns was, that 
7 she was going to start showing us some liver disease, 
8 which is something we always had worried about. 
9 But by the time that the growth hormone was 
10 begun I think those numbers had come back, had started 
11 to come back down. In fact we have some normal, you 
12 know, as early as September, we have pretty much near 
13 normal levels. The GGT remained slightly high off and 
14 on during that period of time. 
15 But I'm not claiming that the growth hormone 
16 normalized liver functions. Its role in my mind is in 
17 stimulating adaptation of the G.I. tract and improving 
18 her tolerance of enteral feedings that could set up a -
19 set the stage for continued adaptation. And the more 
20 enteral feedings she can get the more protection her 
21 liver has. Our kids that can be fed somewhat enterally 
22 have a much lower incidence of progressing on to liver 
23 disease, even if it's partial feedings. In other words 
24 not 100 percent. 
25 But those that can't like she was before, as 
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Ms. Peterson commented on, when she was really having 
difficulty even tolerating 15 cc's an hour, that's a 
tablespoon an hour of an elemental formula, that's — 
that was problematic. That meant her G.I. tract was 
not able to be fed and the risk there was of her liver 
not getting the appropriate stimulation that it likes 
to get to keep it from developing liver disease. 
THE COURT: Okay. With that additional 
information from Dr. Jackson, Dr. Hylen, would that 
still be helpful, that information? 
DR. HYLEN: I think we still need some 
quantification. 
DR. JACKSON: I'll put that together, okay. 
I'll put it together in a flow sheet. 
DR. HYLEN: The other thing that I think 
makes it sort of difficult here at the hearing is not 
having the articles and the editorial. 
DR. JACKSON: I sent all of those articles 
over back in June and I just have some of these other 
recent ones. One's as recent as October. 
MR. GATZEMEIER: Those recent ones would be 
valuable. 
DR. HYLEN: We don't have the recent things. 
DR. JACKSON: Right. 
DR. HYLEN: So I think it's hard for us to 
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1 comment without seeing those. What additional articles 
2 are you going to send us I think is what we'd like to 
3 know? 
4 DR. JACKSON: I could send you an article 
5 from Gastroenterology, 1997 October. I could send you 
6 a recent search on short bowel and growth hormone use 
7 that has the literature summarized from '93. And I 
8 have, you know, the previous articles that I'd sent 
9 over that I could put together and send again. 
10 THE COURT: Okay, that would be very helpful. 
11 DR. JACKSON: There's an editorial on this 
12 one article that's published by the Mayo Clinic. It'll 
13 give you a perspective. You know, it obviously does 
14 not come down saying that everybody should do this. 
15 THE COURT: Okay. Well, what I would 
16 probably like to do after Health Care Financing has had 
17 an opportunity to review all that is maybe continue the 
18 hearing briefly by telephone just so you can — they 
19 can ask you questions and vice versa. Do you have any 
20 other questions right now? 
21 DR. HYLEN: I don't, no. 
22 THE COURT: Mr. Gatzemeier? 
23 MR. GATZEMEIER: Yes. First of all, Dr. 
24 Jackson — well, first of all I want to know if you've 
25 read your contract with the University of Utah, the 
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1 fine print. I understand the University of Utah has in 
2 fine print that nobody up there can use the word "cold 
3 fusion." 
4 DR. JACKSON: That's right. 
5 MR. GATZEMEIER: Anyway, the concern I have 
6 is that the reason we refused this was not on medical 
7 necessity. 
8 THE COURT: I need to swear you in, too, now 
9 that you7re presenting your case. 
10 MR. GATZEMEIER: We're just cross-examining. 
11 THE COURT: You were cross-examining but — 
12 okay. 
13 MR. GATZEMEIER: I'm just asking him some 
14 questions. 
15 THE COURT: Okay. 
16 MR. GATZEMEIER: You can swear me whenever 
17 you want. 
18- THE COURT: No, whenever you7re ready. 
19 MR. GATZEMEIER: Or we can not swear, we can 
20 attest. 
21 THE COURT: Whenever you're ready to present 
22 your case we'll swear you in. If you're 
23 cross-examining go ahead. 
24 MR. GATZEMEIER: Okay. Dr. Jackson, the 
25 reason that was given for the state denying this was 
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1 not medical necessity, it was on experimental. Now, as 
2 1 understand your testimony you indicated that this 
3 practice was still considered experimental? 
4 DR. JACKSON: I think there's a lot of 
5 therapies that we use that are rightfully considered 
6 experimental which in terms of — if you think of it in 
7 terms of data being accumulated and evaluating the 
8 efficacy, the appropriate dosage, the appropriate 
9 indications, things like that. And this one 
10 particularly as early a therapy as this is, as young a 
11 therapy I guess as this is would definitely I think 
12 have to be considered that. 
13 In my — the strict interpretation of 
14 experimental in my mind would be is she on an 
15 experimental protocol of like one patient in a study. 
16 And I guess I don't consider it that. I consider it 
17 more of a situation of taking a therapy that's been — 
18 that is in use, that is new, that is not 100 percent 
19 validated and may very well have certain subjects, 
20 certain patients in which it works in and certain 
21 patients that it doesn't. That stuff is all being 
2 2 worked out. 
23 And so I see this more as just a decision in 
24 the — I guess -- I don't know whether you call it the 
25 art of medicine but it's the idea of taking data, what 
/ # -
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1 data is available, and a desperate clinical situation 
2 and adding up pluses and minuses and trying to come to 
3 a judgment. And that judgment could be deemed 
4 erroneous by peers or other people, but on the other 
5 hand there are a number of different peers and 
6 superiors to me who agree with trying this kind of 
7 therapy, so they have been my guide. 
8 So I see it in that sense as more of a 
9 medical judgment. I think that's what — I think 
10 that's what's interesting about this whole process here 
11 is how do you decide, based on the rules and 
12 regulations and your charge to take care of lots of 
13 people with that pool of money, what's the best way to 
14 spend that money? Is this a gamble? Is this, you 
15 know, is this foolishness that should not be supported? 
16 And I think that just comes down to where you make it. 
17 If I'm her physician my judgment is that I 
18 would like to try this. I have a certain idea of how 
19 to use it. We don't have all the information or 
20 details and we often don't in making practice decisions 
21 and making clinical decisions, we often don't. We 
22 don't know that this indeed is what cured the patient 
23 or this indeed is what did anything. A lot of times we 
24 just claim credit for things that would have gotten 
2 5 better anyway. 
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1 You look at antibiotic use for ear infections 
2 or for all around -- I mean huge expenditures of money 
3 on therapies that are given to people who would get 
4 better anyway. There's a lot of therapies like that 
5 that are out there. And I'm weighing this against a 
6 therapy that you do pay for, that is approved for 
7 non-life threatening short stature related to 
8 idiopathic growth hormone deficiency, and I'm comparing 
9 that to paying for that for a child who has a 
10 life-threatening problem in which some people, and 
11 people that have worked hard and have produced some 
12 evidence in favor of it, suggest that that can be 
13 beneficial. 
14 The data in pediatrics is later, much later 
15 than the data in adults in this case, which is often 
16 the case. And so we had that other issue from 
17 pediatrics where we apply things — there are many 
18 drugs that are used that have never been verified or 
19 proved in pediatrics. You look through the PDR or any 
20 of the drug reference groups for most of the 
21 medications that we use it says pediatric indications 
22 and use have not been established. That's just a fact 
23 of life for practicing pediatrics. 
24 And part of it is that the society has not 
25 deemed it necessary to study children in that regard. 
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It's expensive to do that and there's concerns about 
the well being of children in those situations. So 
what's happened to pediatricians is they have to take 
those drugs that aren't approved for pediatrics and use 
them. And there's a very, very long tradition of doing 
that, both for good and for bad for children. 
So I guess I fit myself within that tradition 
of making a physician's decision weighing the evidence. 
And obviously I'm at the mercy of the court for looking 
at the letter of the law and making a decision that 
way, as is Markelle. So I would — what I was 
proposing was a self-limited, short-term use of this 
within the reason — you know, the reasonable use of 
this drug as it has been used with patients that have 
growth hormone deficiency to see if it's going to make 
a difference. 
And are we validated by what's happened in 
the last three months by her being treated? Well, it 
certainly hasn't gone the other — hasn't gone the 
wrong direction, and she seems to have made some 
progress. So that does not prove anything. I don't 
think there's anything you could write an article about 
or it'd be a very dubious case report. I don't know 
what kind of a case report that would be at this point. 
But it was not done within an experimental protocol. 
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1 It would be something — it's not the kind of thing 
2 that I would deem purely an experiment that way. It's 
3 more of a medical just judgment decision based on a 
4 certain amount, perhaps not optimal amount, of data 
5 that's out there. 
6 THE COURT: Okay. Any more questions? 
7 MR. GATZEMEIER: Yeah. Dr. Jackson, I'm sure 
8 you're aware of the fact that the reasons — and I 
9 agree 100 percent with what you're saying on — you 
10 know, you have to use things as you deem appropriate 
11 from a medical perspective to try and treat things. 
12 Unfortunately we are in a situation in Medicaid where 
13 we are governed totally by rules. The federal 
14 government because of some of the inappropriate use of 
15 federal programs in the MO's and '50's have totally 
16 eliminated the ability to utilize things that are 
17 considered experimental predominantly, primarily 
18 because they were used in a poor context previously. 
19 And, you know, in the MO's and '50's they 
20 took groups and used experimental procedures which were 
21 not beneficial to the groups but were negative to the 
22 groups. And so when the Medicaid law was written it 
23 basically said you do not use things which are 
24 experimental on any of these groups. That, as most 
25 laws, cuts both ways. Cuts to cut out the 
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1 inappropriate experimentation, but it also eliminates 
2 the ability to experiment with things that could in 
3 fact be beneficial. 
4 And that is one of our concerns, is that even 
5 though procedures and things may be considered 
6 beneficial — and we don't know. You know, we just had 
7 this situation with Phen-Phen where everybody thought 
8 we had a wonderful miracle thing. But the fact is we 
9 are limited to doing things which are proven or 
10 considered proven, recognizing Phen-Phen was a 
11 non-label use. 
12 DR. HYLEN: No, it was an off-label. 
13 MR. GATZEMEIER: All right. But it was 
14 approved by the FDA for that purpose. 
15 DR. HYLEN: No. 
16 MR. GATZEMEIER: Wasn't it? 
17 THE COURT: Well, that's not relevant, let's 
18 not get into that. 
19 MR. GATZEMEIER: Either way. The fact is 
20 this is an off-label use as we understand it of this 
21 drug and the fact is because it's an off-label use it's 
22 considered experimental to us and we have a real 
23 difficulty dealing with both the federal regulations 
24 and the state regulations. Do you have any 
25 information, doctor, that shows that this drug has been 
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approved by either the FDA or the drug manufacturer for 
on-label use for this purpose? 
DR. JACKSON: Nof nof I don't think so. Not 
in the — as far as I know it's not. There might be an 
INDf you know, for the people that are doing — are 
using it in a research setting. There has to be. But 
as far as I know it's not approved as an extended — 
you know, as an indication for this. 
MR. GATZEMEIER: Okay. That's — 
THE COURT: Any other questions? 
Okay. Duane Park has a question. 
MR. PARK: Just one question, doctor. Before 
you started the supplemental use of the growth hormone 
did you do a blood level to determine what the normal 
circulation was? 
DR. JACKSON: Yes, I did, actually. I 
checked IGF-1 which is a marker for that. And she has 
normal levels of IGF-1. And that's not — as I 
understand the information I have, literature, that's 
not -- that would be expected. They don't have low — 
they don't have those kind of indications. In other 
words she doesn't have growth hormone deficiency. The 
use of growth hormone came out of observations that in 
resection growth hormone levels go up. And the 
products that that stimulates that stimulate growth — 
lib 41 
KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS 
JANE G. SAVILLE. C.S.R. 
Markelle Frei-Peterson Hearing, 12/8/97 
1 THE COURT: Excuse me, doctor, I have to flip 
2 the tape. I'm sorry. 
3 (Whereupon, the hearing was briefly 
4 interrupted to begin Side 2 of Tape 1.) 
5 THE COURT: Okay. 
6 DR. JACKSON: Basically the fact that your 
7 growth hormone levels are normal does not necessarily — 
8 does not mean -- that's not the reason that the growth -
9 why the growth hormone is being used. It's higher than 
10 normal levels of growth hormone are observed in 
11 patients that have lost small bowel, and the idea that 
12 they stimulate growth factor production in the body, 
13 including epidermal growth factors, things like that 
14 that work on the lining of the intestine to stimulate 
15 growth. 
16 And those are -- the other — another 
17 experimental line has been in animals that have 
18 excessive growth, have tumors that express growth 
19 hormone, excessive growth hormone, have hyperplasia of 
20 their small bowel. And so the idea basically is that 
21 if you give excessive growth hormone it induces 
22 transcription of the genes for all these growth factors 
23 and stimulates growth of the small bowel. 
24 So basically the goal here is to use it as a 
25 pharmacologic agent rather than a replacement agent. 
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1 Though the indications for using growth hormones for 
2 people of short stature is one based on replacement of 
3 something that is missing. In this case it's being 
4 used in the lines of a pharmacolgic agent to actually 
5 stimulate the kind of growth factors that would be 
6 required to try to make the small bowel develop and 
7 grow more. 
8 THE COURT: Sort of like a catalyst? 
9 DR. JACKSON: Nof it would be more actually 
10 as a growth hormone, as something that you would — I 
11 mean, I guess Schwartzenegger could use it. But it's 
12 along those lines of a drug. In other words you7re 
13 using it at a higher superphysiologic level. 
14 We're not monitoring levels, for example, of 
15 IGF-1 and things like that. Should that be done? I 
16 don't know. That might be an — some of those things 
17 might be some of the things that people have not — 
18 they've looked at those things in the studies but 
19 they've not used that as a marker for adjusting the 
20 dose. They've just taken pretty much a standard dose. 
21 There's a lower dose that someone has used, much lower 
22 than what we're using, and so there's some 
23 experimentation. There's some people trying different 
24 doses. 
2 5 THE COURT: Okay. Any other questions? 
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1 MR. GATZEMEIER: Yeah. Doctor, you mentioned 
2 that — 
3 THE COURT: This is Steve Gatzemeier for the 
4 record. 
5 MR. GATZEMEIER: Yes, I'm sorry. 
6 You mentioned that Markelle is receiving 
7 growth hormone at this point. Who's supplying that, 
8 how is that happening? 
9 THE COURT: I believe he testified he didn't 
10 know. But do you know, doctor? 
11 DR. JACKSON: I think I.H.C. is doing it. 
12 Julie Rich would know. I think I.H.C. 
13 MS. PETERSON: Primary Children's funds is 
14 supplying that for us. 
15 DR. JACKSON: Oh, Primary Children's — 
16 MS. PETERSON: Primary Children's pennies, 
17 their charity is providing the funds right now. 
18 THE COURT: That was Heidi Peterson. 
19 Anything else? 
2 0 Did you have anyone else you wanted to 
21 testify for you on Markelle Frei's condition that would 
22 be relevant or has the doctor pretty much covered 
2 3 everything? 
24 MS. RICH: Well, I was case manager for a 
25 brief time with Markelle. I'm Julie Rich. And I'd 
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1 just like to say that what Heidi has seen at homef if 
2 you look at Markelle as a holistic person that we want 
3 to make developmental milestones and progress then we 
4 need to support her in this. The fact that she was 
5 having so much stool output it made it difficult for 
6 her to meet any of her milestones or progress at all. 
7 It's made it a lot easier to care for her. And it 
8 makes it easier for us to even look at decreasing 
9 nursing hours in the home. 
10 THE COURT: Okay. Do you solemnly swear or 
11 affirm that the testimony that you have just given and 
12 may be about to give is the truth, the whole truth, and 
13 nothing but the truth? 
14 MS. RICH: Yes. 
15 THE COURT: And your name? 
16 MS. RICH: My name's Juliana Rich. 
17 THE COURT: Okay. And was there anything 
18 that you wanted, either of you... 
19 MS. SMITH: I'm Abby Smith. 
2 0 THE COURT: Okay. Raise your right hand, 
21 please. 
22 ABBY SMITH, 
23 appearing as a witness, having been first duly 
24 sworn, testified as follows: 
25 THE COURT: Your name for the record? 
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1 MS. SMITH: Abby Smith. 
2 THE COURT: Okay. 
3 MS. SMITH: I'm from I.H.C. Access. We don't 
4 provide anything in the way of drugs for any Medicaid 
5 patients so we would really not be able to do anything 
6 for Markelle. 
7 THE COURT: Okay. 
8 MR. GATZEMEIER: Were you able to hear that, 
9 doctor? 
10 DR. JACKSON: I lost her after she said "We 
11 are not able to provide anything but..." 
12 MS. SMITH: Medicaid provides all of the 
13 drugs for I.H.C. Access patients. So we are not 
14 allowed to provide monies for drugs. 
15 MR. GATZEMEIER: The pharmacy portion of the 
16 Medicaid program is not funded through I.H.C. Access. 
17 They're being paid for other services but the actual 
18 expenditures of the pharmacy comes directly from the 
19 state. 
2 0 THE COURT: Okay, any more questions from 
21 Medicaid — 
22 MR. GATZEMEIER: Not at this time. He may 
23 have some questions. 
24 THE COURT: Would you like to go ahead and 
25 present --
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1 MR. GATZEMEIER: Certainly. Should we swear 
2 all of us at the same time? 
3 THE COURT: Yes. I'm going to swear Health 
4 Care Financing in now. And I'm going to point to you 
5 after I administer the oath and if you'll state your 
6 name then for the record. 
7 (All witnesses for Health Care Financing 
8 were sworn.) 
9 MR. PARK: Yes. Duane Park. 
10 DR. HYLEN: I do. John Hylen. 
11 MR. GATZEMEIER: Yes. Steve Gatzemeier. 
12 MS. NAHLEY: Yes. Penny Nahley. 
13 THE COURT: Thank you. 
14 PENELOPE NAHLEY, 
15 appearing as a witness on behalf of Health 
16 Care Financing, having been first duly sworn, 
17 testified as follows: 
18 EXAMINATION 
19 BY MR. GATZEMEIER: 
20 Q Okay. Miss Nahley, you were the one who 
21 initially took the action to deny this request. Can 
22 you tell us what process you went by to deny that and 
23 what the rationale was for denying the request? 
24 A Well, I went — I got out the both criterias 
25 to see if she met any of that and she did not meet that 
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1 the criteria. I asked for additional documentation 
2 from the physicians knowing that this was not a common 
3 use for the drug according to our criteria. So I had 
4 asked for additional information to be sent and that 
5 was to include any literature they had that would 
6 support the use of this drug. I asked for liver 
7 function tests, her clinical records, what type of TPN 
8 she was on, her entero products, that sort of thing. 
9 That all came in and it was reviewed. I 
10 reviewed it. I took a lot of notes on it and then 
11 presented it to the Check Utilization Review Committee 
12 and they reviewed it and agreed that this was not a 
13 typical use for this drug, that it was an experimental 
14 and we denied it. 
15 Q Okay. When you say you took it to the Check 
16 Utilization Review Committee can you tell us what the 
17 constitution of that committee is. 
18 A It's made up of physicians and nurses. 
19 Q Okay. I believe there's also a social worker 
20 or a check portion of it? 
21 A I believe she is — she's a social worker and 
22 then there's the consultants. We have OTPT 
23 consultants. 
24 Q Okay. And that committee reviewed this 
25 request and determined that it was denied. What was 
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1 the rationale again? 
2 A It was to be denied that the documentation 
3 indicated it was an experimental procedure. 
4 Q Okay. You also indicated, Miss Nahley, that 
5 you looked at the criteria for growth hormones and it 
6 did not meet the criteria. Specifically what criteria 
7 did it not meet? 
8 A She did not have a documented failure of 
9 growth due to an endogenous growth hormone secretions. 
10 Or she did not have insufficiency due to kidney 
11 failure. 
12 Q Okay. Now, the doctor has already testified 
13 that this isn't really the rationale for providing this 
14 drug, however this is the rationale and the 
15 documentation that the state uses to determine whether 
16 the drug should be prior authorized. Can you tell us 
17 where this is found, what this comes from? 
18 A Where this criteria comes — 
19 Q Yes. 
20 A This comes from our pharmacy provider manual. 
21 Q Okay. And the pharmacy provider manual 
22 outlines the state's policy related to particular drugs 
23 or utilization of — 
24 A Yes. 
25 Q Drug types? 
/2L- 49 
KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS 
JANE G. SAVTT.T.F . C . R . P 
Markelle Frei-Peterson Hearing, 12/8/97 
1 A Yes. 
2 THE COURT: Are you going to be submitting 
3 that into evidence? 
4 MR. GATZEMEIER: Yes, we will. 
5 THE COURT: Do you have any objection to 
6 that, Dr. Jackson? 
7 DR. JACKSON: Oh, no. 
8 THE COURT: Okay. 
9 Q (By Mr. Gatzemeier) Okay. So you looked at 
10 the information, you issued a denial letter, you got a 
11 request for reconsideration. Was there any additional 
12 information that you looked at following that denial? 
13 A I'm not really sure how that came. I believe 
14 in with the hearing request there were some other 
15 documentation on studies that have been done. And so 
16 that was looked at — 
17 Q You did review that information? 
18 A — at that time. Uh-huh. 
19 Q Did that change at all your position? 
20 A No, it's definitely stated in there that 
21 these were small groups and that it was study groups 
22 that were being done. Still didn't meet our criteria. 
23 It still was experimental. 
24 Q Okay. What is the documentation or the 
25 justification for the denial on experimental? In the 
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1 denial letter you have a citation. Can you tell us 
2 where that came from? 
3 A Let me just find it real quick. Okay, that's 
4 Utah Administrative Code R414-10-6, Physician's Covered 
5 Services. And it states, "Experimental or medically 
6 unproven physician services or procedures are excluded 
7 from coverage." 
8 MR. GATZEMEIER: Okay. That's all the 
9 questions I have. Are there any questions of Miss 
10 Nahley? 
11 THE COURT: Do you have any questions for 
12 Miss Nahley, Dr. Jackson? 
13 DR. JACKSON: No, that's okay. Thank you. 
14 THE COURT: Okay. Are you going to be 
15 submitting those — 
16 MR. GATZEMEIER: Yes. Well, that is part of 
17 the denial letter — 
18 THE COURT: Oh, that's part of the — okay, 
19 that will be Respondent's --
20 MR. GATZEMEIER: — that you already have. 
21 THE COURT: Oh, it's part of the record 
22 already? 
23 MR. GATZEMEIER: Yes. 
2 4 THE COURT: Okay. 
25 MR. GATZEMEIER: Okay. Then we'd like to 
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1 call Dr. Hylen. 
2 THE COURT: Okay. Dr. Hylen, want to be 
3 sworn? 
4 MR. GATZEMEIER: Well, we'd like to call 
5 Duane Park. Duane, you've been sworn in. You might 
6 want to get up close to a microphone. 
7 DUANE PARK, 
8 appearing as a witness for Health Care 
9 Financing, having been first duly sworn, 
10 testified as follows: 
11 EXAMINATION 
12 BY MR. GATZEMEIER: 
13 Q Can you tell us what your credentials are? 
14 A I'm a registered pharmacist and have a 
15 master's in health administration. My job is to 
16 coordinate and develop the drug utilization review 
17 process for the state of Utah, which is mandated by the 
18 over laws of 1990, '93, and more recently in the 
19 Reconciliation Act of 1997. 
20 MR. GATZEMEIER: Can you hear him okay, 
21 doctor? 
22 DR. JACKSON: Yes, thank you. 
23 MR. GATZEMEIER: Okay. 
24 Q (By Mr. Gatzemeier) Mr. Park, in your 
25 capacity with the state are you familiar with the Drug 
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1 Utilization Review Board? 
2 A Very familiar with it. 
3 Q Can you tell us what that board is and who 
4 constitutes it? 
5 A This is a review board composed of 
6 physicians, pharmacists, one advocate for clients or 
7 patients, and one advocate for the drug manufacturers' 
8 organization called Pharma, and also one dentist. It's 
9 a 12-member board as defined by law what the membership 
10 will be derived from. So the numbers are set for the 
11 number of physicians, pharmacists, one dentist, one 
12 advocate, and one manufacturer representative. 
13 Q Okay. What is the purpose of that board? 
14 A This board is to do drug review and 
15 utilization. Their job is to see that the drugs used 
16 by Medicaid are in fact used according to the law and 
17 in a cost effective and patient effective manner. 
18 Q Okay. Has that board at all looked at the 
19 possibility of — you've heard testimony by Dr. Jackson 
20 that this particular drug that we're looking at is 
21 basically an off-label use. It's a new use of the drug 
22 other than what the drug was originally identified for. 
23 Has the drug utilization review board ever looked at 
24 the possibility of utilizing drugs for off-label use? 
25 A They have. Growth hormone was placed on 
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1 prior approval through the action of the DUR board. 
2 They have recently passed a policy on off-label use, 
3 That was independent of the recent Reconciliation Act. 
4 That use recognized label use, listed unlabel user and 
5 unlisted uses that would fall into the experimental 
6 area. 
7 MR. GATZEMEIER: Okay. We do have a copy of 
8 the notes and the action of that board which we would 
9 like to submit — 
10 THE COURT: Do you have any objection to 
11 that, Dr. Jackson? 
12 DR. JACKSON: Oh, no. 
13 THE COURT: Okay. What number? Is that 
14 Respondent's Exhibit 1? 
15 MR. GATZEMEIER: Are we at 1 now? 
16 Respondent's Exhibit 1. 
17 THE COURT: Okay, it was part of the record 
18 already. 
19 MR. GATZEMEIER: This was not, Respondent's 
2 0 Exhibit 1 just came in. The other was part of the 
21 record. 
22 THE COURT: Okay, it's admitted. 
23 (Whereupon, Respondent's Exhibit 1 was 
24 received into evidence.) 
25 Q (By Mr. Gatzemeier) All right. Mr. Park, 
/ * ^54 
KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS 
JANE G. SAVILLE, C.S.R. 
Markelle Frei-Peterson Hearing, 12/8/97 
1 based on the actions of that board and as I understand 
2 it you are the Department of Health staff to that 
3 board; is that correct? 
4 A That is correct. 
5 Q Okay. Based on the actions of that board and 
6 the drug that we've been talking about this morning how 
7 would use of that drug fall within the adopted policy 
8 of that board? 
9 A This policy was developed to address a 
10 mechanism for dealing with drugs just such as growth 
11 hormone that have enormously broad application. It 
12 recognizes that the current technology and information 
13 that's coming out so rapidly has yet to be codified and 
14 put into approved or FDA reviewed status. So it's 
15 merely a policy that gives physicians like youf Dr. 
16 Jackson, a mechanism to go to the board and request 
17 that this particular drug be considered for — by the 
18 board for coverage for a select cne-on-one patient. 
19 Q Okay. Based on that action of the board is 
2 0 the current requested use of the recombinant human 
21 growth hormone that we're talking about in this hearing 
22 covered — would it be covered under Medicaid 
23 currently? 
24 A No, it would have to be — the determination 
25 would have to come from the DUR board, your peers, for 
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1 this specific client. 
2 MR. GATZEMEIER: And I do think that that is 
3 an important notef Dr. Jackson. That board does meet 
4 monthly. What our position would be currently, and 
5 this is kind of — I guess it's kind of testimony. 
6 Currently is that the drug is not covered but that 
7 board does have the ability to say a drug will be 
8 covered for a specific purpose, which in this case it 
9 would seem that that might be something that you would 
10 want to take to that board and say, "Can this drug be 
11 approved for this purpose?" 
12 Recognizing we also have the capability 
13 through this hearing process to review that, but, you 
14 know, to preclude situations like this from happening 
15 in the future if the board says that is a covered 
16 Medicaid process we would not have to be in the hearing 
17 process to review it. 
18 THE COURT: Would the board be reviewing the 
19 use in that way for just this particular patient or for 
20 all similar — 
21 THE WITNESS: So far they have only used this 
22 policy one time. It was for a particular patient. 
23 THE COURT: For a particular patient. 
24 THE WITNESS: For a singular use of a drug. 
25 THE COURT: So that is a possibility should — 
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1 THE WITNESS: Uninvestigated possibility at 
2 this point, yes. 
3 THE COURT: Okay. Should the — 
4 DR. HYLEN: I think they also could take a 
5 class of patients for unlabeled. So I think it's 
6 either way. 
7 THE COURT: Okay. Thank you for that 
8 clarification. 
9 DR. JACKSON: Could I ask a question? 
10 THE COURT: Yes. 
11 DR. JACKSON: What is DUR? Utilization 
12 Review? 
13 THE WITNESS: Drug Utilization Review Board. 
14 DR. JACKSON: Thank you. 
15 MR. GATZEMEIER: You do have a representative 
16 from the University of Utah — actually I think it's 
17 the School of Pharmacy — that is on that board. 
18 THE WITNESS: That's correct. Dr. Lynda 
19 Oderda from the College of Pharmacy serves on the 
20 board. We also have Dr. Hare from the College of 
21 Medicine who serves on the board. 
22 THE COURT: Okay. Should he not prevail at 
23 this hearing can you give him any more information on 
24 how to approach that? 
25 THE WITNESS: If the policy was sent to him 
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1 he could see that there is an avenue that he can 
2 explore which would be very similar to this one. He 
3 would provide all the current articles he has to the 
4 board for their review and then they would determine 
5 whether it's covered or not. 
6 MR. GATZEMEIER: Could you see that a copy of 
7 that is sent to him so that he will have that avenue 
8 available to him? 
9 THE WITNESS: May I have your fax number, 
10 doctor? 
11 MR. GATZEMEIER: We have the information. We 
12 can give it to you afterward. 
13 THE COURT: Okay. Do you have any other 
14 questions for Mr. Park, Dr. Jackson? 
15 DR. JACKSON: Nof thank you. 
16 MR. GATZEMEIER: I was mistaken. We 
17 apparently don7t. So if we have that information we 
18 can send it to him. 
19 THE COURT: Okay. Apparently they do need 
2 0 your fax number. 
21 DR. JACKSON: It's 588-2375. 
22 THE COURT: Okay. Was there anything else 
2 3 that... 
24 MR. GATZEMEIER: Yes we'd like to call Dr. 
25 Hylen. 
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1 THE COURT: Dr. Hylen is going to testify 
2 now. Thank you, Mr. Park. 
3 THE COURT: You've already been sworn, 
4 doctor. 
5 DR. HYLEN: Yes, I have. 
6 JOHN HYLEN, M.D., 
7 appearing as a witness on behalf of Health 
8 Care Financing, having been first duly sworn, 
9 testified as follows: 
10 EXAMINATION 
11 BY MR. GATZEMEIER: 
12 Q Okay, Dr. Hylen, you've reviewed the 
13 situation related to this case? 
14 A Yes, I have. 
15 Q Okay. Can you tell us what your findings 
16 are? 
17 A Maybe we should start with my credentials. 
18 Q Okay. Can you tell us what your credentials 
19 are? 
20 A Yes, I have a doctorate in medicine, and a 
21 master's of public health, and I'm board certified in 
22 internal medicine, cardiovascular medicine, and 
23 geriatric medicine. 
24 Q Okay. Can you tell us what your finding and 
25 conclusions were related to this case? 
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1 A Well, I think one of the things that concerns 
2 me is that this is an area where the Drug Utilization 
3 Review Committee by federal law has been set up to have 
4 controls over off-label use. And so I think that it's 
5 important that they be involved in any decision that 
6 would open this up. I think I have concern that 
7 they're going to approve the use of this drug in this 
8 case since their judgment has to be not only based on 
9 the findings of this case but also a review of the 
10 literature. And I think Dr. Jackson has testified that 
11 growth hormone for this use could be disapproved, which 
12 to me sounds like that it hasn't been proven yet that 
13 it's effective in preventing liver disease and 
14 preventing the need for liver transplants. 
15 And the other thing I think we have to be 
16 concerned about, what are the toxicities. You know, if 
17 you're going to use this for more than a year what are 
18 the toxicities for children. 
19 So I think there's several things that are of 
20 concern in this case. One certainly is expenses. It's 
21 an expensive medication. I have concerns about whether 
22 the side effects and also if it is not documented to 
23 prevent liver disease, progression of liver disease and 
24 liver transplantation, if this is only a medication 
25 that promotes feeding then are there other more 
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1 cost-effective ways to get the child or infant to eat. 
2 So I think there are a lot of unanswered questions. 
3 THE COURT: The biggest one I have is is it 
4 Health Care Financing's contention that I don't have 
5 the jurisdiction to — if I were to pay — to say this 
6 should be paid for in this case because of the DUR? 
7 I'm — 
8 MR. GATZEMEIER: No, no, no. It's Health 
9 Care Financing's — 
10 THE COURT: Otherwise it shouldn't have come 
11 this far to me. 
12 MR. GATZEMEIER: No, it's Health Care 
13 Financing's contention that there is a — there is an 
14 administrative process set up to establish these. The 
15 hearing process is also an administrative process which 
16 has been set up. I don't know that they have to work 
17 against each other. I think that the mechanism is such 
18 that one could utilize the other. 
19 THE COURT: I'm just concerned about judicial 
20 efficiency and wasting everybody's, potentially wasting 
21 everyone's time. 
22 DR. HYLEN: I don't have the answer to that. 
23 Certainly administrative hearings have been around a 
24 lot longer than the DUR Committee. But the federal 
2 5 government did set up and mandate, I mean, who's there, 
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1 and you will function, and you will control the 
2 utilization of what medications are used and how 
3 they're used amongst Medicaid clients. And so... 
4 And the other thing is that I think is very 
5 pertinent to the court is that the DUR has addressed 
6 unlabeled uses and has set up mechanisms for approval 
7 both of for individual patients and for classes of 
8 patients that they can set up guidelines so that — so 
9 that it's not an impossibility to receive medications 
10 on it for unlabeled uses. 
11 THE COURT: Uh-huh. Okay, thank you. Do you 
12 have questions for Dr. Hylen, Dr. Jackson? 
13 DR. JACKSON: No. I just reiterate that it's 
14 not — the growth hormone's indication for this 
15 petition is not to try to make Markelle eat simply as 
16 an appetite stimulant or anything like that. It's 
17 really specifically to get her to reduce her dependence 
18 or eliminate her dependence on parenteral nutrition. 
19 And that's the principal reason and... 
2 0 DR. HYLEN: And I would agree with that. 
21 MR. GATZEMEIER: And we would all agree with 
22 that. And that's basically the reason I think the 
23 state has taken for saying this is not covered. Growth 
24 hormone according to the state provider manual, the 
25 drug criteria manual, is utilized — there's two 
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1 groups. Both of them are growth failure. We all 
2 recognize that is what the primary or the initial 
3 rationale for utilizing this drug was. This is a 
4 different approach to utilizing the drug. It's not 
5 covered in policy as far as this is one of the things 
6 we can approve. So until we get some change of policy, 
7 which is what the DUR would address — 
8 DR. JACKSON: I understand that was the 
9 motivation for the hearing, otherwise it would have 
10 been pretty simple. 
11 THE COURT: That's exactly what I was talking 
12 about a couple of minutes ago. You knowf if I don't 
13 have the jurisdiction to do this it should have just 
14 gone to the DUR Board. But apparently I believe I do 
15 have jurisdiction to make the ruling independent of the 
16 DUR Board. I think they're two separate administrative 
17 processes. 
18 UNIDENTIFIED FEMALE SPEAKER: Were we 
19 notified about the DUR before we came this far? 
2 0 THE COURT: No. 
21 MR. GATZEMEIER: No. 
22 THE COURT: And I wasn't aware how that 
23 process worked either. 
24 MR. GATZEMEIER: And that's one of the things 
25 we wanted to flush out in here is what processes there 
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1 I were, what other mechanisms and options there were. 
2 UNIDENTIFIED FEMALE SPEAKER: And this is an 
3 avenue we could have taken months ago? 
4 MR. GATZEMEIER: Yeah. Now, they just 
5 addressed the issue of off-label drug use policy 
6 November 13th. So they have been — 
7 DR. HYLEN: Well, they've been addressing it 
8 over a long period of time, but this particular policy 
9 came out. But they've been looking at that issues for 
10 a long — 
11 UNIDENTIFIED FEMALE SPEAKER: So our first 
12 denial we could have started this avenue? If we would 
13 have been notified about this process we could have 
14 started? 
15 MR. GATZEMEIER: Right. 
16 UNIDENTIFIED FEMALE SPEAKER: Okay. 
17 THE COURT: I'd just like to encourage you, 
18 Dr. Jackson, to get any other information you can in to 
19 us and would five business days — 
20 DR. JACKSON: Sure. I'll just have them just 
21 fax it to you and Dr. Hylen. 
22 THE COURT: Andf Dr. Hylen, how long would it 
23 take you to review that? 
24 DR. HYLEN: Well, since they're going to have 
25 more current data I think we probably should do the 
I7S-' 64 
KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS 
JANE G. SAVILLE, C.S.R. 
Markelle Frei-Peterson Hearing, 12/8/97 
1 same. But that shouldn't take long. 
2 THE COURT: What I'd like then is both sides 
3 to exchange — 
4 DR. JACKSON: I'll send the search that I 
5 have and I have copies of those articles. 
6 THE COURT: Then I'd like to ask Dr. Hylen to 
7 send his — the results of his research to you. 
8 Hopefully we don't have to have — 
9 DR. JACKSON: Sure. We may have the same — 
10 THE COURT: — another hearing. If you'd 
11 like to, you know, comment in writing — you know, I 
12 don't know if it's going to do any good to have another 
13 continuation of the hearing where we discuss the 
14 literature. I think, you know, if Dr. Hylen decides 
15 that — based on this literature that it should be 
16 approved then that's fine. We know we wouldn't have to 
17 go further in the hearing. Otherwise I think I will 
18 just make a decision on all the documents that are 
19 submitted, and the evidence in the record, and the 
2 0 testimony. 
21 DR. JACKSON: I think that's fine. We have a 
22 point of closure. 
2 3 THE COURT: Yes. 
24 UNIDENTIFIED FEMALE SPEAKER: I have a 
25 question. 
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1 THE COURT: Yes. 
2 UNIDENTIFIED FEMALE SPEAKER: In this 
3 information can it be provided from pharmacy and also 
4 from Dr. Jackson or my insurance how much Markelle, 
5 where we're talking about cost efficiency, how much it 
6 would cost today for the growth hormone, how much she 
7 costs to live for her TPN, her nutrition, my nursing, 
8 and all of that so that the cost efficiency can be 
9 determined in that way also? 
10 THE COURT: Yes. 
11 UNIDENTIFIED FEMALE SPEAKER: Because in the 
12 long run if this does help her that would eliminate a 
13 big cost every month. 
14 THE COURT: Okay. 
15 UNIDENTIFIED FEMALE SPEAKER: So could that 
16 be included someplace? 
17 THE COURT: Uh-huh. Do you know how long 
18 that would take — 
19 UNIDENTIFIED FEMALE SPEAKER: We have figures 
20 and I know myself I called pharmacies to self pay for 
21 the growth hormone. 
22 THE COURT: Would five business days be 
23 sufficient? If you have any trouble with that time 
24 period let me know. If you 711 submit a copy of that to 
2 5 the court — 
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1 UNIDENTIFIED FEMALE SPEAKER: Okay. 
2 THE COURT: And also to Health Care Financing 
3 so Dr. — 
4 UNIDENTIFIED SPEAKER: Yes. 
5 MR. GATZEMEIER: One question. We need to 
6 clarify that it's our position that one does not 
7 preclude the other. This growth hormone is an 
8 experimental process. Theoretically it could lead to 
9 elimination of the other costs but there is no cause 
10 and effect proved right now. We're saying we will try 
11 this and see if it can reduce these costs. But trying 
12 this does not necessarily -- it's not given that we 
13 would reduce the other costs by doing the growth 
14 hormone. 
15 THE COURT: Understood. But I — yeahf I can 
16 give the evidence the weight that I determine that it 
17 should have based on what it is. 
18 MR. GATZEMEIER: We would also — it would 
19 probably be advantageous if when we're giving this 
20 information to Dr. Jackson if we send him a copy of 
21 this Respondent's Exhibit 1. 
22 THE COURT: Respondent's Exhibit 1, okay. 
23 You can fax that right after the hearing. Is there 
24 anything else? 
2 5 DR. JACKSON: Not from my side. 
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1 II THE COURT: Is there anything else from 
2 Health Care Financing? 
3 MR. GATZEMEIER: No, I think that's — 
4 THE COURT: okay, thank you very much for 
5 your time, Dr. Jackson. 
6 DR. JACKSON: Thank you. 
7 THE COURT: Thank you all. 
8 DR. JACKSON: Goodbye. 
9 THE COURT: Goodbye. 
10 (Whereupon, the proceedings were 
11 || concluded for the day.) 
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Off-Label Use Drug Policy 
November 13, 1997 
OFF-LABEL USES 
Utah restricts the covered drug products on the open formulary to uses approved and documented 
by the officially recognized compendia [OBRA 1993, section 1927 (d) (6)]. The designated 
compendia are: 
1. package insert, FDA approved uses 
2. American Hospital Formulary Service Drug Information (AHFS) 
3. American Medical Association Drug Evaluation (AMADE) 
4. United States Pharmacopeia Drug Information Drug Information (USP- DI) 
5. DRUGDEX 
The DUR Board may approve an unlisted off-labeled use for a given drug if the off labeled use 
meets the following criteria. 
1. Use must be diagnosis specific as defined by an ICD9 code (s). 
2. Off-labeled use must be supported by one major multi-site study or three smaller 
studies published in JAMA, NEJM, Lancet or specialty peer review medical 
journals such as Journal of Cardiology. Articles must be current - within five 
years. 
3. Off-labeled use must have a defined dosage regimen. 
4. Off-labeled use must have a defined duration of treatment. 
5. The off-labeled use shows clear and significant clinical or economic advantage 
over existing approved drug regimens. 
The UMA, Utah based Group Practices or Utah based prescribers may have the option of 
petitioning the DUR Board for coverage for an unlisted off-labeled use of a given drug. The 
petitioner(s) must schedule an appearance before the Board to present the case for the petitioned 
drug. Petitioners must provide documentation including one published major multi-cite study or 
a minimum of three recent (five years) articles from JAMA, NEJM, Lancet or peer review 
specialty medical journals such as the Journal of Cardiology, supporting the petition's 
position. The documentation must be submitted six weeks in advance of the scheduled DUR 
Meeting. 
dp/pol icy/offlabel_use_4 
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Addendum D 
Short Bowel Rehabilitation Program: A Unique Approach 
Including Glutamine, Growth Hormone and Special Diet 
D. Wilmore, Boston 
The short bowel syndrome is a lethal disease which lacks an effective low-cost method 
of treatment. Because the bowel can hypertrophy following resection, we have evaluated therapy 
which will enhance future compensation of the residual bowel following enterectomy. A variety 
of animal studies have demonstrated the trophic effects of growth hormone (GH), glutamine 
(GLN) and dietary fiber in enhancing intestinal growth and absorption of nutrients from the 
gastrointestinal tract. To evaluate this effect in humans, we initially studied 15 TPN-dependent 
short-bowel patients over 3-4 weeks in the Clinical Research Center; the first week served as 
a control period and during the next 1-3 weeks the specific treatment was administered and 
evaluated. Throughout the study, food of known composition was provided and all stool was 
collected and analyzed to determine absorption across the remaining bowel. The effect of a high-
carbohydrate, low-fat diet (DIET), GLN and GH administered alone or in combination with the 
other therapies (GH+GLN+DIET) was evaluated. While both GH and GLN demonstrated 
some independent effects, these studies indicated improvement in absorption of protein by 39% 
accompanied by a 33% decrease in stool output with the combination therapy. Because of the 
clinical improvement which occurred with the GH+GLN+DDET, the study was expanded to 47 
adults (25 men, 22 women) with the short bowel syndrome, dependent on TPN for 6±1 years. 
The average age was 46+2 years and the average jejunal-ileal length was 50+7 cm (median 35 
cm) in those with all or a portion of colon and 102+24 cm (median 102 cm) in those with no 
colon. After 28 days of therapy, the patients were discharged on only GLN + DIET. Forty 
percent of the group remain off TPN and an additional 40% have reduced their TPN 
requirements, with the longest follow-up being over 5 years. In addition to the adults, 12 
children have been treated to date and these patients have shown enhanced growth velocity and 
improved absorption. 
This approach offers a potential method for providing cost effective rehabilitation of 
surgical patients who have the short bowel syndrome or other complex problems of the 
gastrointestinal tract. This therapeutic combination may also be useful to enhance bowel 
function in patients with other gastrointestinal diseases or to consider in those patients where 
gastrointestinal disease or its treatment prevents a full growth potential. 
Support Lin 
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A New Treatment Option for Patients with 
Short Bowel Syndrome: Bowel Rehabilitation with 
Growth Hormone, Glutamine, and a Modified Diet 
Theresa A. Byrne, DSc, RD, CNSD; Barbara Browning, BSN, CRNI; Natalie Tu, RD, CNSD; Douglas W. Wilmore, A 
Introduction 
Short bowel syndrome (SBS) is a 
disorder characterized by the signs, 
symptoms, and metabolic alterations 
that occur due to the loss of functional 
absorptive surface area of the gastroin-
testinal tract. The patient presents with 
diarrhea, dehydration, electrolyte dis-
turbances, malabsorption and progres-
sive malnutrition. SBS is usually the 
result of extensive small-bowel resec-
tion following intestinal infarction due 
to mesenteric vascular disease, intesti-
nal volvulus, trauma, malignancy, con-
genital abnormalities, or complications 
of Crohn's disease. Less often the 
defect is functional, rather than ana-
tomical, as in patients with radiation 
enteritis or active Crohn's disease. 
The severity of this disorder depends 
upon the length, location, and health of 
the remaining bowel and the degree to 
which the remnant bowel adapts fol-
lowing intestinal resection. The mini-
mal length of small bowel required to 
maintain enteral autonomy is 50-70 
cm of jejunum-ileum (if the colon is 
left intact) or 110-150 cm if the resec-
tion is associated with a colectomy. If 
less bowel remains or if the remnant 
bowel is severely diseased or dam-
aged, dependence upon total parenteral 
nutrition (TPN) is usually permanent. 
In some individuals, bowel adaptation 
may occur with time, and TPN is 
needed for only 6-24 months. 
Maximal bowel adaptation is achieved 
within 1-2 years following resection. 
However, if the patient is still depen-
dent on TPN at this time in spite of 
optimal medical and nutrition manage-
ment, it is unlikely that the bowel will 
undergo sufficient adaptation to sup-
port the individual. In these cases, 
dependence on parenteral nutrition is 
usually permanent (1-3) (Table 1). 
Contributions and Limitations of 
Long-term TPN 
The first comprehensive report of 
small-bowel resection in humans was 
published by Haymond in 1935 (4). 
From his analysis of 257 patients, he 
concluded that resections of greater 
than 50 percent of the small bowel 
were associated with metabolic com-
plications and a poor outcome. The 
Table 1: Primary Factors Determining Long-term Dependence on TPN 
Inadequate bowel length 
< 50-70 cm of jejunum-ileum with colon 
< 110-150 cm of jejunum-ileum with no colon 
Incomplete bowel adaptation 
maximized 1-2 years following resection 
overall operative mortality u 
percent and only 20 percent« 
patients survived more than < 
With time, developments of 
diagnostic techniques and ad 
intraoperative management a 
for prompt surgical intervent 
improved operative survival. 
it was the demonstration in 1 
that weight gain, growth, anc 
ment could be achieved if all 
nutrients were administered f 
that has had the most dramat: 
ence on the survival of patier 
ing massive intestinal resecti* 
Shortly thereafter, the concep 
care evolved, and it became [ 
provide TPN in the home. As 
of these developments, it has 
mated that approximately 70 
of patients with SBS are disci 
from the hospital and a simik: 
are alive one year later (6). B< 
(Continued on t 
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TPN's dramatic impact on patient sur-
vival, this form of therapy quickly 
became the standard approach to the 
care and management of patients with 
severe SBS. 
Although long-term parenteral nutri-
tion is a life-sustaining therapy for 
these individuals, the complications 
and extraordinary costs are now 
recognized. The complications include 
hepatic dysfunction (7), progressive 
renal insufficiency (8), bone deminer-
alization (9), numerous nutrient defi-
ciencies (10, 11) and catheter sepsis 
(12). Patients receiving home TPN are 
hospitalized on average twice a year, 
usually for septicemia. In addition, the 
cost of home-administered TPN is now 
estimated to be approximately $100,000 
per patient year (12). Because of the 
expense, many patients remain on 
medical disability even though the 
majority want to return to daily activi-
ties, including work. Socialization and 
rehabilitation are often suboptimal. As 
the patient remains dependent upon 
TPN, the quality of life often deterio-
rates, and two-thirds of the population 
report problems such as the loss of 
friends, failure to find employment, 
and depression (13). 
Treatment Options 
Because of the risk, complications, 
limitations, and costs associated with 
long-term TPN, researchers have 
explored alternative therapeutic options 
aimed at reducing or eliminating long-
term parenteral nutrient requirements. 
Surgical procedures to lengthen short 
intestines and/or slow intestinal transit 
have resulted in relatively poor clinical 
outcomes (14). Successful cases of 
intestinal transplantation have been 
reported; however, this form of therapy 
remains experimental and is associated 
with significant morbidity and mortality 
and tremendous costs ($500,000 per 
transplant and $20,000 per patient year 
for medical follow-up and immunosup-
pressive medications) (15). There is also 
concern about the potential development 
of lymphoproiiferativc disease (eg, lym-
phomas) in transplanted bowel seg-
ments; this problem is only no 
addressed by a variety of resea 
cols. Others have explored the 
of bowel rehabilitation, which 
the administration of specific g 
factors, nutrients, and/or enten 
enhance the normal physiologi 
of bowel adaptation/compensa 
BOWEL REHABILITATIC 
Intestinal Adaptation in She 
Syndrome 
One of the most intriguing •< 
SBS is the gradual improver™ 
symptoms following intestina 
tion. Bowel adaptation, first d 
by Flint in 1912 (16), is assoc 
with a decrease in diarrhea an 
sorption and an increase in tol 
enteral feedings with time. Th 
process is characterized by el< 
and dilation of the remnant be 
an increase in villus height, cr 
depth, cell proliferation, and e 
activity. Although the precise 
nisms that account for these al 
in bowel morphology and fun< 
not known, similar changes ca 
when one administers various 
factors (eg, growth hormone, i 
like growth factor 1 [IGF-1]), 
exposure of the mucosa to spe 
nutrients (eg, glutamine, short 
fatty acids) and from the vario 
tors brought into play by the p 
of enteral feedings (eg, enteric 
mones, pancreatic biliary seen 
Together these trophic stimuli 
the remnant bowel to adapt (h] 
phy) (17). In addition, the com 
of the diet can greatly influenc 
ability of both the small and la 
bowel to compensate followinj 
sive intestinal resection. 
Growth Hormone and the In 
Tract 
The exogenous administratio 
growth hormone (GH) or its an 
has been shown to influence bo 
adaptation by enhancing mucos 
hyperplasia following extensive 
nal resection in animals (18, 19 
Christensen and colleagues hav 
Wnmwwiimimm 
that GH administration increases 
colonic mass (20); an effect that may 
enhance the reservoir function of the 
colon. The exogenous administration of 
IGF-1, which is regulated by GH, has 
been shown to enhance bowel hyper-
plasia and hypertrophy in rats follow-
ing extensive jejuno-ileal resection 
(21). Others have demonstrated that 
IGF-1 induces ornithine decarboxylase 
(22, 23), the rate-limiting enzyme in 
the synthesis of polyamines (sub-
stances that are necessary for normal 
cellular growth and differentiation). 
While the inhibition of ornithine decar-
boxylase activity suppresses DNA syn-
thesis and results in the complete 
absence of intestinal adaptation follow-
ing resection (24), the intraileal infu-
sion of IGF-1 has been shown to 
increase polyamine synthesis and pro-
duce a significant trophic effect on the 
gastrointestinal mucosa (25). 
In addition to the morphologic 
effects of GH and IGF-1 on the bowel, 
exogenous GH exerts specific func-
tional effects. Growth hormone 
increases water and sodium transport 
in the small intestine and in the colon 
(26, 27) and appears to regulate intesti-
nal amino acid absorption in several 
animal models (28). More recently, 
others (29) have demonstrated that the 
exogenous administration of GH 
increases amino acid transport in the 
human jejunum and ileum. 
Glutamine and the Intestinal Tract 
Like GH, glutamine (GLN) exerts 
important morphologic and functional 
effects on bowel. Glutamine is a major 
fuel source for both the enterocytes 
and the colonocytes (30) and is neces-
sary for the maintenance of intestinal 
structure, in both normal and stress 
states. In animals, infusion of giutami-
nase markedly reduces the concentra-
tion of blood GLN: simultaneously 
diarrhea, villous atrophy, mucosal 
ulcerations, and intestinal necrosis 
results (31). In vitro studies demon-
strate that the addition of GLN to an 
incubation medium stimulates crypt-
cell proliferation in healthy human 
ileum, proximal, colon, and rectosig-
moid colon (32). Animai studies have 
documented that the addition of GLN 
to standard amino acid solutions pre-
vents the villous atrophy associated 
with the provision of TPN in the 
absence of enteral feedings (33-36). In 
hospitalized patients unable to take 
adequate enteral nutrition, the addition 
of GLN to standard TPN solutions has 
been shown to prevent TPN-induced 
gut permeability (37). Enteral (rather 
than parenteral) GLN has also been 
shown to induce trophic or regenerative 
effects on the bowel (38,39). 
Glutamine is also now recognized 
as a required substrate following 
extensive small-bowel resection in 
both animals (40) and humans (41). 
Intravenous GLN supplementation has 
been shown to accelerate post-resec-
tion hyperplasia following massive 
intestinal resection in several animal 
models (42,43). 
Enteral GLN also appears to play an 
important role in maximizing bowel 
function by influencing nutrient 
absorption. The luminal (or enteral) 
administration of GLN enhances glu-
cose absorption (44), an effect that was 
not observed when GLN was adminis-
tered intravenously. Others have 
described the ability of enteral GLN to 
enhance sodium absorption in various 
models of experimentally induced 
diarrhea (45-48). The administration 
of oral GLN has also recently been 
shown to increase circulating levels of 
GH in humans (49), an effect that 
could indirectly contribute to impor-
tant trophic and functional effects 
within the resected bowel. 
The Role of Diet 
Enteral nutrition is essential to the 
process of bowel adaptation. Intestinal 
adaptive hyperplasia does not occur in 
the absence of enteral feeding — even 
when the necessary calories are given 
via the intravenous route (50). The 
intestinal mucosa of parenterally fed 
animals becomes hypoplastic and 
hypofunctional (51). Levy et al (52) 
provide evidence that the provision of 
luminal nutrients during the t 
adaptive phase of SBS incre: 
likelihood of enteral autonon 
patients who would otherwis 
dependent. Although some a 
elemental or peptide-based f 
facilitate absorption, Levy et 
suggest that polymeric diets 
equally or more effective in 
SBS patients during the earl' 
erative period. The hyperosr 
some of these solutions is th 
contribute to diarrhea and lin 
delivery of adequate calories 
However, these concerns m£ 
unfounded, for there are no ? 
which prospectively, randon 
patients with very short segr 
bowel to the various (eleme: 
elemental, polymeric, etc.) 1 
mulas and systematically ev 
effect on nutrient absorptior 
long-term TPN dependence 
In addition to the role of e 
nutrition in stimulating the p 
intestinal adaptation during 
postoperative period, specifi 
ommendations are often inte 
further assist the bowel in cc 
ing for the limited surface ai 
minimizing nutrient malabs< 
Although some clinicians fa 
continued use of liquid fonr 
the long-term nutrition man; 
most patients are successful 
tioned to solid foods. The oi 
position of these diets deper 
length and location of the re 
functional small bowel and 
ence of colon. 
Although estimates of adi 
intestinal length vary from 
(or about 365-600 cm) (53, 
nal intubation studies have 
absorption of carbohydrate, 
and simple fatty acids begir 
duodenum and is complete 
100 cm of jejunum (55). Th 
ineff ciency in absorption ii 
is the uptake of triglyceride 
proximal intestine is also th 
area for the absorption of ir 
(Continued oi 
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cium, and water-soluble vitamins. If 
the jejunum is removed, the ileum 
adapts and assumes its absorptive 
function. However, there are functions 
that are unique to the ileum; they 
include the absorption of vitamin B 12 
and bile salts. In addition, the ileum 
has a marked effect on slowing transit. 
When less than 100 cm of ileum is 
resected, watery cholerheic diarrhea 
with little or no steatorrhea often 
results. When more than 100 cm of 
ileum is resected, bile salt loss in the 
stool can be considerable (56). 
The presence of unabsorbed bile 
salts can alter the tonicity of the lumi-
nal contents and produce a secretory 
state within the colon. Consequently, 
there are fewer bile salts available in 
the jejunum, which limits the absorp-
tion of fats and fat-soluble vitamins, 
resulting in steatorrhea. The unab-
sorbed free fatty acids bind with cal-
cium, magnesium, and zinc to form 
insoluble intraluminal soaps. The for-
mation of unabsorbable calcium soaps 
prevents intraluminal calcium from 
binding to dietary oxalates. The 
unbound oxalates pass to the colon, 
where they are reabsorbed and subse-
quently excreted in the urine. This 
state of hyperoxaluria, particularly 
when associated with a state of mar-
ginal hydration and decreased renal 
perfusion, renders the patient more 
prone to the development of calcium-
oxalate nephrolithiasis. An additional 
factor influencing calcium absorption 
is the reduction in serum 25-hydroxy 
vitamin D levels, which is related in 
part to the loss of ileal surface area and 
the associated malabsorption of fat-
soluble vitamins. The suboptimal lev-
els of calcium and vitamin D are 
thought to contribute to the osteopenia 
and osteomalacia of the SBS (9,57). 
Thus, for patients who have under-
gone extensive ileal resections (with or 
without jejunal resection), the restric-
tion of fat is thought to minimize steat-
orrhea, reduce the excessive loss of 
divalent cations and associated compli-
cations, and if the colon is present. 
diminish the bile salts that can induce 
secretory diarrhea. Others have sug-
gested that the absorptive capabilities 
for high-fat and high-carbohydrate 
diets (58) are similar in patients with 
SBS, and argue that restriction of 
dietary fat deprives these patients of 
important calories (58,59). However, 
because the majority of patients in 
these studies did not have colons, such 
recommendations cannot be applied 
when the colon remains in continuity 
with the remnant small bowel. 
For patients with colons, low-fat, 
high-carbohyrate diets aid in the com-
pensatory response following resection. 
The anaerobic bacterial metabolism of 
carbohydrates (fibers and proteins) that 
either resist digestion or escape ab-
sorption in the upper intestinal tract 
result in the production of short-chain 
fatty acids (acetate, propionate, and 
butyrate), hydrogen gas, carbon diox-
ide, methane, and water. The short-
chain fatty acids (SCFA), the major 
byproducts of bacterial fermentation, 
are readily absorbed by the colonic 
mucosa and utilized for energy (60). 
Thus, some of the carbohydrate calo-
ries that would have otherwise been 
lost because of upper-intestinal tract 
malabsorption can be salvaged by this 
process (61). Under normal circum-
stances, it has been estimated that the 
absorption of short-chain fatty acids 
from the colon provides 5 to 10 per-
cent of daily energy requirements (62). 
For patients with short bowel syn-
drome, Nordgaard et al demonstrated 
that a change to a 60 percent high-car-
bohydrate, 20 percent low-fat diet 
diminished the fecal loss of calories, 
compared with a diet with the reversed 
ratios (63). The percentages of calories 
absorbed were significantly increased 
on the high-carbohydrate diet (69%) 
compared to the high-fat diet (49%). 
For patients without colons, the per-
centage of absorbed energy was similar 
with both the high-carbohydrate and a 
high-fat diet. In addition, the authors 
noted thai intake of either diet (high-
fat or high-carbohydrate) did not sig-
nificantly affect the daily total < 
of stool or jejunostomy output < 
total fecal nitrogen content. Th< 
suggest that dietary manipulate 
alone could not adequately proi 
independence from parenteral n 
infusions that provide not only 
quate calories but other imports 
nutrients and necessary fluid. 
CLINICAL TRIALS 
Because of the stimulatory efl 
GH and GLN on bowel structur 
function, it was hypothesized th 
substances could enhance nutrie 
absorption and thereby eliminat 
reduce TPN requirements when 
alone or in combination with an 
diet designed to enhance bowel 
pensation in patients with seven 
Preliminary human studies ev 
ing the effect on nutrient absorp 
GH, GLN, or a high-carbohydn 
modified oral diet alone produo 
minor biochemical changes (65 
Subsequently, their combined a< 
tration (GH + GLN + Diet) was 
ated in a small group of SBS pa 
(n = 8) that were far beyond the 
of maximal adaptation (6 ± 1 ye 
from the time of resection) and I 
jejunal-ileal lengths (mean = 37 
with colonic remnant) that class 
them as individuals who would 
dependent on TPN for life. All [ 
were admitted to a metabolic wj 
28 days; the first week served as 
trol period when nutrition (enter 
parenteral) and medical manage 
simulated their usual home then 
Thereafter, exogenous GH. supp 
mental IV, oral GLN, and a mod 
high-carbohydrate, fiber-contain 
diet were administered. The effii 
of net nutrient absorption (perce 
absorbed) for total calories, prot< 
fat, carbohydrate, water, and sod 
was calculated from the measure 
nutrient intake and stool losses. 
Following three weeks of treat 
with GH, GLN, and the modifiec 
total caloric absorption increasec 
60.1 ± 6.0 to 74.3 ± 5.0 percent ( 
0.003), protein absoiption from < 
um 
1 Table 2. Effects of GH+GLN+Diet on TPN requirements. 
Patient characteristics 
Sex 
Age 
Years on TPN 
Jejunal-ileal length 
Results 
Off TPN 
Reduced TPN 
No Change in 
TPN Requirements 
25 men, 22 women 
46 ± 2 years 
6± 1 
50 ± 7 cm (median = 
102 ± 24 cm (median 
n=19(40%) 
n= 19(40%) 
n = 9 (20%) 
35 cm) with colon, 
= 102 cm) with no 
n=43 
colon, n =4 
Table 3. TPN requirements and selected indices of 
nutritional status before and after treatment with GH+GLN+Diet. 
Before GH+GLN+Diet 
TPN volume (L/week) 11 ± 1 
TPN calories (kcal/week) 8,816 ± 941 
TPN protein (gms/week) 434 ± 27 
Body weight (pounds) 132 ± 4 
1 Serum albumin (gm/dL) 3.7 ± 0.1 
Values represent the Mean ± SEM. 
* After = 10 ± 1 months following treatment. 
+ = p< 0.0001, #= p< 0.001 vs before treatment. 
After* GH+GLN+Diet 
7 ± 1 + 
5,201 ± 880 # 
230 ± 33 + 
130 ± 4 
3.8 ±0.1 
4.8 to 63.0 ± 5.4 percent (p < 0.006), 
and carbohydrate absorption from 60.0 
± 9.8 to 81.5 ± 5.3 percent (p < 0.02). 
Fat absorption did not change (61.0 ± 
5.3 to 60.3 ± 7.9 percent, p = NS), and 
appeared to be adversely affected by 
the intake of soluble fiber. Water and 
sodium absorption increased from 45.7 
± 6.7 to 65.0 ± 7,3 percent (p < 0.002) 
and from 49.0 ± 9.8 to 69.6 ± 6.5 per-
cent (p < 0.04), respectively. These 
absorptive changes resulted in a 33 
percent decrease in stool output (1,783 
±414 g/day control period vs 1,308 
±404 g/day by the third week of 
treatment, p < 0.05). 
Thus, the combined administration 
of GH, GLN and a modified diet sig-
nificantly enhanced the ability to 
absorb calories, protein, carbohydrates, 
water and sodium from the remnant 
bowel following massive intestinal 
resection. These changes occurred in a 
group of patients that had previously 
failed to adapt to the provision of 
enteral nutrients. 
Because of the positive effects of 
GH+GLN+Diet on nutrient absorption, 
a subsequent study was conducted to 
determine whether GH+GLN+Diet 
could eliminate or reduce TPN require-
ments in patients with severe SBS 
(65). Forty-seven adult patients who 
were also far beyond the period of 
maximal adaptation and had jejunal-
ileal lengths that would classify them 
as individuals who would be depen-
dent upon TPN for life were studied 
(Table 2). All patients received exoge-
nous GH, supplemental IV and/or oral 
GLN and a high-carbohydrate, modi-
fied oral diet for a minimum of 26 
days. Thereafter, GH was discontinued 
and patients were discharged home on 
supplemental oral GLN and the modi-
fied diet. 
The administration of GH+GLN+Diet 
markedly altered TPN requirements. 
With an average follow-up of 1 year 
(range 5 months to 5 years), 40 percent 
of the group remain off TPN 
another 40 percent have redu 
TPN requirement (Table 2).' 
percent of the patients expen 
significant change in TPN re 
ments (65). 
Thirty-one of the patients p 
pated in a prospective study : 
to evaluate the effects of this 
on specific TPN requirement 
selected indices of nutritiona 
± 1 months following dischai 
3). The significant decrease i 
calories, protein and fluid rec 
ments allowed patients to elii 
reduce TPN days per week (\ 
turn decreased TPN-related c 
Despite these significant redi 
TPN requirements, body wei: 
serum albumin concentration 
adequately maintained. Addit 
low-up studies have also indi 
serum electrolytes and param 
renal and liver function have 
mained stable following treatn 
Summary 
These data suggest that tres 
with GH+GLN+Diet offers ai 
tive alternative to long-term 1 
some patients with severe SB 
Prospective, randomized trial: 
underway to determine wheth 
use of only one of the treatme 
modalities (GH, GLN or the f 
bohydrate diet) will produce e 
lent results to the combined tfc 
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A New Treatment for Patients with 
Short-Bowel Syndrome 
Growth Hormone, Glutamine, and a 
Modified Diet 
Theresa A. Byrne, M.S., R.D., Rebecca L Persinger, M.S., R.D., Lorrie S. Young, M.S., R.D., 
Thomas R. Ziegler, M.D., and Douglas W. Wilmore, M.D. 
From the Laboratories for Surgical Metabolism and Nutrition, Department of Surgery, Brigham 
and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and the Nutritional 
Restart Center, Hopkinton, Massachusetts 
Objective 
The purpose of this study was to initially determine if growth hormone or nutrients, given alone or 
together, could enhance absorption from the remnant small bowei after massive intestinal 
resection. If clinical improvement were observed, this therapy would then be used to treat patients 
with the short-bowel syndrome over the long term. 
Summary Background Data 
Patients who undergo extensive resection of the gastrointestinal tract frequently develop 
malabsorption and require long-term parenteral nutrition. The authors hypothesized that the 
administration of growth factors and/or nutrients could enhance further compensation of the 
remnant intestine and thereby improve absorption. Specifically, animal studies have shown that 
there is enhanced cellularity with the administration of growth hormone (GH) or glutamine (GLN), 
or a fiber-containing diet. 
Methods 
Initially, 17 studies were performed tn 15 total parenteral nutrition (TPN)-dependent short-bowel 
patients over 3 to 4 weeks in the clinical research center; the first week served as a control period, 
and during the next 1 to 3 weeks, the specific treatment was administered and evaluated. 
Throughout the study, food of known composition was provided and all stool was collected and 
analyzed to determine absorption across the remaining bowei. The effect of a high-carbohydrate, 
low-fat diet (DIET), the amino acid glutamine (GLN) and growth hormone (GH) administered alone 
or in combination with the other therapies (GH 4- GLN + DIET) was evaluated. The treatment was 
expanded to 47 adults (25 men, 22 women) with the short-bowel syndrome, dependent on TPN 
for 6 ± 1 years. The average age was 46 ± 2 years, and the average jejunal-ileal length was 50 ± 
7 cm (median 35 cm) in those with ail or a portion of colon and 102 ± 24 cm (median 102 cm) in 
those with no colon. After 28 days of therapy, the patients were discharged on only GLN + DIET. 
Results 
The initial balance studies indicated improvement in absorption of protein by 39% accompanied 
by a 33% decrease in stool output with the GH + GLN + DIET. In the long-term study, 40% of the 
group remain off TPN and an additional 40% have reduced their TPN requirements, with follow-up 
averaging a year and the longest being over 5 years. 
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Conclusion 
GH + GLN + DIET offers a potential method for providing cost-effective rehabilitation of surgical 
patients who have the short-bowel syndrome or other complex problems of the gastrointestinal 
tract. This therapeutic combination also may be useful to enhance bowel function in patients with 
other gastrointestinal diseases and those requiring extensive intestinal operations, including 
transplantation. 
Intestinal resection is a commonly performed opera-
tion that is usually without complications. Occasionally, 
however, removal of large segments of the small bowel 
with or without a portion of the colon is necessary be-
cause of thrombosis of a mesenteric vessel, progressive 
inflammatory disease, major abdominal injury, or the 
presence of congenital abnormalities. These operative 
procedures result in short-bowel syndrome, a disorder 
characterized by an intestinal absorptive surface area 
that is insufficient to support the host. This intestinal loss 
results in malabsorption of fluid, electrolytes, and other 
essential nutrients; severe diarrhea; dehydration; and 
progressive malnutrition.1 
Surgeons have long been aware of the ability of the 
small bowel to compensative after massive intestinal re-
section. This response, first described by Hint2 in 1912 
and later characterized in greater detail by many oth-
ers,3"5 is accompanied by elongation and dilation of the 
remnant bowel and hypertrophy of the intestinal villi, 
resulting in a greater absorptive surface area and pro-
longed transit time. With bowel compensation, absorp-
tion of enteral nutrients is gradually enhanced and diar-
rhea and malabsorption are reduced6; occasionally the 
clinical problems resolve. Although this adaptive re-
sponse may support normal hydration and nutrition in 
individuals with resection of up to 80% of the small 
bowel, patients with less than 50 to 70 cm of jejunum-
ileum (approximately I */2—21/2 ft) with an intact duode-
num and a portion of colon in continuity usually require 
total parenteral nutrition (TPN) for life.17 Other factors, 
such as normal structure and function of other gastroin-
testinal organs, health of the intestinal mucosa, the pres-
ence and length of the remaining colon, and the age of 
the individual, also determine the ability of a patient to 
adapt and become independent of parenteral support. 
Although TPN is regarded as lifesaving to patients af-
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ter massive bowel resection,8 data emerging over the pai 
20 years have detailed both short- and long-term compl 
cation rates of this therapy,9'" described the effect c 
nightly infusions on the disruption of a normal lift 
style,12 and quantitated the costs associated with the thei 
apy.13 All of these factors have limited more compreher 
sive rehabilitation and shortened longevity, and invest: 
gators are now seeking alternative methods of care fc 
this group of patients. Reconstructive procedures on th 
remnant bowel and intestinal transplantation are area 
of special interest to surgeons working in this field. 
This report provides details of the evolution of a treai 
ment program that enhances absorption of nutrient 
from the remnant bowel through the use of growth fac 
tors and specialized nutrients. Absorption has been er 
hanced by using a combination of therapeutic agent 
and this approach has now been applied to a larger grou 
of patients with short-bowel syndrome to reduce orelim 
inate the need for TPN for prolonged periods. 
MATERIALS AND METHODS 
Absorption Studies 
Patients 
Seventeen studies were performed in 1 5 patients ( 
women, 6 men; mean age, 44 years; range. 24-68 yean 
with severe short-bowel syndrome. All patients had pre 
viously undergone extensive bowel resection for traum* 
mesenteric infarction, or inflammatory bowel diseas 
with or without colonic resection. The average length c 
jejunum-ileum in the group, as determined from opera 
tive reports and confirmed by perioperative radiograph! 
was 54 cm (range, 8-120 cm) in the 12 patients with 
portion of colon in continuity and 60 cm (range, 40-10 
cm) in those without a colon. All patients were chroni 
cally dependent on specialized nutritional support. Th 
patients were ambulatory, clinically stable, and did nc 
demonstrate evidence of infection or active inflamma 
tory bowel disease. In addition, they had no extradiges 
tive organ failure, were free of cancer and diabetes, am 
did not have a history of cancer for the past 5 years. A! 
patients were able to tolerate an ad libitum oral diei 
however, without parenteral support they were unable t< 
adequately maintain hydration and/or nutritional sta 
tus. The protocol was approved by the Brigham an< 
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Women's Hospital's Committee for the Protection of 
Human Subjects from Research Risks, and informed 
consent was obtained from all subjects. 
Study Design 
The patients were admitted to the Clinical Research 
Center of the Brigham and Women's Hospital for a 21 to 
35 day stay. For the patients receiving a high-carbohy-
drate low-fat (HCLF) diet alone or diet plus growth hor-
mone plus glutamine, the first week served as a control 
period during which time the patients' nutritional (par-
enteral feedings, tube feedings, and ad libitum oral in-
take) and medical management (antidiarrheal agents, 
etc.) simulated their usual home therapy. The patients 
were instructed to consume the quantity and type of 
foods and beverages that best represented their usual eat-
ing habits and food preferences. Only foods and bever-
ages of known nutrient composition were provided. 
Meals and snacks were made available six times per day 
and beverages were readily available on an ad lib basis. 
During the control period, the infusions of parenteral 
nutrients and fluid volumes were matched to those pre-
scribed by the patient's physician. 
During the remaining 3 weeks, these patients received 
a diet high in complex carbohydrates and low in fat but 
nearly isocaloric and isonitrogenous to that which the 
patient received during the control period. The diet was 
targeted to provide approximately 60% of total calories 
from carbohydrate, 20% from fat, and 20% from protein. 
Calories and protein were divided into six feedings and 
provided as meals or snacks throughout the day. Near-
isotonic fluids containing glucose and sodium (Gatorade, 
The Gatorade Company, Chicago, IL, and Pedia-
lyte, Ross Laboratories, Columbus, OH) replaced both 
hypo-osmolar and hyperosmolar fluids and served as the 
primary source of enteral hydration. 
Two of these 10 patients received the modified diet 
(HCLF diet) only. The remaining eight patients received 
recombinant methionyl growth hormone (Protropin, 
Genentech, Inc., San Francisco, CA) at a dose of 0.14 
mg/kg/day by parenteral administration. They also re-
ceived supplemental parenteral and/or enteral L-gluta-
mine (given as an average dose of 0.6 g/kg/day (Ajino-
moto USA, Raleigh, NC). 
The seven additional studies examined the effects of 
administering glutamine alone or growth hormone 
alone. The patients received a fixed diet throughout the 
entire 21 to 28 day period, which involved foods of their 
choice on a 2-day rotational schedule. After the first 
week, either glutamine or growth hormone was provided 
as described above and the diet continued. Intravenous 
feedings, fluid volume, calories, and protein were main-
tained at a constant level of intake throughout the entire 
study period. 
During all investigations, all enteral intake and stool 
output was weighed and the nitrogen, water, and sodium 
contents determined. Enteral nutrient balance and ab-
sorption were then calculated from the measured enteral 
intake and stool losses. Body weight was recorded daily. 
Blood samples were analyzed biweekly to monitor the 
response to therapy and to adjust electrolytes added to 
the parenteral solution. 
Determination of Nutrient Intake 
All food and fluid was weighed and prepared by the 
Clinical Research Center's metabolic kitchen. The total 
daily intake of protein, calories, carbohydrate, fat, so-
dium, and water (including the water content of all foods 
and beverages) was determined by a computer program 
(GCRC Diet Planner, Version 2.03, Clinical Study Cen-
ter, University of California, San Francisco, CA), which 
translated the gram weight of intake into nutrient com-
position. For foods not analyzed or available on the com-
puter program, nutrient values were determined by re-
ferring to Handbook 814 or other standards.15 On ran-
dom days of the study, duplicate patient trays were 
prepared and analyzed to confirm the nitrogen, fat, and 
sodium content of the diet. 
Measurement of Nutrient Losses 
All stool was collected for consecutive 24-hour periods 
between 7:30 A.M. and 7:30 A.M. beginning on the morn-
ing after admission and continuing until completion of 
the study. Samples were prepared frozen at -20 C and 
analyzed for water, nitrogen, sodium, and, in selected pa-
tients, fat and calories as previously described.16 Body 
weight was recorded each morning to the nearest 0.1 kg 
using a leveled platform scale (model SR2MI01, Acme 
Scale, Oakland, CA). All blood chemical and urine anal-
yses were determined using standard hospital analytical 
techniques. 
Calculations of Nutrient Absorption 
The absorption of nitrogen and sodium was calculated 
by subtracting the quantity of the substance present in 
the stool from the enteral intake for each 24-hour period. 
Stool output was the mean of the 24-hour measurements 
for each week. Because nutrient intake was constant, nu-
trient absorption of sodium and nitrogen was calculated 
by subtracting the balance of the final study week from 
the first or control week. This was expressed as a percent-
age change in absorption by dividing this difference by 
the control value and multiplying it by 100. The percent-
age change in stool weight (output) was calculated in a 
similar manner. 
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Patient 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
Gender 
M 
F 
M 
F 
M 
F 
F 
F 
M 
M 
M 
F 
M 
M 
F 
F 
F 
F 
F 
M 
M 
F 
M 
M 
F 
M 
M 
F 
F 
M 
M 
M 
M 
M 
M 
F 
F 
F 
F 
M 
F 
M 
F 
M 
M 
F 
M 
T a b l e 1 . P A T I E N T C H A R A C T E R I S T I C S A N D 
Age 
(yr) 
44 
40 
29 
44 
47 
42 
42 
31 
48 
19 
68 
34 
27 
54 
57 
34 
58 
50 
30 
71 
47 
45 
44 
28 
42 
61 
65 
44 
65 
70 
40 
54 
26 
51 
57 
46 
55 
46 
38 
76 
34 
48 
54 
24 
70 
30 
53 
Cause of Resect ion 
SMA thrombosis 
Small bowel volvulus 
Small bowel volvulus 
Small bowel volvulus 
SMA thrombosis 
Small bowel volvulus 
Small bowel volvulus 
Trauma to SMA 
SMA thrombosis 
Malrotation 
Crohn's disease 
Venous ectatic disease 
Trauma 
SMA thrombosis 
Small bowel obstruction 
secondary to adhesions 
Mesenteric infarction 
Portal vein thrombosis 
SMA thrombosis 
SMA thrombosis 
SMA thrombosis 
SMA thrombosis 
Trauma 
Volvulus 
Small bowel volvulus 
Small bowel obstruction 
secondary to adhesions 
Mesenteric infarction 
SMA thrombosis 
Multiple resections secondary 
to adhesions 
Crohn's disease 
SMA thrombosis 
Crohn's disease 
Volvulus 
Crohn's disease 
Crohn's disease 
SMA thrombosis 
Crohn's disease 
Mesenteric infarction 
Crohn's disease 
Congenital malrotation 
Small bowel obstruction 
secondary to adhesions 
Crohn's disease 
Volvulus 
Crohn's disease 
Crohn's disease 
Crohn's disease 
Crohn's disease 
Small bowel obstruction 
secondary to adhesions 
Jejunum-
Ileum (cm) 
0 
0 
0 
8 
8 
10 
15 
15 
20 
20 
20 
24 
30 
30 
30 
30 
30 
30 
30 
30 
30 
35 
40 
43 
43 
45 
46 
46 
53 
58 
60 
67 
75 
75 
76 
80 
83 
90 
91 
91 
100 
100 
112 
122 
137 
159 
240 
R E S P O N S E S T O T H E R A P Y 
ICV 
(+/-) 
_ 
-
-
+ 
-
-
-
-
-
-
+ 
-
-
-
+ 
+ 
-
+ 
-
-
-
-
+ 
-
~~ 
-
-
+ 
-
+ 
+ 
+ 
-
-
-
-
-
-
+ 
-
+ 
-
-
-
-
+ 
Colon 
Rectum 
TDR 
TDR 
TDR 
TDR 
TDR 
TDR 
All 
TDR 
TDR 
All 
All 
DR 
TDR 
TDR 
AT 
All 
TDR 
All 
TDR 
TDR 
TDR 
TDR 
All 
TDR 
TDR 
None 
TDR 
AT 
TDR 
TDR 
All 
All 
TDR 
TDR 
TDR 
TDR 
TDR 
TDR 
All 
None 
TDR 
All 
None 
DCR 
TDR 
None 
TDR 
TPN 
(yr) 
5 
4 
13 
13 
3 
10 
3 
1.5 
5 
15 
1 
7 
3 
13 
4 
8 
0.6 
1 
6 
i r 
7 
11 
7 
2 
1 
4.4 
2 
9 
5 
9 
8 
2 
3 
10 
0.3 
1 
14 
9 
10 
6 
6 
3 
7 
9 
10 
8 
5 
Discharge 
TPN 
Off 
Reduced 
Reduced 
No change 
Reduced 
Off 
Reduced 
Off 
Off 
Off 
Off 
No change 
Off 
Off 
Off 
Reduced 
Off 
Off 
Off 
Off 
Off 
Reduced 
Off 
Off 
Off 
No change 
Reduced 
Off 
Reduced 
No change 
No change 
Reduced 
Off 
Reduced 
Off 
Off 
Reduced 
Reduced 
Off 
Reduced 
Off 
Off 
No change 
Off 
Reduced 
Off 
Off 
Current 
TPN 
Reduced 
Reduced 
No change 
Reduced 
Reduced 
No change 
No change 
Off 
Reduced 
Off 
Off 
No change 
Reduced 
Off 
Reduced 
Reduced 
Off 
Off 
Off 
Off 
Off 
No change 
Off 
Off 
Off 
No change 
No change 
Off 
Reduced 
Reduced 
Reduced 
Reduced 
Reduced 
Reduced 
Off 
Off 
No change 
Reduced 
Off 
Reduced 
Off 
Off 
No change 
Reduced 
Reduced 
Off 
Reduced 
TDR = transverse and descending colon and rectum; TPN = total parenteral nutrition; DCR •= descending colon and rectum; AT = ascending and transverse coion; + - with 
Heal cecal valve; - = without ileal cecal valve; SMA = superior mesenteric artery. 
* Received TPN and intermittent tube feedings during this time. 
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Bowel Rehabilitation 
Patients 
This portion of the clinical investigation was per-
formed at the Bngham and Women's Hospital Boston 
Massachusetts, and at the Nutritional Restart Center 
Hopkinton, Massachusetts, the latter a low-cost unit for 
adults and children with severe malabsorptive disorders 
Study protocols were approved by the Bngham and 
Women's Hospital's Committee for the Protection of 
Human Subjects from Research Risks, and informed 
consent was obtained 
Forty-seven adult patients with short-bowel syndrome 
(25 men, 22 women, age 46 years [range, 19-76 years]) 
were admitted for study The clinical characteristics and 
primary diagnoses of the patients are given in Table 1 
All patients had undergone extensive small-bowel resec-
tion with or without colonic resection Combined jeju-
noileal length of the 43 patients with a colonic remnant 
was 50 cm ± 7 cm For the four patients with no colon, 
the combined jejunoileal length averaged 102 cm ± 24 
cm Most patients (n = 39) were referred for rehabilita-
tive therapy while they received TPN This group, on av-
erage, had received intravenous feedings for 6 years ± 1 
vear Some patients (n = 8) were referred because of lack 
of central venous access and progressive malnutrition 
Seven patients in this category were treated without the 
use of TPN On admission, all patients were clinically 
stable and without evidence of infection Patients with 
diabetes mellitus, cancer within 5 years of treatment 
clinically active inflammatory bowel disease, s>mptom-
atic strictures or bowel adhesions, or severe gastrointesti-
nal dysmotility that precluded oral intake were excluded 
from study This series represents a group of patients 
studied in a consecutive manner with no other exclu-
sions 
Method of Treatment 
On the morning after the day of admission, a baseline 
assessment of the patient's nutritional and hydration sta-
tus was performed Weight was recorded to the nearest 
0 1 kg, whole-body bioelectncal resistance (ohms) was 
measured by a plethysmograph (model 101 A, RJL Sys-
tems, Mt Clemens, MI), and the readings were used to 
calculate body water as described previously l7 In a sub-
group of 31 patients followed prospectively, blood was 
obtained to determine concentrations of selected nutri-
ents (vitamins, trace elements, and essential fatty acids) 
and indicators of organ function using standard analyti-
cal techniques Unne was collected to determine 24-hour 
volume and creatinine excretion 
Thereafter, recombinant growth hormone was admin-
istered by subcutaneous injection at a dose ranging from 
0 03 to 0 14 mg/kg/day (average dose of 0 II mg ± 0 01 
mg/kg/day) Supplemental glutamine was provided by 
both the parenteral and enteral routes As stool output 
decreased, TPN (including the quantity of intravenous 
glutamine) was reduced Parenteral glutamine dose av-
eraged 0 16 ± 0 02 g/kg/day Because it was not possible 
to determine the proportion of enteral glutamine that 
was absorbed, a standard daily dose of 30 g was adminis-
tered (5 g of enteral glutamine powder were mixed with 
a hypotonic, cold beverage and taken six times per day) 
In addition to growth hormone and glutamine, ail pa-
tients underwent extensive diet modification and nutn-
tional education l6 The quantity and frequency of TPN 
administered was gradually reduced as enteral intake 
and 24-hour unne volumes increased and stool output 
decreased Blood was drawn biweekly to monitor serum 
electrolyte concentrations 
In all but three of the persons studied, body weight, 
total body resistance, intravenous fluid volume and cal-
ones, enteral fluid volume and calones, and stool and 
unne volumes were measured daily. The mean of the 
first 3 days (baseline) was compared with the mean of the 
last 3 days of treatment (discharge) to evaluate the effect 
of 4 weeks of therapy 
On completion of the 26-day protocol, growth hor-
mone was discontinued and the patients were discharged 
home on oral glutamine (30 g/day) and the modified oral 
diet The parenteral nutnent prescnption on discharge 
was individualized for each patient, based on the indi-
vidual's overall response to treatment with growth hor-
mone plus glutamine plus HCLF diet For those patients 
whose baseline nutntional assessment indicated an es-
sential fatty acid deficiency, parenteral lipid emulsions 
were prescribed Parenteral and/or enteral vitamin, trace 
element, and electrolyte supplements were prescnbed at 
dosages to conect nutnent deficiencies identified dunng 
the baseline assessment and to maintain normal serum 
concentrations 
Follow-up data were collected at regular intervals and 
compared with the baseline data in the group of 31 pa-
tients entered into the prospective protocol This evalua-
tion included TPN requirements (days of infusion per 
week, volume of fluid per week, intravenous protein and 
calones administered per week), serum albumin concen-
tration, and body weight Cost of pretreatment intrave-
nous feedings and current TPN requirements were cal-
culated using Medicare reimbursement rates ,8 
At discharge, patients were classified into one of three 
categones based on their response to treatment off*, re-
duced, and no change Off was defined as a patient who 
was removed from TPN at the end of therapy In addi-
tion, patients who were referred for central line place-
ment and received this treatment and were discharged 
without the need for TPN were placed in this group 
However, several of these patients occasionally received 
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Diet(n = 2) 
Sodium 
Protein 
GLN(n = 3) 
Sodium 
Protein 
GH (n = 4) 
Sodium 
Protein 
Table 2. 
GH + GLN + DIET(n = 8) 
Sodium 
Protein 
SODIUM AND PROTEIN INTAKE AND 
Oral Intake 
(g/day) 
4.26 ±0.49 
135.2 ±24.8 
3.27 ±1.40 
64.2 ±11.7 
4.52 ± 0.89 
118.2 ±8.3 
3.48 ± 0.56 
88.6 ±18.8 
BALANCE, AND 
SPECIFIC TREATMENT PROTOCOLS 
Control Period 
Intestinal 
Balance 
(9/day) 
+2.24 ± 0.60 
+99.0 ± 12.8 
+ 1.25± 1.06 
+30.9 ± 11.8 
+2.77 ± 0.05 
+70.6 ±7.3 
+ 1.51 ±0.68 
+45.3 ±12.3 
Stool 
Weight 
(9/day) 
1117 ± 332 
1953 ±231 
2268 ± 437 
1783 ±418 
STOOL WEIGHT DURING 
Final Week of Treatment Period 
Oral Intake 
(g/day) 
4.66 ±0.82 
117.5 ±19.6 
4.88 ±0.84 
68.3 ±10.2 
5.77± 1.16 
110.5± 14.8 
3.73 ± 0.50 
86.7 ±15.3 
Intestinal 
Balance 
(g/day) 
+2.46 ± 0.60 
+79.4 ± 3.8 
+ 1.11 ±0.86 
+30.5 ±11.9 
+4.45 ± 0.02 
+73.2 ±11.0 
+2.55 ± 0.36 
+54.2 ±10.7 
Stool 
Weight 
(g/day) 
1334±508 
2197 ±669 
1872 ±351 
1308 ±408 
% Change 
with 
Treatment 
+ 16.3 ±10.$ 
+10.6 ±3.2 
-19.0 ±6.7 
+8.5 ± 20.: 
+35.3 ± 34.S 
+ 1.2±14.i 
-12 .9±11 . ' 
+60.8 ± 3.5 
+6 .4±16 i 
-33.1 ± 10.C 
+37.1 ± 4 0 i 
+38.8 ±13.$ 
Values are mean ± SEM. 
+ « improved protein or sodium absorption: - = decreased stool loss. 
• Different from other treatment groups, p < 0.05. 
specific nutrients intravenously to treat a deficiency. In 
addition, these patients may have required occasional 
hydration fluid. Patients who continued to receive sim-
ilar amounts of TPN when compared with baseline were 
considered unaffected by therapy. This was confirmed by 
analyzing costs, which also demonstrated no change. Pa-
tients who were classified as reduced were, those who had 
a decrease in their TPN requirements and also experi-
enced a cost reduction. 
STATISTICAL ANALYSIS 
Data were analyzed using standard statistical software 
(Statview No. 512, Abacus Concepts, Inc., Berkeley, CA, 
on a Macintosh SE personal computer, Apple Com-
puter, Cupertino, CA). For normally distributed data, 
the paired Student's t test was used to determine differ-
ences between the control period and the last week of the 
treatment period. For nonnormally distributed data, the 
Wilcoxon signed rank test was used. Analysis of variance 
was used to identify between-group differences. Simple 
and multiple linear regression analyses were used to 
identify which variables significantly influenced re-
sponse to therapy. A probability value of less than or 
equal to 0.05 was considered statistically significant. Re-
sults are expressed as mean ± SEM. 
RESULTS 
Absorption Studies 
All patients were clinically stable throughout the study 
period. Weight gain over the 3 to 4 weeks of study was 
gradual and averaged approximately 1 kg/week. The on 
dietary intake remained relatively constant throughoi 
the study. The patients consumed about 2800 kcal/da 
and 100 g protein/day by the enteral route, althoug 
there were large variations among individuals due t 
food intolerances and preferences (calories ranged fror 
a group average of 1800-3700 kcal/day, and protein ir 
take ranged from 64-135 g/day). 
With diet modification only, sodium and protein at 
sorption did not change significantly, and stool outpi 
increased slightly compared with the control period (T< 
ble 2). When glutamine was added to a fixed standar 
diet, sodium absorption was slightly enhanced (approx 
mately 35%, not significant), and protein absorption an 
stool volume were likewise unaffected. Administratio 
of growth hormone alone also tended to improve sodiui 
absorption and somewhat enhanced protein uptake bi 
reduced stool output slightly. With the administration c 
all three treatment components (growth hormone pli 
glutamine plus diet) there was a 37% increase in sodiui 
absorption (not significant) and a 38% improvement i 
protein absorption (p < 0.02). Stool loss decreased b 
about one third (p < 0.05) (Fig. 1). This decrease in sto( 
output was accompanied by a reduction in the frequenc 
of bowel movements and often a change in stool chara< 
ter from liquid to semiformed. 
Response to Four Weeks of Therapy 
All subjects entered into the protocol were able t 
complete the treatment program, and there were n 
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Vd.222«No.3 New Treatment for Short-Bowel Syndrome 249 
O ft; 
lOOh 
80 h 
60 (-
40 
20 
§ 
^ I 
^ 
I 
O 
o 
to 
o 
-20 
50 
40 
30 
20 
10 
-10 
-20 
20 
10 
0 
-10 
-20 
-30 
-40 
-50 
1111 
' p<0.02 vs. other groups 
V 
-
P$ T (3MSH 
•p <0.0 5 vs. other groups 
ipf 
"i 
\
 f
 <*\ 
i 
* Diet GLN GH GH+GLN+Diet 
Figure 1. The effect of HCLF diet, glutamine. growth hormone, and 
growth hormone plus glutamine plus HCLF diet on absorption of (top 
panel) sodium, (middle panel) protein, and (bottom panel) stool output. An 
increase in absorption above the 0 balance line indicates enhanced up-
take; a negative change indicates decreased absorption A negative 
change in stool output indicates a reduction in stool volume 
dropouts. The major side effect of the treatment was fluid 
retention, manifested by peripheral edema and arthral-
gia, which varied depending on growth hormone dose. 
This problem was attenuated by limiting fluid intake, re-
ducing the growth hormone dose, or administering di-
uretics. In this group of 47 patients, 15 febrile episodes 
occurred; many were attributable to upper respiratory 
tract infections, and these individuals were treated symp-
tomatically. Patients diagnosed by culture with bacterial 
infections (urinary tract, sinusitis, catheter sepsis) were 
treated with specific antibiotics. 
For the group, the 4 weeks of therapy resulted in weight 
gain, an increase in intake of enteral calories and fluid, 
maintenance of urine output, and diminished need for in-
travenous fluid and nutrients (Table 3). These responses 
were variable, however; at the end of the treatment period, 
27 of the 47 patients (57%) did not require TPN, 14 (30%) 
had reduced TPN requirements, and 6 (13%) required ap-
proximately the same quantity of parenteral support as 
was necessary at the start of therapy. For each subgroup, 
the changes in absorption of nutrients and fluid during 
the 4-week treatment period are shown in Table 3. An 
examination of the characteristics of the subjects in each 
group revealed that the patients who could not be weaned 
from TPN were slightly older (p = 0.02) and had Crohn's 
disease as the cause of resection (p = 0.04) compared with 
the other patients who were weaned from or received re-
duced intravenous nutrition (Table 4). In addition, the pa-
tients who failed the therapy (no change) initially had 
larger stool output (p < 0.002) than the other two groups 
(Table 3). There was no significant difference in bowel 
length among the three groups. 
Evaluation of Long-Term Effect 
The length of follow-up for all patients has been be-
tween 5 months and 5 years. During this time, most of 
the patients have been cared for by their primary care 
physicians and the nutritional support team located in 
their immediate geographic area. Nutritional compli-
ance was constantly reinforced and hydration state eval-
uated by frequent telephone interviews between our-
selves and the patients. This information was conveyed 
to the primary care and home care providers, who like-
wise emphasized the nutritional plan. We cared for and 
followed directly a smaller group of patients who lived 
in the New England area. Over the past 18 months, 31 
patients have been entered into a prospective study to 
Discharge Current 
Figure 2. The TPN status of patients after discharge after 28 days of 
treatment and approximately 1 year after treatment. "Off" indicates no 
TPN, "Reduced" indicates less than what was initially given, and "No 
Change" indicates similar volume and calories to those initially adminis-
tered. 
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evaluate periodically the effect of the therapy on lonj 
term nutritional intake, route of feeding, costs, and ni 
tritional status. 
Eight of the 27 patients who had had TPN discor 
tinued eventually experienced increased requireraenl 
for TPN. This occurred because of recurrence of diseas 
in three patients (e.g., recurrence of active inflammator 
bowel disease), dietary noncompliance in three patient* 
and inappropriate removal from TPN by the care tear 
in two patients. With follow-up at 1 year, 40% of th 
group were off TPN, 40% received a reduced TPN pre 
scription, and the remaining 20% of the patients receive 
TPN similar to their initial pretreatment requiremen 
(Fig. 2). At this time of follow-up (approximately 1 year 
body weight and serum albumin concentration were we 
maintained, despite the reduction of intravenous calc 
ries and protein (Fig. 3, Table 5). 
For the 31 patients followed prospectively, we could « 
timate the cost savings that occurred with decreased us 
of TPN. In those patients weaned from TPN, the anniu 
savings was $102,270/year, and those with reduced TPI 
volume, calories, and protein saved approximatel 
$25,338/year (Table 4). If one assumes that all patient 
would have received TPN for the coming year, applyin 
these savings to the entire group in the proportion showi 
at 1 year (see Fig. 2), the money saved for TPN alone wouli 
equal $2,310,396/year, or about $49,157/patient/year. 
DISCUSSION 
The treatment of patients with loss of large segment 
of the intestinal tract has evolved rapidly over the past 31 
years. In the early 1960s, it was common to simply clos 
the abdomen of a patient after laparotomy if extensiv 
bowei loss was identified, because no treatment wa 
available after massive intestinal resection. The develop 
ment of TPN provided a method for stabilization an< 
support of these patients with the hope that adaptatioi 
of the remnant bowel would occur over time. Althougi 
this has occurred in many patients who have had ade 
quate lengths of remaining small bowel, it has not beei 
the case in many other persons with inadequate smal 
intestine. It has been estimated that about 10,000 t< 
20,000 patients with short-bowel syndrome in th 
United States are now at home being maintained on in 
tra venous feedings.13 That these persons can be main 
tained out of the hospital over the long term is a remark 
able accomplishment, and it should be realized that pa 
tients with short-bowel syndrome served as the stimulu 
for the growth of a new health service industry—homi 
care—which has facilitated this process. However, th 
long-term experience with home TPN now reveals tha 
a variety of short- and long-term complications occur 
including repeated episodes of catheter sepsis, nutri 
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n 
Age (yr) 
Gender (male:femaie) 
Jejunum-iieum length (cm) 
With colon (mean) 
(median) 
Without colon 
Years of TPN 
Values are mean ± SEM. 
TPN = total parenteral nutrition. 
Table 4. CHARACTERISTICS OF PATIENTS IN GROUPS 
Off 
27 
4 3 ± 3 
15:12 
53±10(n = 26) 
30 
159(n = 1) 
5 ± 1 
Reduced 
14 
51 ± 4 
7:7 
49± 11 (n = 11) 
46 
91 (n= 1) 
7 ± 1 
No Change 
6 
50±6 
3:3 
38±13(n = 4) 
41 
78(n = 2) 
8 ± 1 
tional deficiencies, progressive failure of the liver and 
kidneys, and severe osteoporosis. These problems, asso-
ciated with the compromised lifestyle and major costs 
(about $ 100,000/year for the TPN alone), have resulted 
in other initiatives to solve the problems of patients with 
short-bowel syndrome. Surgeons are evaluating the 
effects of bowel reconstruction19 and intestinal trans-
plantation20 in this group of patients. 
In the past 10 years, however, several important exper-
imental developments have contributed to the evolution 
of the approach presented in this report. First, it was dis-
covered that glutamine was the major nutrient for the 
bowei. Providing parenteral feedings that contained this 
amino acid supported mucosal growth under a variety of 
conditions,21 including mucosal hypertrophy that oc-
curred after extensive small-bowel resection.22 Other 
studies have documented improved bowel function, in-
cluding absorption, when L-glutamine was provided by 
parenteral23 and/or enteral feedings.24 
Second, both animal and human studies have demon-
strated that growth hormone, now available in recombi-
nant form, stimulates intestinal growth25 and enhances 
transport of nutrients across the small bowel.26 Although 
we observed few significant clinical effects when these 
Weight Albumin 
Hta " 
B 
Sill 
xiHiiiP 
aselii 
• 
• 1 
ie Current 
4.0 
3.0 
2.0 
1.0 
0 
g/dL 
Baseline Current 
Figure 3. Body weight and albumin at baseline and currently at approxi-
mately 1 year. 
agents were administered alone, under the conditions of 
our study, enhanced absorption was observed when the 
agents were given together. Animal studies have revealed 
a molecular basis for this proliferative response using 
combined agents.27 
The issue of optimizing dietary intake is more contro-
versial, and investigators have differed in their preference 
for a low-fat28 or a high-fat (unmodified) diet.29 Absorp-
tion was maximized by providing a diet that contained 
20% to 25% fat, similar to recent recommendations by 
others.28 However, for these patients with very short seg-
ments of jejunum-ileum, we were unable to document 
major effects of diet alone. The exception to this finding 
occurred when a patient consumed a high-fat intake 
(>40% of total calories) during the control period and 
was then placed on a 20% fat diet during the treatment 
period. In addition, we have found that many patients 
were sensitive to lactose and also increased their stool 
output and complained of bloating with the ingestion of 
simple sugars (fructose and glucose). We therefore have 
provided a diet tailored to the individual but that pro-
vides about 60% of calories as complex carbohydrates, 
20% as protein, and the remainder as fat. This is pro-
vided as six feedings given throughout the day, with nu-
trients distributed into three meals and three snacks. Vi-
tamins and minerals are supplemented by the oral route. 
Hydrogen-blocking drugs were often helpful to diminish 
gastric secretion; in contrast, we have observed little ben-
efit with the administration of somatostatin analogues, 
even in the patients with high stool losses. 
In this clinical trial, each subject served as his or her 
own control. This approach was chosen because of the 
large variation among subjects in terms of bowel disease, 
length of remnant bowel, and volume of stool lost. We 
found that it was possible to wean a large proportion of 
these patients from TPN using this combined therapeu-
tic approach; another sizable segment of this group was 
able to reduce their weekly TPN requirements, thus giv-
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Table5. CHANGES IN TPN REQUIREMENTS, ANNUAL COSTS, AND NUTRITIONAL INDICES 
BEFORE TREATMENT AND AT THE PRESENT TIME 
Off(n = 7) Reduced(n=16) No Change (n = 6) 
TPN days/wk 
TPN voJume/wk (L) 
TPN protein/wk (g) 
TPN caJof les/wk (kcai) 
Annual costs ($/yr) 
Weight (kg) 
Albumin (g/dL) 
Values are mean ± SEM. 
Baseline 
6 ± 1 
12±2 
387 ±80 
9451 ±2909 
102,270 
57.7 ± 3.6 
3.8 ±0.1 
Current 
0 
0 
0 
0 
0 
54.0 ±2.7 
3.9 ±0.1 
TPN • total parentefal nutrition; NS = not significant. 
P 
0 0001 
0.002 
0 003 
0.018 
0.0002 
NS 
NS 
Baseline 
6 ± 0 
12± 1 
476 ± 32 
9188±1088 
107,143±7117 
59.5 ± 2.7 
3.6 ±0.1 
Current 
4 ± 0 
7 ± 1 
259 ± 28 
5744 ± 950 
81,805 ±7081 
60.4 ± 2.7 
3.8 ±0.1 
P 
0.0001 
0.0006 
0.0001 
0.0001 
0.0003 
NS 
0.1 
Baseline 
6 ± 1 
11 ± 2 
392 ±15 
7518 ±1719 
95,227 ±12,271 
62.7 ± 4.5 
3.6 ±0.1 
Current 
6 ± 1 I 
10±2 I 
375 ± 72 I 
8665 ±1953 I 
107.911 ±13,182 I 
60.4 ± 4.5 0 
3.6 ± 0.2 I 
ing them nights off from infusion. Body weight and se-
rum albumin, major indicators of nutritional status, 
were stabilized over the follow-up period, which aver-
aged 1 year. This series represents the largest group of 
adult patients with short-bowel syndrome studied to date 
by a single group of investigators, and additional 
multicenter trials are in progress involving both adults 
and children to evaluate the effect of this approach in 
randomized trials. 
It could be argued that the patient's response to growth 
hormone plus glutamine plus HCLF diet occurred be-
cause special attention was given to provide the appro-
priate diet or that specific nutrients were provided to sat-
isfy deficiencies or because the investigators have a so-
phisticated understanding of the underlying fluid, 
electrolyte, and nutritional derangements that occur in 
this group of patients. Although this is possible, we be-
lieve our initial study in the Clinical Research Center in-
dicates that this combination of therapeutic agents, cou-
pled with sound nutritional and physiologic manage-
ment, resulted in the responses observed—the ability to 
take patients off or keep them off TPN or reduce their 
requirements in more than 80% of this population. Nu-
merous patients were referred to us after failure to re-
spond to growth hormone or glutamine administered by 
their own physicians, and all of these patients demon-
strated decreased stool output when growth hormone 
plus glutamine plus HCLF diet were administered in 
combination. In addition, 14 of 21 patients who were 
discharged without TPN and who have maintained their 
nutritional state in follow-up had less than 50 cm of jeju-
num-ileum. This is an important observation, because 
this length of intestine is consistently regarded as less 
than the necessary length for adequate absorption and 
nutritional maintenance by enteral feedings.1,7 
Not only did the patients respond to 4 weeks of ther-
apy, but also, many were able to maintain this state of 
independence during the year after the initial treatme 
Our longest-term patient has been independent of Tl 
for 5 years (patient 8,15 cm jejunum anastomosed to I 
transverse colon), and during the last year she becai 
pregnant, carried a normal child to term, had a nom 
delivery, and breast-fed the infant, events that reflect I 
capacity to withstand additional nutritional stress. O 
ers have been free of TPN, but short-term illness has; 
cessitated brief intervals of intravenous support. In th< 
eight persons who were initially weaned from TPN I 
who eventually required intravenous feedings, about c 
third were placed back on TPN because of recurrei 
of their underlying disease; dietary noncompliance v 
another cause of failure in several other persons. C 
plans need to be developed allowing for all of these p 
sons to receive appropriate long-term care to cc 
effectively support the patient with short-bowel s 
drome through intercurrent illness. For example, sevc 
days of intravenous fluid may be necessary during p 
ods of viral gastroenteritis, but with resolution of the 
ness and adequate hydration, enteral feeding can be 
started. In addition, some patients may need to be 
treated with growth hormone plus glutamine plus HC 
diet at appropriate time intervals and/or have diet 
compliance frequently reinforced by their care pro> 
ers. Further adaptation may occur with time—we h 
worked with several patients with large daily stool IOJ 
(>3 L/day) who have reduced their stool output in 
subsequent 12 months after therapy to about one hal 
this volume while the diet and fluid intake have sta; 
the same or increased. 
Physiologic and morphologic changes occur in 
bowel after therapy. With treatment, small-bowel i 
further hypertrophy, the bowel dilates and elongates, i 
intestinal transit time becomes prolonged. Colonic 
sorption is thought to be enhanced via the process oft 
terial fermentation. This process stimulates fluid «' 
~2 - 7 
VOL 222-No. 3 New Treatment for Short-Boweteyndrome 2 5 3 
electrolyte absorption and salvages both carbohydrate 
and protein calories, which are malabsorbed by the small 
bowel remnant.30 In addition, volatile fatty acids gener-
ated in the colon enhance mucosal growth and prolong 
transit time.31 
Because the bowel is constantly renewing its surface 
area, this organ is ideal for modification by administra-
tion of selected nutrients and growth factors. Other hor-
mones are also known to exert effects on the bowel, but 
growth hormone and glutamine are currently approved 
agents, readily available, safe, and reasonably inexpen-
sive compared with the other therapeutic options. This 
method of treatment should be evaluated and considered 
for patients with inflammatory bowel disease, those un-
dergoing intestinal transplantation, and those with dys-
functional loops of distended bowel who require rehabil-
itation. Various laboratory and clinical observations sug-
gest that these therapeutic agents administered singly or 
in combination affect intestinal structure and function 
in a wide variety of conditions. These observations of pa-
tients with short-bowel syndrome may demonstrate for 
the first time that we can use growth factors and nutrients 
together to enhance the proliferative response of specific 
tissue and therefore improve function. This concept may 
have broad applications to support or enhance the 
growth and function of other organs and thus improve 
care of patients. 
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Discussion 
DR. JOHN L ROMBEAU (Philadelphia, Pennsylvania). Dr. 
Wilmore and colleagues and a number of members of this As-
sociation have created a very exciting new area of surgical nu-
trition and metabolism; namely, the area of nutritional phar-
macotherapy This is broadly defined as providing some nutri-
ents that indeed seem to have more pharmacologic effects than 
nutritional effects per se, in addition to giving some drugs that 
in turn either enhance nutrient utilization or modify the meta-
bolic environment of the host. 
We have been very interested in the effects of the ammo acid 
glutamine on the transplanted small intestine In a model of 
transplanted small intestine in the rat, we compared the effects 
of supplemental glutamine given either intravenously or di-
rectly into the graft on small bowel glucose absorption as mea-
sured with C-14 labeled glucose As shown, the addition of glu-
tamine, when compared with an isonitrogenous controlled diet 
balanced with a mixture of nonessential amino acids, signifi-
cantly enhanced the ability of the small intestine to absorb glu-
cose nearly equivalent to baseline pretransplant levels 
I have one question for Dr Wilmore, and this relates to the 
human short bowel setting There is very limited information 
obtained from intestinal biopsies in patients that have suffered 
from short bowel syndrome This information shows that the 
small intestine seems to reach a maximal rate of adaptive hy-
perplasia somewhere between 2 and 3 years postoperatively 
In Dr Wilmore's study, 10 of the 19 patients that remained 
off total parenteral nutrition had been on total parenteral nu-
trition for periods greater than 3 years In fact, one of these 
patients had actually been on total parenteral nutrition for 15 
years prior to the usage of this combined therapy 
My question is, what are the mechanisms by which this com-
bined therapy enhances the absorptive function of the remain-
ing gut in an intestine that has already had at least 3 years to 
adapt endogenously? 
DR. PAUL R. SCHLOERB (Kansas City, Kansas) I am as im-
pressed by this paper as I was a quarter of a century ago when 
Doug Wilmore, working with Dr Rhoads, Dr Dudnck, Dr 
Vars, and others in Philadelphia, maintained an infant for 
many, many weeks by total parenteral nutrition for the first 
time 
When you have reviewed this manuscript, as I have had the 
privilege of doing, I think you will agree that this kind of study, 
with careful clinical observations and measurements, could 
only be canned out in a clinical research center, although it was 
not called that at the Bngham when Dr Francis Moore set 
up 47 years ago 
One may philosophize, I suppose, to the extent that natu 
has a way of correcting defects like this The more weight th 
is lost, the less nutrients are required 
But it is worth emphasizing as Doug pointed out, that p 
tients with less than 50 cm of jejunum-ileum are almost de 
tined to require total parenteral nutrition. Two thirds of the 
patients in this category were taken off total parenteral nuti 
tion. 
Weight gam to the tune of approximately I kg per week w, 
observed in their study And I have to ask whether this weigl 
was in fact water, because growth hormone does indeed pn 
duce fluid retention 
These favorable results are probably due in large measure 1 
the effect of growth hormone, and yet the patients were di 
charged while not receiving growth hormone. So my questic 
is, what did growth hormone do9 What effect did it have th< 
continued beyond the administration of growth hormone? 
Whether it is pediatric cardiac surgery, orthotopic liver tran 
plantation, or carcinoma of the pancreas, the best results ai 
obtained by centralized patient care I think centralization < 
care applies to this rather unusual circumstance of short-gi 
syndrome. Dr. Wilmore makes reference to the possibility < 
multicenter trials, and I wonder if he would share with us som 
of his plans and ambitions in this regard 
And finally, in terms of centralized care, I wonder, Doug, 
you would acquaint us a little more with the so-called Nutr 
tional Restart Center, which, from mv limited understandinj 
represents a real boon to patients with short-gut syndrome. 
DR STANLEY J DuDRiCK(Waterbury, Connecticut): I thoi 
oughly enjoyed this impressive paper, which is in an area < 
great personal clinical and scientific interest to me. I, too, ha 
the opportunity to read the manuscript, which is replete wit 
data that were not able to be presented here in its entirety. D 
Wilmore did not have time to explain all aspects of the entr 
criteria and the therapy, and, therefore, I would like to ask hir 
a few questions To reduce some of the variables, patients wit 
active infection and inflammatory bowel disease, cancer withi 
5 years of treatment, diabetes melhtus, other extra digestive oi 
gan failure, and severe gastrointestinal dysmotihty, were e* 
eluded I wonder if the team had any experience treating som 
of these patients that were excluded from the study? Furthei 
more, do you have any recommendations for how one migh 
manage patients with those exclusionary comorbid factors? 
Regarding your choice of the recombinant hormone, hoi 
did you determine the dosage used7 Was the final recom 
mended dose arrived at by trial and error? Or did you giv 
growth hormone to the point at which you began to have com 
plications and then back off? Or were you able to discern som 
optimal dose above which you had no additional beneficia 
effects9 Additionally, what does a course of growth hormon 
cost? 
In measuring body water, did you fractionate the total bod 
water into intracellular and extracellular water7 If so, wouI< 
you share those data with us7 
In the paper, you described a pregnant woman with short 
bowel syndrome who came off the total parenteral nutntioi 
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and eventually completed her pregnancy with delivery of the 
child, apparently resulting in both a healthy mother and infant. 
Did you have to reinstitute total parenteral nutrition at any 
point to support her through this additional stress? Or was she 
able to sustain her child and herself nutritionally entirely with-
out the total parenteral nutrition? 
Lastly, do you have any thoughts about the future use of 
growth factors, including growth hormone, administered to-
gether with nutrient substrates, in the management of the fail-
ure of other single organs such as the liver, kidney, pancreas, 
and brain? 
I thank the authors for the opportunity to read and discuss 
this fine paper, and I thank the Association for the privilege of 
the floor. 
DR. DONALD D. TRUNKEY (Portland, Oregon): Doug, I en-
joyed your paper very much. A couple of questions about your 
no-change group. 
You imply that these were patients who had chronic in-
flammatory bowel disease. I postulate that when you started 
them in the study, they were probably in remission. My ques-
tion is, what percent of the protein loss in these patients repre-
sents stool white cells? If they did get an exacerbation, did that 
protein loss increase because of the white cells? 
DR. W. GARDNER SMITH (Baltimore, Maryland): A clinical 
question for Dr. Wilmore. Nowadays, when we explore a pa-
tient who has had an acute ischemic event to their intestine, is 
there ever any indication to do what we used to do in 1965 and 
simply quit? If there are indications for this course of action, 
are there parameters that can help us to make that judgment, 
such as length of viable intestine remaining or the age of the 
patient? 
DR. DOUGLAS W. WILMORE (Closing Discussion): Thank 
you for the thoughtful questions and clear discussion. 
The mechanisms of adaptation clearly appear related to vil-
lus hypertrophy and elongation of the remnant bowel. In ani-
mals, there is thickening of the muscularis mucosa and transit 
time becomes prolonged; initially in these patients, it takes ap-
proximately 15 minutes to see barium reach the colon from the 
mouth, but after 4 weeks of treatment, this time is about an 
hour or so. So simply the prolongation of transit times allows 
increased nutrient exposure to the absorptive surface area. 
Dr. Schloerb, as you know, the weight gain in these patients 
was in part water and in part protein. The patients lose some of 
the water as they come off the growth hormone. The enhanced 
absorption probably continues for a prolonged period of time 
for several reasons. One, we are giving oral glutamine to main-
tain the nutrition of the mucosa and maintain cell turnover. 
But we are also using the colon as an organ for fermentation 
and nutrient absorption. The unabsorbed carbohydrate and 
protein that reach the colon are processed by bacteria and the 
by-products absorbed so that we are converting these individu-
als to hind-gut ruminants. 
Two multicenter trials of this therapy are being performed 
in adults in the United States and in Europe. There is also a 
multicenter trial being formed to use the therapy in a group of 
children. 
We care for the patients in a low-cost, assisted-Iiving center 
where we have designated beds for patients with malabsorption 
disorders. Patients have their own apartments, but interact with 
the nurses, dietitians, and physicians on a regular and sched-
uled basis. 
The doses of growth hormone we used were determined from 
dose-response studies. Growth hormone costs about $300 per 
day at this dose. However, growth hormone is going off orphan 
drug status and will be less expensive in the next year or so as 
other pharmaceutical companies bring their growth hormone 
to market. 
If we maintain the proportion of patients that we were able 
to take off total parenteral nutrition at I year—that is, 40% off, 
40% reduced, and 20% no change—the number of dollars that 
we save from total parenteral nutrition cost alone is about $2.3 
million a year, or approximately $50,000 per patient. 
Patients who could not be taken off total parenteral nutrition 
did not have active acute inflammatory disease. Which patients 
should not be considered for this therapy? This is an issue of 
debate because some pediatric surgeons feel that babies with 
congenital lesions and little hope of survival should not be 
treated. We have not treated patients with cancer or those with 
known motility disorders. In general, younger patients from 20 
to 55 years of age or so who have losses of large segments of 
bowel are good candidates for rehabilitation. Older patients 
should still receive the therapy, but may not respond as well, 
particularly if they have associated heart disease and other co-
morbid disorders. 
Thank you for the opportunity to present this work. 
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Growth Hormone, Glutamine, and a Modified Diet Enhance Nutrient 
Absorption in Patients With Severe Short Bowel Syndrome 
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ABSTRACT. Background: Massive loss of intestinal surface 
area results in the short bowel syndrome characterized by 
malabsorption of fluid, electrolytes, and other nutrients. 
Although the remaining bowel undergoes morphological and 
functional adaptation, often these changes are inadequate to 
support the individual by enteral feedings, and parenteral 
nutrition is required to prevent dehydration, electrolyte 
disturbances, and malnutrition. Substances such as growth 
hormone, glutamine, and fiber exert bowel-specific trophic 
effects and either directly or indirectly influence nutrient 
absorption. This study was undertaken to determine whether 
the co-administration of exogenous growth hormone, supple-
mental glutamine, and a modified fiber-containing diet could 
enhance nutrient absorption in patients who had undergone 
massive intestinal resection. Methods: Ten patients (5 men, 5 
women, aged 43 ± 4 years) with short bowel syndrome were 
studied 6 ± 1 years after surgical resection. All patients were 
admitted to the Clinical Research Center for a 28-day period; 
the first week served as a control period when nutritional 
(enteral and parenteral) and medical management simulated 
usual home therapy. Thereafter, eight patients received 
exogenous growth hormone, supplemental glutamine, and a 
modified high-carbohydrate, high-fiber diet Two patients were 
treated with the modified diet alone. The efficiency of net 
Extensive loss or dysfunction of the intestinal 
absorptive surface area results in the short bowel 
syndrome. This symptom complex is characterized by 
diarrhea, dehydration, electrolyte disturbances, malab-
sorption, and progressive malnutrition. The severity of 
this disorder depends upon the length, location, and 
absorptive function of the remaining bowel and its ability 
to accommodate the reduced absorptive surface area.1 
The compensatory process may occur for 1 to 2 years 
before adaptation is maximal and during this period 
parenteral nutrition is frequently required. In patients 
with very short segments of jejunum or ileum (< 60 
cm), sufficient adaptation of the remnant bowel to 
support the individual by enteral feedings is unlikely, 
and dependence on parenteral nutrition may be perma-
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nutrient absorption (percent absorbed) for total calories, 
protein, fat, carbohydrate, water, and sodium was calculated 
from the measured nutrient intake and stool losses. Results: 
Three weeks of treatment with growth hormone, glutamine. 
and a modified diet increased total caloric absorption from 
60.1 ± 6.0% to 74.3 ± 5.0% (/> < .003), protein absorption 
from 48.8 ± 4.8% to 63.0 ± 5.4% (fi < .006), and carbohydrate 
absorption from 60.0 ± 9.8% to 81.5 ± 5.3% (p < .02). Eat 
absorption did not change (61.0 ± 5.3% to 60.3 ± 7.9%, p = 
NS). Water and sodium absorption increased from 45.7 ± 6.7% 
to 65.0 ± 7.3% (p < .002) and from 49.0 ± 9.8% to 
69.6 ± 6.5% (p ^ .04), respectively. These absorptive changes 
resulted in a decrease in stool output (1,783 ± 414 g/d control 
period vs 1,308 ± 404 g/d third week of treatment, p < .05). 
Treatment with diet alone did not influence nutrient absorption 
or stool output Conclusions: The combined administration of 
growth hormone, glutamine, and a modified diet enhanced 
nutrient absorption from the remnant bowel after massive 
intestinal resection. These changes occurred in a group of 
patients that had previously failed to adapt to the provision 
of enteral nutrients. This therapy may offer an alternative to 
long-term dependence on total parenteral nutrition for patients 
with severe short bowel syndrome. (Journal of Parenteral ana 
Enteral Nutrition 19:296-302, 1995) 
nent2 Although parenteral nutrition is life^ustaining, it 
can be associated with debilitating complications, 
repeated hospitalizations, and significant costs (at least 
$75,000 to $150,000 per patient year).3 
For the patient with short bowel syndrome, various 
operative approaches have been employed in attempts 
to prolong intestinal transit or expand absorptive surface 
area. Intestinal transplantation has also been proposed 
as a solution to the problem of intestinal failure. 
However, these procedures have major limitations,4*6 and 
there remains a need for a relatively safe and 
cost-effective treatment for these patients. We postulated 
that one such therapeutic approach might be to enhance 
the normal physiologic process of intestinal adaptation 
by administering substances that are trophic to the 
bowel and/or directly or indirectly influence nutrient 
absorption. 
Intestinal growth and adaptation are mediated in part 
by factors extrinsic to the gastrointestinal tract (eg, 
growth hormone and thyroxine) and in part by local 
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factors brought into play by the provision of enteral 
feedings (eg, exposure of the mucosa to specific 
nutrients, pancreatic-biliary secretions, or enteric hor-
mones).6 The amino acid glutamine is a primary energy 
source for the gastrointestinal tract;7 it exerts trophic 
effects on the bowel8 and stimulates nutrient absorp-
tion.910 Similarly, fiber is a specific component of the 
diet that may enhance bowel adaptation by promoting 
bowel growth and cell proliferation11 by slowing 
gastrointestinal transit time.12,13 Although previous pilot 
studies investigating the effect of growth hormone or 
glutamine alone on nutrient absorption in patients with 
short bowel syndrome produced minor biochemical 
changes, no significant clinical effects were observed. 
Others studies have shown that simple dietary manipu-
lation (eg, restricting fat or increasing carbohydrate 
intake) fails to significantly enhance nutrient absorp-
tion.14"16 Because a single treatment modality is unlikely 
to induce all the adaptive changes that occur within 
the resected gastrointestinal tract, we hypothesized that 
the co-administration of trophic substances such as 
growth hormone and supplemental glutamine in combi-
nation with a low-fat, high-carbohydrate, fiber-containing 
diet would significantly enhance nutrient absorption 
from the remnant bowel of patients who had undergone 
massive intestinal resection. 
METHODS 
Patients 
Ten patients (5 females, 5 males, mean age 43 i 4 years) with 
severe short bowel syndrome were admitted to the Clinical Research 
Center of the Brigham and Women's Hospital, Boston, MA. All patients 
had undergone extensive small bowel resection with or without colonic 
resection. The lengths of the remaining gut structures were determined 
from operative reports and confirmed by perioperative radiographs 
(Table I). Patients were ambulatory and clinically stable and without 
evidence of uncontrolled infection or active inflammatory bowel 
disease. In addition, they had no extradigestive organ failure, were 
free of cancer, and did not have a history of cancer. All patients 
were able to tolerate an ad libitum diet; however, without parenteral 
support they were unable to adequately maintain hydration and/or 
nutritional status. The protocol was approved by the Hospital's 
Committee for the Protection of Human Subjects from Research Risks, 
and informed consent was obtained. 
Study Design 
• The patients were admitted to the Clinical Research Center for a 
2&day stay. The first week served as a control period during which 
the patients' nutritional (parenteral and enteral feedings and ad libitum 
oral intake) and medical management (antidiarrheal agents, etc) 
simulated their usual home therapy. Patients were instructed to 
consume the quantity and type of foods and beverages that best 
represented their usual earing habits and food preferences. Only food 
and beverages of known nutrient composition were provided. Meals 
and snacks were made available six times per day. Self-selected 
beverages were made available 24 h/d. The supplemental enteral tube 
feeding that two patients received at home before admission was 
provided and administered at the same rate and concentration. During 
the control period, the infusion of parenteral nutrients and fluid 
volumes was matched to those that had been prescribed by the 
patient's primary-care physician before the research protocol. The 
nutrient solutions were prepared daily in the hospital pharmacy as 
previously described." Electrolytes were added daily to the nutrient 
solution in quantities necessary to maintain normal serum concentra-
tions. •. 
Daring the remaining 3 weeks, all patients received a diet that 
wis high in complex carbohydrates and low in fat, but nearly isocatoric 
and lspnitzogenous to that which the patient received during the 
control period. The diet was designed to provide approximately 
of total calories from carbohydrate, 20% from fat, and 20% 1 
protein. Total dietary fiber (defined as the sum of insoluble fib 
soluble fiber) intake increased as complex carbohydrates repl; 
simple sugars. In addition, a soluble fiber supplement (Apple p< 
powder, Solgar, Lynbrook, NY) was added to specific food item 
tolerated. Calories and protein were distributed into six feedings 
served throughout the day. Near-isotonic fluids containing glu 
and sodium (Gatorade, The Gatorade Company, Chicago, IL, 
Pedialyte, Ross Laboratories, Columbus, OH) replaced both hypo-
hyperosmolar fluids and served as the primary source of em 
hydration. Two of the 10 patients were treated with this mod 
oral diet alone (Diet). 
In addition to the modified diet, eight patients received recombt 
methionyi-growth hormone (Protropin, Genentech Inc, South 
Francisco, CA) at a dose of .14 mg/kg per day by parent 
administration. They also received supplemental parenteral an 
enteral L-glutamine (Ajinomoto USA, Raleigh, NO) (GH+GLN+D 
During the 3-week treatment period, parenteral protein requirem 
were provided by administering a commercially available amino 
solution rich in essential amino acids (Renamine, Baxter Health < 
Corporation, McGraw Park, IL) supplemented with crystalline h 
tamine (average parenteral dose = .42 g/kg per day). The glutam 
supplemented amino acid mixture was combined with hypext 
glucose and fat emulsion to provide an isocaloric and isonitroger 
infusion that was comparable to that received during the cor 
period. Vitamin and trace elements were added to the glutamine 
riched solution as had been prescribed during the control pei 
and electrolytes continued to be adjusted to maintain normal bl 
concentration. For those patients not receiving parenterally inft 
nutrients, i^glutamine powder was provided enterally at an avei 
dose .63 g/kg per day, which was slightly higher than the parent 
dose because it was assumed that a portion of enterally administe 
glutamine would be malabsorbed. 
Throughout the entire 28-day study period, all enteral intake 
stool output were weighed, and the calorie, nitrogen, fat, water, 
sodium contents were determined. Nutrient balance and net absorpi 
were then calculated from the measured enteral intake and si 
losses. Weight was recorded daily. Twenty-four hour urinary creatir 
was measured daily during the control period to identify the deg 
of skeletal muscle mass depletion. Blood samples were analy 
biweekly to monitor response to therapy. 
Details of the Study 
Determination of nutrient intake. All enteral diets were provi* 
by the Clinical Research Center's metabolic kitchen. Over the en 
28-day study period, all administered food was weighed and fl 
measured before consumption. The total daily intake of profc 
carbohydrate, fat, sodium, and water (including the water content 
all food and beverages) was determined by a computer prog! 
(GCRC Diet Planner, Version 2.03, Clinical Study <3enter, Unrvei! 
of California, San Francisco, CA), which translated the gram wei 
of intake into nutrient composition. For food sources not listed 
the computer program, nutrient values were determined either fr 
product information or from Bowes and Church's Food Values 
Portions Commonly Used u The nutrient composition of all tube feedii 
was determined from the manufacturer's specifications. On rand 
days of the study, duplicate patient trays were prepared and fc 
analyses confirmed the nitrogen, fat, and sodium content of the di 
Daily caloric intake was expressed as the gross energy content 
the diet (ie, the heat of combustion) rather than metabolizable enei 
(heat of combustion minus fecal and urinary calories).* The calculal 
values were then confirmed by actual food analysis determined ' 
bomb calorimetxy (Hazelton Laboratories America, Inc., Madison, W 
The total and soluble dietary fiber content of the control and treatm* 
diets was calculated from standard tables.**1 Supplemental solul 
fiber dose was determined by weighing a proportioned serving at f 
beginning and the end of each 24-hour study period. 
Measurement of nutrient losses. All stool was collected for consecuti 
24-hour periods between 7:30 AM and 7:30 AM beginning on the morni 
after admission and continuing until completion of the study. Sampl 
were frozen at -20°C. At the end of the study, the samples w« 
thawed; liquid stool was blended and known quantities of distill 
water added to semi-solid stool before blending. The homogenir 
stool samples were then analyzed for calories, nitrogen, and Cat 
previously described." Stool nitrogen (grams) was converted to stc 
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protein (grams) by multiplying by 6.25. Calories (kcai) derived from 
stool protein were determined by multiplying the gram quantity of 
stool protein by 5.65 (23.64 kJ).* Stool fat calories (kcai) were 
determined by multiplying the quantity of stool fat (grams) by 9.35 
(39.12 kJ)." Stool carbohydrate calories were determined by subtracting 
the sum of stool protein and fat calories from the total stool calories. 
The gram quantity of stool carbohydrate was then estimated by 
dividing stool carbohydrate calories (kcai) by 4.2 (17.57 kJ).** The 
sodium concentration of the stool was determined by use of a flame 
photometer (Instrumentation Laboratory, Lexington, MA). Stool wet 
and dry weights were determined by weighing the samples before 
and after 72 hours of drying in a 90°C oven (Precision Scientific Co, 
Chicago, EL). Stool water was defined as the difference between the 
wet and dry weight of the stool. 
Nutritional assessment and patient monitoring. Body weight was 
recorded each morning to the nearest .1 kg using a leveled platform 
scale (model SR2MI01, Acme Scale, Oakland, CA). Ideal body weight 
was determined from standard tables.0 All blood chemical and urine 
analyses were determined using standard hospital analytical techniques. 
Creatinine height index (CHI) was calculated from the mean 24-hour 
urinary creatinine excretion rate during the control period. Actual 
excretion was compared with the expected excretion rate for an 
individual of similar height, frame size, and sex, and the values were 
expressed as a percent of the standard.0 A radioimmunoassay technique 
was used to determine the plasma concentration of insulin-like growth 
factor-one (IGF-1).* 
Calculations of nutrient absorption. The net absorption of nitrogen, 
fat, carbohydrate, calories, sodium, and water was calculated by 
subtracting the quantity present in the stool from the enteral intake 
for each 24-hour period. The efficiency of nutrient absorption (percent 
of intake absorbed) was calculated by dividing the quantity absorbed 
by nutrient intake and multiplying the result by one hundred. The 
ability to absorb food weight was determined by subtracting 24-hour 
stool weight from the total weight of all food and beverages consumed 
during that 24-hour period. The percent of food weight absorbed was 
calculated by dividing the quantity absorbed by the total weight of 
intake and multiplying the result by one hundred. 
Statistical Analysis 
Data were analyzed using standard statistical software (StatView 
No. 512, Abacus Concepts, Inc, Berkeley, CA) on a Macintosh SE 
personal computer (Apple Computer, Cupertino, CA). Paired Students 
t tests were used to determine differences between the control period 
and the final week of study. Non-paired Student's t tests were used 
to identify differences in nutrient intake between the GH+GLN+Diet-
treated patients and those treated with the modified Diet alone. Simple 
linear regression analysis was used to describe the relationship between 
dependent and independent variables. A p value s .05 was considered 
statistically significant. Results are expressed as means ± SEM. 
RESULTS 
The clinical characteristics of the patients are provided 
in Table L The time elapsed since the last surgical resection 
averaged 6 ± 1 years. Mean jejunal-ileal length was 37 
cm (range 8 to 90 cm) for the GH+GLN+Diet-treatec 
patients. The jejunal-ileal length of the two patients treatec 
with Diet alone ranged from 65 to 120 cm. In all patients 
the remnant of small intestine was in continuity with the 
remaining colon Before admission, six patients receivec 
parenteral nutrition at home 6 to 7 d/wk. Two patienfc 
(#2 and #7) were unable to receive IV nutrient infusion* 
due to central vein thrombosis and received daih 
administration of elemental or semi-elemental entera 
tube feedings; these patients were severely undemour 
ished when their weight and CHI were compared witl 
healthy individuals (Table I). Two additional patient 
(#5 and #10) were maintained at home on an oral die 
supplemented occasionally with infusion of isotonic 
fluids and electrolytes to maintain normal hydration anc 
serum electrolyte concentrations; these patients wen 
also less than optimally nourished (Table I). 
At the time of admission, body weight was 87 ± 49 
of ideal body weight22 Creatinine height index was 79.< 
± 5.9% of normal.23 All patients remained clinicall: 
stable throughout the study period. Weight gain ove 
the 28-day admission period averaged 5.4 ± 1.2 kg 
Blood concentrations of urea nitrogen, creatinine 
glucose, aspartate-aminotransferase, alkaline phos 
phatase, and total bilirubin did not vary significant!; 
throughout the study. Treatment with GH+GLN+Die 
resulted in a significant increase in plasma concentration 
of IGF-1 (110 ± 25 \Lg/L at baseline to 478 ± 112 \vgfi 
by the end of the fourth week, p ^ .01). Serun 
concentrations of IGF-1 remained relatively stable fo 
the patients treated with Diet alone (152 ± 7.5 jig/L a 
baseline to 184 ± 23.5 u.g/L by the end of the fourti 
week). 
Nutrient Intake 
Average daily enteral intake during the control perio* 
and the final week of treatment is provided in Tab! 
n. For the GH+GLN+Diet-treated patients, the compc 
sition of the enteral diet consumed during the contrc 
period consisted of 51.7 ± 4.8% of total caloric intak 
as carbohydrate, 29.6 ± 4.3% as fat, and 18.7 ± 1.4S 
as protein. Total dietary fiber intake averaged 1 g pe 
TABLE I 
Patient characteristics 
Pa 
GH + 
1 
2 
3 
4 
5 
6 
7 
8 
Diet 
9 
10 
tient group 
GLN + Diet 
Sex 
M 
M 
F 
F 
F 
F 
M 
F 
M 
M 
Age 
(y) 
51 
68 
44 
37 
28 
31 
45 
42 
52 
34 
Diagnosis 
Small bowel volvulus 
SMA thrombosis 
Crohn's disease 
SMA thrombosis 
Trauma to SMA 
Venous ectatic disease 
SMA thrombosis 
Small bowel volvulus 
Small bowel volvulus 
Crohn's disease 
Yean since 
resection 
0.5 
8 
9 
7 
6 
5 
7 
11 
1 
5 
Remaining 
Jejunum/ 
(cm) 
65 
30 
90 
30 
15 
24 
30 
8 
65 
>120 
bowel 
Ileocecal 
valve 
+ 
-
-
-
-
-
-
-
+ 
-
Colon/ 
rectum 
All 
TDK 
TDR 
TDR 
TDR 
SCR 
TDR 
TDR 
All 
TDR 
Nutritional status 
Ideal body weight 
(percent of ideal) 
74.3 
69.9 
95.2 
113.0 
93.9 
89.6 
77.1 
94.3 
80.1 
81.6 
Creatinine 
height index 
(percent of normal) 
54.5 
61.9 
89.7 
100.0 
90.1 
77.7 
50.7 
96.2 
75.1 
100.0 
—i or«o i,*A «w%L\n mr\A nreMnt: - . absent / / , 
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-220 kcal (921 kJ\ Soluble fiber provided approximately 
20% of total fiber intake. The composition of the baseline 
enteral intake of the two patients treated with Diet 
alone was similar to the other patients: 48.6 ± 3.4% of 
total caloric intake from carbohydrate, 30.1 ± 2.3% from 
fat, and 21.4 ± 1.0% from protein. Total dietary fiber 
intake averaged 1 g per -180 kcal (753 kJ) with soluble 
fiber providing approximately 19% of total fiber intake. 
During the control period, food weight, water, and 
sodium intakes were also similar among all patients. 
For the GH+GLN+Diet-treated patients, the percent 
of total calories derived from carbohydrate increased 
significantly to provide 61.3 ± 4.1% of total caloric 
intake (p ^ .03 vs the control period); percent fat intake 
decreased significantly to 17.9 ± 3.1% (p < .01 vs the 
control period), and protein intake remained relatively 
constant at 20.8 ± 1.7%. There was a tendency for 
caloric intake to decrease as dietary fat was replaced 
with carbohydrate and fiber-containing foods, which 
provided greater food volume. Total dietary fiber intake 
increased to provide 1 g of fiber per -100 kcal (p < .002 
vs control period). Soluble fiber intake also increased 
significantly (from 2.47 g/d during the control period to 
5.58 ± 1.37 g/d by the fourth week of study, p < .05) 
and provided -24% of the total fiber intake. The composition 
of the modified enteral intake of the two patients treated 
with Diet alone was similar to the other patients: 60.6 
± .8% carbohydrate, 20.0 ± .6% fat, and 19.4 ± .3% protein. 
Both total and soluble fiber intake was similar to that 
which was consumed by the GH+GLN+Diet-treated 
patients during their final week of treatment For all 
patients, food weight and the mean intakes of water 
and sodium were well matched to that which was 
consumed during the control period (Table II). 
For the GH+GLN+Diet-treated patients, parenteral 
nutrition provided 26 ± 4 kcal/kg per day (109 ± 17 
kJ/kg per day) and 1.2 ± .2 g of protein/kg per day 
during the control period. These values did not differ 
significantly from the calories or protein infused during 
the final week of study, 23 ± 6 kcal/kg per day (96 
± 25 kJ/kg per day) and 1.1 ± 2 g of protein/kg per 
day. For the patients treated with Diet alone, parenteral 
nutrition provided 29 ± 7 kcal/kg per day (121 ± 30 
kJ/kg per day) during the control period and 25 ± 6 
kcal/kg per day (105 ± 25 kJ/kg per day) during th< 
final week of treatment. Because the Diet-treated patient 
tended to consume a greater quantity of enteral protein 
IV protein was provided at a slightly lower dose thai 
that which was administered to the GH+GLN+Diet 
treated patients (0.8 ± .2 g/kg per day during the contro 
penod and .7 ± .2 g/kg per day during the final weel 
of treatment). Total protein intake (enteral + parenteral 
during the control period (2.4 ± .2 g/kg per daj 
GH+GLN+Diet vs 2.8 g/kg per day Diet alone) and th( 
final week of treatment (2.4 ± .2 g/kg per da] 
GH+GLN+Diet vs 2.5 ± .3 g/kg per day Diet alone) die 
not differ between the two groups. 
Nutrient Absorption 
Stool output of the GH+GLN+Diet-treated patients wa< 
1,783 ± 414 g/d during the control period and decreasec 
to 1,308 ± 404 g/d (p < .05) during the fourth week oi 
study. This decrease in stool output was associated with 
significant increases in the ability to absorb food weight 
(p < .0001), calories (p < .003), protein (p < 0.006) 
carbohydrate (p ^ .02), water (p s .002), and sodium 
(p < .04) (Table HI). The efficiency of fat absorption did 
not change (61.0 ± 5.3% to 60.3 ± 7.9%, p = NS). 
However, fat absorption was inversely correlated with the 
change in soluble fiber intake (r = .80, p ^ .02). 
Stool output of the two patients treated with Diet 
increased from 1,117 ± 329 to 1,334 ± 503 g/d. Treat-
ment with Diet alone did not influence the ability to 
absorb food weight, calories, protein, fat, carbohydrate, 
water, or sodium (Table III). 
The percent changes in the efficiency of nutrient 
absorption from baseline to the final week of study for 
the GH+GLN+Diet-treated patients are shown in Figures 
1 and 2 for the patients treated with Diet alone. The 
percent changes in stool volumes are also shown. 
DISCUSSION 
Upon admission, the patients in this study were unable 
to maintain adequate hydration or nutritional status with 
enteral intake and thus required the parenteral admini-
stration of nutrients. Body weight was less than optimal 
and the baseline determination of CHI identified 
moderate-to-severe skeletal muscle depletion. Although 
TABLE II 
Enteral intake 
Control 
GH + GLN + Diet Diet 
Week 4 
GH + GLN + Diet Diet 
Weight (g/d) 
Calories (kcal/d)* 
Protein (g/d) 
Fat (g/d) 
Carbohydrate (g/d) 
Total fiber (g/d) 
Soluble fiber (g/d) 
Water (L/d) 
Sodium (mEq/d)|| 
3352 ± 464 
2692 ± 520 
88.6 ± 18.6 
96.1 ± 26.0 
307.9 ± 51.2 
12.42 ± 1.99 
2.47 ± 0.44 
2.826 ± 0.392 
151.4 ± 24.4 
3368 ± 351 
3553 ± 483 
135.2 ± 24.6 
115.6 ± 24.5 
406.9 ± 27.5 
19.7 ± 0.15 
3.69 ± 0.05 
2.439 ± 0.143 
185.3 ± 21.1 
3540 ± 414 
2367 ± 374 
86.7 ± 15.1 
44.9 ± 9.3t 
347.0 ± 54.9 
23.6 ± 3.5* 
5.58 ± 1.37§ 
2.900 ± 0.368 
162.3 ± 23.4 
3913 ± 803 
3433 ± 612 
117.5 ± 19.4 
73.0 ± 11.0 
497.0 ± 95.2 
24.7 ± 5.6 
4.35 ± 0.9 
2 840 ± 0.366 
202.7 ± 35.5 
•1 kcal = 4.184 kJ. 
\p ^ .03 as control period. 
tp ^ .002 vs control period. 
§t> ^ .05 vs control iveriod. Ucl 
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Weight (g/d) 
Calories (kcal/d)t 
Protein (g/d) 
Fat (g/d) 
Carbohydrate (g/d) 
Water (L/d) 
Sodium (mEq/d)ti 
TABLE III 
Weight and nutrient absorption 
Control Week 4 
GH + GLN + Diet 
(percent absorbed) 
Diet 
(percent absorbed) 
GH + GLN + Diet 
(percent absorbed) 
50.6 ± 6.5 
60.1 ± 6.0 
48.8 ± 4.8 
61.0 ± 5.3 
60.0 ± 9.8 
45.7 ± 6.7 
49.0 ± 9.8 
66.3 ± 4.9 
84.5 ± 5.0 
73.9 ± 4.0§ 
91.3 ± 4.2§ 
84.8 ± 6.0 
57.6 ± 8A 
54.9 ± 20.3 
68.2 ± 7.1* 
74.3 ± 5.0t 
63.0 ± 5.4? 
60.3 ± 7.9 
81.5 ± 5.3** 
65.0 i 7.3tt 
69.6 ± 6.5§§ 
Diet 
(percent absorbed) 
67.14 ± 6.08 
81.6 ± 4.25 
68.9 ± 8.2 
81.6 ± 10.2 
85.5 ± 1.2 
56.6 ± 11.2 
56.7 ± 22.6 
*p < .0001 ts control period. 
t l k c a l = 4.184 kJ. 
Xp ^ .003 «s control period. 
§/> < .04 wGH + GLN + Diet. 
\p < .006 t* control period. 
**p < .02 is control period. 
f tp ^ .002 us control period. 
t t = 1 mEq = 1 mmol. 
§§p < .04 «s control period. 
patients with the short bowel syndrome are frequently 
encouraged to increase enteral food intake in an attempt 
to decrease dependency on parenteral nutrition, the 
patients in this study had failed to adapt to the provision 
of enteral nutrients. 
The exogenous administration of growth hormone (or 
its analogue) has been shown to influence bowel 
adaptation by enhancing mucosal hyperplasia after 
extensive intestinal resection in animals.25*26 Growth 
hormone is also known to increase colonic mass and 
biomechanical strength;27 these effects may enhance the 
reservoir function of the colon or influence peristalsis, 
thus prolonging transit time. In addition, IGF-1 produc-
tion, which is regulated by growth hormone, has been 
shown to enhance bowel hyperplasia and hypertrophy 
in rats after extensive jejuno-ileal resection.28 Further-
more, exogenous growth hormone increases water and 
sodium absorption in the small intestine and in the 
colon29 and appears to regulate amino acid absorption.30 
Glutamine is a primary fuel source for both the 
enterocytes and the colonocytes and serves as an 
essential precursor for purine and pyrimidine biosyn-
thesis.7 Supplemental glutamine has been shown to 
accelerate postresection hyperplasia,8 prevent intestinal 
atrophy in humans receiving parenteral nutrition,31 and 
enhance glucose9 and sodium absorption.10 
Growth hormone in combination with glutamine may 
exert an additive effect on bowel morphology and 
function. IGF-1 induces ornithine decarboxylase,32 the 
rate-limiting enzyme in the biosynthesis of polyamines, 
which play a central role in intestinal cell growth and 
proliferation.33 Glutamine is a required substrate for 
ornithine decarboxylase and an essential precursor for 
nucleotide biosynthesis. Animal studies have demon-
strated that the inhibition of ornithine decarboxylase 
prevents enhanced cellularity in residual bowel after 
intestinal resection,34 whereas glutamine-supplemented 
nutrition administered in combination with IGF-1 en-
hances protein deposition in the residual mucosa after 
small bowel resection compared with trophic effects of 
glutamine or IGF-1 alone.36 Furthermore, both growth 
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FIG. 1. Changes in the efficiency of nutrient absorption and stool output 
with growth hormone, glutamine, and diet Treatment with 
GH+GLN+Diet produced significant changes in the efficiency of nutri-
ent absorption. These changes resulted in a significant decrease in stool 
output •/> < .0003, Xp ^ .03, Xp < .009, §/> < .008, \p < .01. 
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Fte. 2. Changes in the efficiency of nutrient absorption and stool output 
with diet alone. Treatment with Diet alone produced no change in the 
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processes that may be enhanced by the provision of 
bowel-specific fuels such as glutamine. 
In addition to growth hormone and glutamine, the patients 
in this study received a high-carbohydrate, low-fat diet 
supplemented with fiber. Although controversy exists over 
the role of diet in the management of the short bowel 
syndrome, several studies have demonstrated that dietary 
manipulation (eg, restricting fat) does not significantly 
influence nutrient absorption.14"16 These authors argue that 
clinicians should adopt a more liberal attitude regarding 
the enteral diets of these patients. Others, however, 
recommend diets restricted in fat,35-37 but high in 
carbohydrate38 and specific fibers.39 A recent report has 
documented that a high-carbohydrate, low-fat diet provided 
for a 4-day period can decrease the fecal loss of calories 
in short bowel patients with normal colons.38 
The rationale for providing an increased carbohydrate 
or fiber-containing diet to patients with short bowel 
syndrome is that the malabsorbed carbohydrates and 
nondigestible fibers pass into the colon, where they can 
be fermented by bacteria to produce short-chain fatty 
acids. These organic acids are rapidly absorbed by the 
colonic mucosa and can be used for energy;40 thus, 
some of the carbohydrate calories that would have 
otherwise been lost because of upper-intestinal malab-
sorption can be salvaged by this process.41 Furthermore, 
short-chain fatty acids are known to enhance sodium 
and water absorption42 and exert trophic effects both 
in the small intestine and in the colon.43 In addition to 
their role in the production of short-chain fatty acids, 
specific soluble fibers have been shown to prolong 
gastrointestinal transit time1213 and elicit stimulatory 
effects on small and large bowel mucosal growth and 
cell proliferation.11,44 Thus, because all patients in our 
study had colonic remnants, a high-carbohydrate, low-fat 
diet supplemented with fiber was provided in an attempt 
to enhance nutrient absorption. However, the provision 
of this diet without glutamine or growth hormone failed 
to alter nutrient absorption in two subjects. 
Three weeks of combined therapy (GH+GLN+Diet) 
significantly enhanced calorie, protein, carbohydrate, 
water, and sodium absorptive efficiency. The effect of 
this therapy on total caloric absorption was somewhat 
blunted by the adverse effect of soluble fiber on fat 
absorption. However, despite the addition of these 
fermentable soluble fibers and other insoluble fibers 
that typically increase stool bulk and weight,46 stool 
output decreased 33.0 ± 10.0% (p < .01). These adaptive 
changes were achieved in all GH+GLN+Diet-treated 
patients, even though seven of the eight individuals had 
undergone resection 5 to 11 years before participation 
in the study. 
Additional studies are now underway to determine if 
this therapy can allow for a reduction or an elimination 
in parenteral nutrient requirements. In addition, a 
follow-up program is in progress to assess the long-term 
effects of this therapy on nutritional status, body 
composition, and liver and kidney function. Additional 
studies are needed both to determine whether such 
treatment would exert greater effects shortly after 
resection and to better define the optimal diet, 
particularly the type and quantity of fiber to admin 
The use of this therapy in patients with high-o 
ostomies has not been systematically evaluated 
would most likely require further dietary modifies 
In summary, the combined administration of e; 
nous growth hormone, glutamine and a diet hit 
complex carbohydrates and fiber and low in fat enha 
nutrient absorption from the remnant bowel after m$ 
intestinal resection. These functional changes occ 
after 3 weeks of therapy in a group of patients whe 
previously failed to adapt to the provision of ei 
nutrients. Additional study is needed to determine t 
therapy can offer an alternative to long-term depenc 
on total parenteral nutrition or intestinal transplant 
for patients with the severe short bowel syndrome, 
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